Investigation of molecular mechanisms involving protein trafficking by Canetti, Diana
  
 
 
 
 
PhD THESIS IN CHEMICAL SCIENCES 
XXIX COURSE 
 
 
INVESTIGATION OF MOLECULAR MECHANISMS 
INVOLVING PROTEIN TRAFFICKING 
 
 
 
 
 
Tutor:         Author: 
Prof. Maria MONTI       Diana CANETTI 
Coordinator: 
Prof. Luigi PADUANO 
 
 
 i 
 
 
 
 
 
 
 
 
 
 
 
 
Intentionally left blank. 
 
 ii 
 
 
 
 
 
 
 
Amor ogni cosa vince 
Leonardo da Vinci 
 
 
 
 
 
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
Intentionally left blank. 
 
 
 
ACKNOWLEDGMENTS 
iv 
Acknowledgments 
UNIVERSITY OF NAPLES FEDERICO II 
DEPARTMENT OF CHEMICAL SCIENCES 
 
Prof. Maria MONTI 
Prof. Piero PUCCI 
 
Prof. Renata PICCOLI 
Prof. Daria Maria MONTI 
 
 
 
TELETHON INSTITUTE OF GENETICS AND MEDICINE 
 
Dr. Roman POLISHCHUK 
Prof. Giancarlo PARENTI 
 
 
UNIVERSITY COLLEGE LONDON 
 
Prof. Vittorio BELLOTTI 
Dr. Patrizia MANGIONE 
Dr. Graham TAYLOR 
 
 
 
 
 v 
 
 
 
 
 
 
 
 
 
 
 
 
Intentionally left blank. 
 
TABLE OF CONTENTS 
vi 
 
Table of Contents 
Abbreviations .................................................................................................................................. x 
Summary ......................................................................................................................................... 1 
1 Chapter 1 – Introduction .......................................................................................................... 5 
1.1 Transport Machinery ........................................................................................................ 5 
1.1.1 Traffic Control System Within/Outside the Cells ..................................................... 7 
1.1.2 Protein Trafficking Defects in Human Disease ......................................................... 8 
1.2 Proteomics ...................................................................................................................... 10 
1.2.1 Functional Proteomics ............................................................................................. 10 
1.2.2 Protein-Protein Interaction in Human Disease ........................................................ 11 
1.2.3 Proteomics Approach for the Study of Protein-Protein Interactions ....................... 12 
1.2.4 Proteomics in Clinical Diagnosis ............................................................................ 13 
1.3 Mass Spectrometry ......................................................................................................... 15 
1.3.1 Tandem Mass Spectrometry .................................................................................... 17 
1.4 Protein Identification ...................................................................................................... 19 
1.5 Aim of the PhD Thesis ................................................................................................... 20 
1.6 References ...................................................................................................................... 22 
2 Chapter 2 – Investigation of Molecular Mechanisms Impaired in Wilson Disease .............. 25 
2.1 Introduction .................................................................................................................... 25 
2.1.1 The Role of Cu-Transporting ATPases in Copper Homeostasis ............................. 25 
2.1.2 ATP7B Protein ........................................................................................................ 27 
2.1.3 Wilson Disease ........................................................................................................ 30 
2.1.4 Treatment of Wilson Disease .................................................................................. 31 
2.1.5 Aim of the Project ................................................................................................... 31 
2.2 Materials and Methods ................................................................................................... 33 
2.2.1 Materials .................................................................................................................. 33 
TABLE OF CONTENTS 
vii 
2.2.2 Methods ................................................................................................................... 33 
2.3 Results ............................................................................................................................ 37 
2.4 Discussion ....................................................................................................................... 47 
2.5 Conclusions .................................................................................................................... 58 
2.6 References ...................................................................................................................... 59 
3 Chapter 3 – Investigation of Molecular Mechanisms Impaired in Pompe Disease ............... 63 
3.1 Introduction .................................................................................................................... 63 
3.1.1 Lysosomes and Lysosomal Enzymes ...................................................................... 63 
3.1.2 Lysosomal Storage Diseases ................................................................................... 64 
3.1.3 Pompe Disease ........................................................................................................ 66 
3.1.4 Possible Therapies in LSDs ..................................................................................... 69 
3.1.5 Aim of the Project ................................................................................................... 73 
3.2 Materials and Methods ................................................................................................... 74 
3.2.1 Materials .................................................................................................................. 74 
3.2.2 Methods ................................................................................................................... 74 
3.3 Results ............................................................................................................................ 79 
3.3.1 Investigation of Wild Type GAA Interactome ........................................................ 79 
3.3.2 Investigation of rhGAA Interactome ....................................................................... 86 
3.4 Discussion ....................................................................................................................... 92 
3.4.1 Investigation of Wild Type GAA Interactome ........................................................ 93 
3.4.2 Investigation of rhGAA Interactome ....................................................................... 99 
3.5 Conclusions .................................................................................................................. 105 
3.6 References .................................................................................................................... 106 
4 Chapter 4 –Investigation of Molecular Mechanisms Impaired in Amyloidosis .................. 109 
4.1 Introduction .................................................................................................................. 109 
4.1.1 Protein Misfolding Diseases: Amyloidosis ........................................................... 109 
4.1.2 Examples of Systemic Amyloidosis: Clinical Features, Diagnosis and Therapies ......... 113 
TABLE OF CONTENTS 
viii 
4.1.3 About Amyloidosis Diagnosis Issues .................................................................... 115 
4.1.4 Apolipoprotein A-I: From Physiological Function to Amyloid Fibrils Formation ......... 115 
4.1.5 Aims of the Project ................................................................................................ 119 
4.2 Investigation of ApoAI Conformational Perturbations in Hereditary Amyloidosis ..... 120 
4.2.1 Materials and Methods .......................................................................................... 120 
4.2.2 Results and Discussion .......................................................................................... 120 
4.2.3 Conclusions ........................................................................................................... 132 
4.3 Development of an Innovative Proteomic Strategy for Typing Amyloid Deposits ..... 133 
4.3.1 Materials and Methods .......................................................................................... 133 
4.3.2 Results and Discussion .......................................................................................... 135 
4.3.3 Conclusions ........................................................................................................... 143 
4.4 References .................................................................................................................... 145 
5 PhD Course Activity Summary ........................................................................................... 149 
 
 
 ix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intentionally left blank. 
 
ABBREVIATIONS 
x 
Abbreviations 
Acronym Meaning 
IAM Iodoacetoamide 
ICP-MS Inductively coupled plasma mass 
spectrometry 
IP  Immunoprecipitation 
IT Ion trap 
JNK c-Jun N-terminal kinase 
LC  Liquid Chromatography 
LSD  Lysosomal Storage Diseases 
M6P Mannose-6-phosphate  
MALDI  Matrix Assisted Laser Desorption 
Ionization 
MAPK mitogen-activated protein kinase  
MBD Metal Binding Domains  
MPR  Mannose-6-phosphate receptor 
MS  Mass Spectrometry 
MS/MS  Tandem Mass Spectrometry  
MSD  Multiple Sulfatase Deficiency  
MVB  Multi Vescicular endosome/Bodies 
MW Molecular weight  
NB-DNJ  N-butyldeoxynojirimycin 
nLC  nanoflow Cromatography Liquid 
PAGE  PoliAcrylamide Gel Electrophoresis 
PBS Phosphate buffer saline 
PC Pre-cleaning 
PCT  Pharmacological Chaperone Therapy  
PD Pompe diseasee 
PM Plasma membrane 
Q Quadrupole 
rhGAA  Recombinant Enzyme GAA 
ROS reactive oxygen species  
SDC Sodium deoxycholate  
SDS  Sodium dodecylsulfate 
SRT  Substrate Reduction Therapy  
TEMED  Tetramethylethylenediamine 
 
 
Acronym Meaning 
ACN  Acetonitrile 
AL Immunoglobulin light chain 
amyloidosis 
AMBIC  Ammonium Bicarbonate 
ApoAI Apolipoprotein AI 
APS  Ammonium Persulphate 
BCS Bathocuproine disulfonate 
BSA  Bovine Serum Albumin  
CFTR Cystic fibrosis transmembrane 
conductance regulator 
CHO  Chinese Hamster Ovary 
CI-MPR  Cation independent-mannose-6-
phosphate receptor  
CID  Collision Induced Dissociation 
Co-IP Co-immunoprecipitation  
CP Ceruloplasmin 
DDA  Data Dependent Acquisition 
DTT  D,L- Dithiothreitol 
EDTA  Acido EtilenDiamminTetraacetico 
ER  Endoplasmic Reticulum 
ERAD ER-associated protein degradation  
ERK Extracellular signal-regulated kinase 
ERT  Enzyme Replacement Therapy  
ESI  Electrospray Ionization 
FTICR Fourier transform ion cyclotron 
resonance 
GAA  Acid alpha-glucosidase 
GlcNAc  N-Acetilglucosammine 
GO Gene ontology 
GT  Gene Therapy 
HDL High density lipoproteins  
HPLC  High Performance Liquid 
Chromatography 
HSCT  Hematopoietic Stem Cell 
Transplantation 
ABBREVIATIONS 
xi 
 
 
 
 
 
 
 
Acronym Meaning 
TFA  Trifluoroacetic acid  
TGN Trans-Golgi Network 
TGS Tris-Glicine-SDS 
TOF Time Of Flight  
TTR Transthyretin 
UPR Unfolded Protein Response  
WD Wilson disease 
WT Wild type 
SUMMARY 
Page 1 of 152 
Summary 
The cellular protein traffic and the molecular mechanisms involved in the transport of each 
individual protein towards a specific destination are crucial events for cell physiology. The 2013 
Nobel Prize in Physiology or Medicine honoured three scientists: Dr. Rothman, Dr. Schekman and 
Dr. Südhof, who have solved the mystery of how the cell organizes its complex transport system. 
They demonstrated that mechanisms employed by a cell to accomplish vesicle transport and fusion 
are independent by cell type, and are the same in all eukaryotic organisms. The description of the 
machinery regulating vesicle traffic, the major transport system in cells, represented a shift in our 
understanding of how the eukaryotic cell, characterised by a complex internal 
compartmentalization, organizes the routing of molecules and proteins to various intracellular 
destinations, as well as to the outside of the cell. The protein traffic plays a very critical role for a 
variety of physiological processes in which vesicle fusion and molecules delivery must be strictly 
controlled, such as during hormones and/ or cytokines release. In absence of this wonderful and 
precise organization, the cell would lapse into chaos. Defective vesicle transport leads to the 
development of a variety of neurological and immunological disorders, as well as in chronic 
pathologies, such as the diabetes. Many of these disorders occur in presence of mutation at level 
of different genes, that often give rise to proteins still catalytically active, but not able to reach the 
right cell compartment where operate, leading often to the pathological accumulation of metabolite 
over a toxic threshold. The comprehension at the molecular level how the protein trafficking 
process occurs in vivo and how it is impaired in pathological conditions might lead to the 
identification of new targets for therapeutic treatments.  
In this perspective, my PhD project was focused on the investigation of molecular mechanisms 
involved in traffic processes of several proteins associated to genetic diseases when they are 
mutated. These investigations have been carried out basically by using functional proteomic 
approaches. The role that a specific protein plays in intra- and extra-cellular processes is clarified 
by the identification of its molecular partners. Indeed, the association of an individual protein, 
whose its function is unknown, with protein complexes involved in well definite cellular processes 
would be strongly suggestive of its biological function. A classical functional proteomics approach 
consists of isolation of protein complexes involving the target protein (bait) from a cell lysate by 
immunoprecipitation. Proteins so purified were then fractionated by SDS-PAGE, digested in situ 
with trypsin and identified by nano-LC-MS/MS methodologies integrated with protein database 
search. 
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In this PhD thesis, the above strategy was employed in the investigation of molecular mechanisms 
impaired in two rare genetic disorders: Wilson and Pompe disease. 
Wilson disease, described in Chapter 2, is a disorder characterised by defective copper excretion, 
due to mutations in copper transporter ATP7B. In normal conditions, ATP7B binds Cu in the trans-
Golgi network and moves to the plasma membrane where delivery the Cu in bile channels. 
Although the most frequent ATP7B mutants, such as ATP7B(H1069Q), potentially are able to 
bind Cu, they cannot reach the plasma membrane where the excess of Cu has to be removed. In 
order to evaluate which molecular pathways result altered by expression of ATP7B mutants, a 
comparison between the interactomes of the wild type protein and the mutant ATP7B(H1069Q) 
was performed by functional proteomics approach. 
Pompe disease, discussed in Chapter 3, is a rare disorder of glycogen metabolism caused by 
mutations in gene encoding GAA, essential enzyme for the degradation of glycogen to glucose in 
lysosomes. Although the biochemistry GAA activity and genetic basis of the associated disorder 
are well characterized, the routes followed by wild type GAA to reach lysosomes and impaired in 
presence of mutants are still unclear. This work was focused on the investigation of the 
intracellular pathways controlling GAA traffic by the identification of protein partners associated 
to the enzyme on the route from ER to lysosomes. Similarly, the uptake pathway of recombinant 
GAA (rhGAA), used in Enzyme Replacement Therapy (ERT), was also studied in order to define 
the fate of recombinant protein once got into the cell. 
In Chapter 4, the investigation of molecular mechanisms impaired in amyloidosis has been 
described. Amyloidosis diseases are associated to the formation of protein aggregates at level of 
different organs, often associated to the presence of genetic variants of secreted proteins. The study 
concerning amyloidosis has been carried out by using a double approach: the conformational 
characterization of some amyloidogenic ApoAI variants was investigated in vitro by a strategy 
based on complementary proteolysis coupled with mass spectrometry (LC-MS). This methodology 
allowed clarifying the effect of single point mutations on the protein folding and stability thus to 
make hypothesis on the structural basis of amyloidosis as protein misfolding/mistrafficking 
diseases. Moreover a new proteomic strategy for typing amyloid deposits was developed during 
the period spent abroad at Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase 
Proteins, Division of Medicine, University College London (Royal Free Campus), London, UK.  
Diagnosis and treatment of systemic amyloidosis depends on the correct identification of the 
amyloid protein triggering the formation of aggregates. In fact, a precise identification of the 
amyloid fibril protein is essential for the definition of an appropriate therapy. In this field, the 
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proteomic analysis of amyloid deposits provides a chemical characterization of fibrillar 
constituents, which add important details to genetic sequencing and immunohistochemistry 
analysis. However, there are ambiguous cases, in which more than one potentially amyloidogenic 
protein is found within the patient’s biopsy and an accurate diagnosis becomes challenging. The 
work was aimed at the development of a methodology based on decellularization of human fat 
biopsies, tryptic digestion and mass spectrometry analysis (LC-MS/MS) in order to eliminate 
background contamination and improve the specificity of amyloid typing. The use of deoxycholate 
detergent and the shaking of fat biopsy in tissue lyser resulted fundamental in decellularization 
procedure. The innovative strategy of decellularization proved to be a simple way to improve the 
accuracy and specificity of proteomic identification of amyloid fibril type removing most of 
cellular and plasma proteins background from tissue without altering properties of amyloid fibrils. 
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1 Chapter 1 – Introduction 
1.1 Transport Machinery 
Eukaryotic cells differ from prokaryotic cells by their more complex intracellular organization. In 
eukaryotes, specific cellular functions are compartmentalized into organelles surrounded by 
intracellular membranes. This compartmentalization is essential because improves the efficiency 
of many cellular functions and prevents potentially dangerous molecules from roaming freely 
within the cell [1]. 
In eukaryotes, an amount of signals, sorting constituents and energy are required in order to 
translocate efficiently the proteins into the endoplasmic reticulum (ER), the nucleus, mitochondria, 
peroxisomes, or to sort precisely vesicles between the membranes of the ER, Golgi, lysosomes, 
endosomes, autophagosomes, and plasma membrane (PM) (Figure 1.1). 
 
Figure 1.1: Schematic representation of intracellular protein trafficking. The distribution of proteins in eukaryotic 
cells relies on the translocation of proteins across membranes (A–E) and the dynamics of membrane structures, 
particularly the coordinated exchange of vesicles (F–P). 
Along the secretory pathway, proteins are transported from the ER via the Golgi to lysosomes, 
endosomes, plasma membrane or to the extracellular space (Figure 1.1: G-M). On the other hand, 
the endocytic route mediates the uptake of peptides, proteins, fluids, and nutrients from the 
extracellular space (Figure 1.1: N-O). Moreover, the retrograde transport is critical for the 
recycling of components of the transport machinery [2]. 
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Most of transport steps occur via vesicles, which work as specialized transport carriers that shield 
their content form the cytoplasm. In general, intracellular vesicle transport occurs through budding 
from a membrane, docking and fusing with a target membrane of another organelle releasing its 
contents (Figure 1.2).  
 
Figure 1.2: Schematic representation about vesicles transport and fusion in cell. 
Following their release from the donor membrane, vesicles can interact with motor proteins, which 
hook them to the microtubules. Their transport on tracks of the cytoskeleton is critical for long-
range transport such as from the ER to the Golgi and subsequently to the plasma membrane in 
mammalian cells like fibroblasts, and is further extremely critical along axons and dendrites of 
neurons during the release of neurotransmitters. 
In addition to vesicular transport system, in eukaryotic cell several other transport system are 
active: for instance, the unfolded protein translocation occurs through a process that often depends 
on the chaperones activity. These proteins are involved in a plethora of processes including the 
folding of newly synthesized proteins, the refolding of misfolded and aggregated proteins, the 
transport of proteins across membranes, the transport of substrates to the proteasome, in particular 
of proteins that are misfolded in the ER and are retro-translocated to the cytosol for degradation 
[3]. 
In general, the specificity in the delivery of molecular cargo is essential for cell function and 
survival. It is required for several cellular processes, such as the release of neurotransmitters into 
the presynaptic region of a nerve cell to transmit a signal to a neighbouring nerve cell or for the 
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hormones export such as insulin to the cell surface. In order to ensure specific delivery of 
molecular cargo within and/or outside the cells, the molecular mechanisms must be strongly 
controlled, also in the time and the space: proteins or other molecules must be delivered to the 
specific place at the right time. [4]. How does the transport of proteins and other biomolecules 
occur with crucial specificity? 
1.1.1 Traffic Control System Within/Outside the Cells 
The 2013 Nobel Prize in Physiology or Medicine honoured three scientists: Dr. Rothman, Dr. 
Schekman and Dr. Südhof, who have solved the mystery of how the cell organizes its complex 
transport system. They demonstrated that mechanisms employed by a cell to accomplish vesicle 
transport and fusion are independent by cell type, and they are the same in human as well as in 
yeast organisms. Dr. Schekman used yeast genetics to identify a set of genes critical for vesicular 
trafficking, showing that these genes are essential for life and regulate different aspects of vesicle 
transport. Dr. Rothman identified proteins on the vesicle and target membranes that form a 
functional complex controlling cell fusion at specific destination.  
Dr. Südhof was interested how vesicle fusion machinery was controlled. He unravelled the 
mechanism by which calcium ions trigger release of neurotransmitters, and identified key 
regulatory components in the vesicle fusion machinery (Figure 1.3). 
The discovery of three scientists about the machinery regulating vesicle traffic, the major transport 
system in cells, represented a paradigm shift in our understanding of how the eukaryotic cell, 
through its complex internal compartmentalization, organizes the routing of molecules and 
proteins packaged in vesicles to various intracellular destinations, as well as to the outside of the 
cell [4][5]. 
 
Figure 1.3: The discovery of three scientists:  identification of the trafficking machinery regulating vesicle traffic, the 
major transport system in cells. 
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1.1.2 Protein Trafficking Defects in Human Disease 
The protein traffic plays a critical role for a variety of physiological processes in which vesicle 
transport and fusion must be strictly controlled. In absence of this precise and well working 
transport system, every cell drops in chaotic condition leading often to the accumulation of 
metabolite over a toxic threshold and consequently leading to the development of several 
disorders. Many of these diseases occur in presence of genetic mutations that give rise to defective 
proteins whose functions in the traffic and / or transport are partially or completely impaired 
(Figure 1.4). 
 
Figure 1.4: Schematic representation of normal and impaired transport system in cell. 
Genetic mutations may often cause protein misfolding with consequently retention in the 
endoplasmic reticulum, followed by degradation; furthermore, aberrant folding behaviour or other 
alterations, such as misfolded proteins or proteins with defective post translational modification, 
like an abnormal glycosylation, might result in the failure of a protein to be correctly trafficked. 
In presence of misfolded proteins, endoplasmic reticulum employs two distinct mechanisms 
responding to this phenomenon: the first is an ER-dedicated stress response termed the unfolded 
protein response (UPR), which acts to remodel the ER so as to increase its folding capacity [6]. 
The second, termed ER-associated degradation (ERAD), specifically recognizes terminally 
misfolded proteins and retrotranslocates them across the ER membrane into the cytosol, where 
they can be degraded by the ubiquitin-proteasome degradation machinery [7]. These two systems 
are intimately linked: UPR induction increases ERAD capacity, loss of ERAD leads to constitutive 
UPR induction, and simultaneous loss of ERAD and the UPR greatly decreases cell viability. 
Ubiquitin-proteasome degradation machinery is normally sufficient to prevent the accumulation 
of misfolded proteins, but under certain pathological conditions, the system of intracellular quality 
control appears to be incapable of recognizing and removing dangerous misfolded proteins. Thus, 
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proteins aggregate and/or interact inappropriately with other cellular components leading to 
impairment of cell viability and eventually to cell death [8]. 
Many disorders are known as misfolding or conformational diseases, in which peptides or proteins 
fail to fold and then aggregate giving arise to intracellular aggregates or extracellular amyloid 
deposits. Misfolded proteins which are not degradated by proteosome can be transported to 
extracellular space. This pathological protein traffic leads to the accumulation of toxic amyloidosis 
fibrils outside the cell. 
Misfolding diseases include a range of sporadic, familial or transmissible degenerative diseases, 
some of which affect the brain and the central nervous system, such as Alzheimer’s disease. Others 
pathologies, such as systemic amyloidoses and type II diabetes, involve peripheral tissues and 
organs like liver, heart and spleen, etc. [9][10]. 
Further examples of disorders caused by protein misfolding and/or mistrafficking are: Wilson 
disease, an inherited disorder of copper metabolism, associated to the presence of ATP7B 
pathological variants that lead to an accumulation of intracellular copper [11]; Pompe disease, a 
metabolic disorder caused by mutations in genes encoding GAA hydrolase, involved in 
degradation of glycogen in lysosomes; the malfunction of GAA causes glycogen accumulation in 
many tissues and organs [12]. Cystic fibrosis, a disease caused by mutations in CF transmembrane 
conductance regulator (CFTR). The most frequent mutation (F508del-CFTR) destabilises native 
protein conformation thus to trigger intracellular degradation of the protein. Therefore, mutated 
protein is not able to reach plasma membrane with a consequent deregulation of chloride 
homeostasis, and tissue damages, mostly at level of lungs, which become very vulnerable to 
bacterial infections which at long term, may eventually lead to death [13]. 
The comprehension at the molecular level how the protein trafficking process occurs in vivo and 
how it is impaired in pathological conditions might lead to the identification of new targets for 
therapeutic treatments. An accurate definition of the protein network involved in traffic processes 
can be pursued by functional proteomic approaches. 
 
CHAPTER 1 – INTRODUCTION – PROTEOMICS 
Page 10 of 152 
1.2 Proteomics 
The term "proteome" was first coined at the end of the last century to denote the set of all proteins 
expressed by a genome of an organism in a precise biological context and time. Proteomics is the 
science focused on the systematic analysis of all the proteins of a proteome, from total cell extracts, 
tissue extracts or whole organisms, which are analysed at the same time and within their biological 
context. 
Since it is now known the complete sequence of the genome of various organisms, including the 
human one, the number of proteins whose function is unknown has grown exponentially in recent 
times. This gave rise to the need to consider the knowledge of the human genome as a starting 
point, and not the end, for the understanding of the cellular processes [14].  
The complexity of the proteome derives not only from the high number of components that 
constitute it, but also by its extreme variability, as it may differ from individual to individual and 
for a certain organism may change over time, in response to changes of the external environment 
or in signals arriving to the cell. Another characteristic of the proteome is its wide dynamic range 
of concentration: therefore few protein species are present in a large amount while a higher number 
of species in a very small quantity.  
The investigation in proteomics field can essentially be divided into two main areas: the expression 
and functional proteomics. The first approach is focused on the qualitative and quantitative 
evaluation of the increase and / or decrease in protein expression levels following the change of 
experimental conditions, such as cellular stress, the presence of diseases, drugs treatments, etc. 
[15]. Functional proteomics aims to define the biological function of proteins whose role is not 
known yet by identifying protein-protein interactions in vivo, for the description at the molecular 
level of cellular mechanisms [16]. 
1.2.1 Functional Proteomics 
The ability of any organism to survive depends on several complex cellular mechanisms that fulfill 
all of the functions needed for cell life. In addition, the cells are able to change the patterns of gene 
expression in response to signals extra- and intra-cellular in order to ensure that the correct amount 
of the appropriate subset of genes are expressed at the right time [17][18]. 
In the past, cellular mechanisms and signal transduction were considered to occur as a set of 
isolated processes where biological functions took place one after the other in a time-dependent 
fashion. The interactions involved in biological processes were first characterized individually, but 
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this approach suffered from a lack of information about time, space, and context in which the 
interactions occur in vivo. 
Nowadays, it is well known that the biological mechanisms are pursued by a wide number of 
proteins gathering together to transiently form large functional complexes [19] or cell pathways 
[20]. Proteins inside the cell do not interact randomly, but protein associations need precise 
regulation. Protein complexes are involved in a continuous dynamic of association-dissociation 
events, in which two variables are very important: the time in which the proteins are associated to 
preside to a specific process, and the space, the place in the cell where this association occurs. 
Once their functions carried out, these complexes dissociate to form individual components free 
to associate with other complexes to perform different activities. In addition, several mechanisms 
and many signaling pathways are able to interact with each other thus to form an intricate network 
that integrates simultaneously extracellular and intracellular signals. These dynamic processes are 
the molecular networks through which signaling information flows within the cell [21][22]. 
A complete description of the intricate signal transcription and transduction pathway and the use 
of network to predict the full range of cellular behaviors are the main goals of systems biology 
[23][24]. A crucial role in the biological sciences contemporary and future can be played by 
functional proteomics, an area in proteomics research addressing the elucidation of protein 
functions and the definition cellular mechanisms at the molecular level [25][26]. 
A comprehensive description of cellular processes at the molecular level is strictly dependent on 
a clear definition of the individual protein components involved in these functional entities. The 
association of a protein, whose function is unknown, with partners belonging to a specific complex 
of proteins involved in particular cellular mechanisms may be strongly indicative of its biological 
function [27][28]. In addition, a detailed description of cellular signaling pathways might greatly 
benefit from the elucidation of protein-protein interactions in vivo. 
1.2.2 Protein-Protein Interaction in Human Disease 
“Life is a relationship between molecules, not a property of any one molecule. So is therefore 
disease which endangers the life” wrote Zuckerkandl and Pauling (1962) in their chapter on 
Molecular disease, evolution and genic heterogeneity. After more than 50 years we are still quite 
far from understanding the molecular mechanisms of most disease and the molecular interactions 
that are established in healthy and diseased organisms [29]. Indeed, many proteins carry out their 
biological function through molecular interactions, which are involved in supramolecular 
assemblies (collagens, elastic fibers, actin filaments), in the building of molecular machines 
(molecular motors, ribosomes, proteasome) and in main biological processes such as immunity 
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(antigen-antibody interaction), metabolism (enzyme-substrate interaction), signaling (interaction 
of messenger molecules, hormones, neurotransmitters with their cognate receptors), and gene 
expression (DNA-protein interactions). The investigation of protein-protein interaction maps 
(interactomes) is crucial to shed light on each protein networks role within the cell and is essential 
to reveal the molecular mechanism of processes that lead to disease. Genetic mutations or 
environmental factors interfere with protein-protein interaction leading to pathology. The kinetics 
of the processes and dynamics of the networks must be considered in order to understand how the 
perturbation of proteins and their interactions lead to the disease. In addition, the specific 
biological context (tissue, stage of disease and response) is also important to consider where the 
protein interaction occurs. At present there is still a gap between the identification of protein 
networks associated with the disease and the complete understanding of the mechanism of the 
disease. We are still far from understanding the etiology of most diseases, but further significant 
advances in technology and experimental field, such as those related to protein interactions, protein 
structure, gene expression, together with computational tools to organize and integrate these data 
will provide a step forward that direction. Since structural studies and the networks investigation 
are complementary approaches, their combination has the potential to be an excellent framework 
for the study of mechanisms impaired in diseases. 
1.2.3 Proteomics Approach for the Study of Protein-Protein Interactions 
For proteomics purposes, entire multiprotein complexes must be isolated and this can be 
accomplished by affinity based-approach or immunoprecipitation (IP) strategies. The latter 
consists in isolation of the protein of interest, also called bait, and its native protein complexes 
from a cellular/tissutal extract containing many thousands of different proteins. This is possible 
using affinity between the bait and an antibody, coupled on a solid substrate (beads), that 
recognizes its antigen. IP procedures essentially fall into two categories: direct 
immunoprecipitation of the endogenous protein bait from cellular extracts or in situ production of 
a tagged form of the bait followed by immunoprecipitation with antitag antibodies. This second 
category is used when there are no antibodies suitable for the protein of interest or when the 
endogenous bait is expressed at too low level. Therefore the protein is trasfected into appropriate 
cell line, in order to be expressed with a small peptide epitope (e.g., FLAG, V5, c-myc), located 
at either N- or C- terminus, thus to not effect protein tertiary structure and biological activity. After 
washing in order to remove unspecific proteins, bait and its partners are eluted in denaturing 
conditions or by competition with a relevant concentration of the free form of the tag peptide. 
Finally, once carried out the immunoprecipitation, protein components are fractionated by sodium 
dodecyl sulfate polyacrilamide gel electrophoresis SDS-PAGE. Protein bands are in situ digested 
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with a specific protease such as trypsin, and the resulting peptide mixtures analyzed by tandem 
mass spectrometry combined with reverse-phase capillary liquid chromatography (nano-LC-
MS/MS), leading to sequence information required for the identification of proteins by database 
search (Figure 1.5). 
 
Figure 1.5: Description of IP strategy and identification of bait interacting proteins  
These approaches usually results in the final identification of a very long list of interactors from a 
single functional proteomics experiment. Since a single protein might be involved in different 
complexes, each endowed with its specific biological function, the attempt to rationalize the list 
of interactors within a biologically significant picture constitutes a major challenge in a functional 
proteomics. Two approaches are normally used to manage these lists: the simplest strategy 
involves the choice of one or few interactors among the various protein candidates on the basis of 
previous data or literature information. The interaction of these proteins with the bait has to be 
confirmed by alternative approaches (such as co-immunoprecipitation and western blot assay) and 
functionally investigated. A second approach aims to assign each protein to a specific functional 
complex by using functional data provided by literature or protein-protein interaction database, 
keeping in mind that each protein might simultaneously belong to different entities since might 
play diverse biological functions. The final purpose of this second approach would be the 
achievement of a global functional overview of the protein bait interactome to be inserted into 
appropriate systems biology studies [16]. 
1.2.4 Proteomics in Clinical Diagnosis 
Several metabolic diseases and genetic abnormalities are known to impair the cellular transcription 
and translation status and thereby creating a variation in proteome [30]. These alterations in 
proteome are an opportunity for development of diagnosis of molecular signatures for several 
diseases and lead to the development of a new area called clinical proteomics [31]. In this regard, 
for example, proteomics analysis is a powerful tool both for the diagnosis and for the investigation 
of molecular mechanisms impaired in amyloidoses, a large class of pathologies associated to 
protein misfolding and aggregation. Proteomics can be useful to elucidate different aspects of these 
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diseases, such as the characterization of amyloidogenic protein precursors in plasma or other 
compartments (with particular attention to post translational modifications); the identification of 
the nature of the fibrillar deposited proteins for disease typing; the investigation of the metabolic 
modifications in amyloid tissues, which lead to cellular toxicity and organ dysfunction; and the 
discovery of new biomarkers useful for the characterization of disease severity and response to 
treatment. In particular, amyloid typing is a key step in the management of amyloidoses, since the 
clinical course, treatment, and prognosis are critically dependent on the amyloid type (assigned on 
the basis of which protein forms the fibrils) [32]. 
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1.3 Mass Spectrometry 
Mass spectrometry (MS) is a powerful analytical methodology used to identify unknown 
compounds, to quantify known compounds, and to elucidate the structure and chemical properties 
of molecules, by generating ions in gas phase and measuring their mass to charge (m/z) ratio, also 
after fragmentation events.  
Every mass spectrometer is composed of three main components: an ionization source, a mass 
analyzer and a detector (Figure 1.6). The ion source converts the sample into ions in gas phase, 
which then move to mass analyzer through an extraction and focusing system of electrostatic lens. 
The mass analyzer resolves the ions by their mass-to-charge ratio (m/z). Finally, the ions sorted 
by mass analyzer move to detector which provides abundances of each ion detected by measuring 
the associated current. 
 
Figure 1.6: Schematic representation of a mass spectrometer. 
Mass spectrometry was restricted for a long time to small, volatile and thermostable compounds 
untill the development, in the late 1980s, of two techniques, the electrospray ionization (ESI) and 
matrix assisted laser desorption/ionization (MALDI), able to generate molecular ions of intact 
biomolecules. These technological innovations dramatically changed the research scenarios made 
peptides and proteins accessible to mass spectrometric analysis. Starting from those years, the 
development of new mass analyzers and complex multistage instruments that would allow proteins 
and proteome analysis has been catalyzed [33]. 
In MALDI ion source, the sample intended for analysis is incorporated into a solid matrix 
containing compounds, such as 3,5-dimethoxy-4- hydroxycinnamic acid (sinapinic acid), which 
absorbs energy at the wavelength of the laser (typically 337 nm). Laser activation of the target by 
UV laser within the ion source leads to the release from the target of peptide/ protein [M+H]+ ions 
into gas phase.  
In contrast to the MALDI, electrospray ionization (ESI) involves the generation of peptide ions 
from aqueous solution. The solution containing the sample passed through a needle subjected to a 
high voltage. The solution stream is ejected from the needle orifice as a spray of droplets. The 
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solvent is eliminated from the droplets by the effect of a heated capillary and/or a desolvatation 
inert gas. Solutions with acidic pH favor protonation of the N-terminus and all basic aminoacid 
side chains, generating multiply-charged molecular-related ions, such as (M+nH)n+. The number 
of charges depends on the chemical-physical characteristics of analytes; thus each analytes could 
assume more than one charge complicating the form assumed by the signal. For this reason this 
source is not useful to analyse complex mixtures except using pre-fractionation systems. In fact 
most uses of ESI-MS are made in combination with chromatographic separation, the so called LC-
MS technique. A great enhancement of ESI ion sources has come from the reduction of the flow 
rate of the liquid used to create the spray to a nano-scale level. The advantages related to the use 
on μLC and nLC are the low consumption of sample and the higher sensitivity of the methods 
because of the increase in the concentration of the analyte as it elutes off the column. 
Once generated gas phase ions, they move to the mass analyzers, which measure the mass-to-
charge (m/z) ratio. Several types of mass analyzers have been developed including quadrupoles 
(Q), ion traps (IT), time-of-flight (TOF) and Fourier transform ion cyclotron resonance (FTICR), 
Orbitrap or combination of these in hybrid instruments, that are commonly use in proteomics 
(Figure 1.7); they differ for their resolution, sensitivity and accuracy and for the types of 
experiments that are able to perform.  
 
Figure 1.7: ESI and MALDI ionization source (upper row); types of mass analysers (lower row: a-f). 
The instrumentations employed to carry out my PhD research projects were equipped with nano 
ESI sources and Ion Trap and/or Orbitrap as analysers.  
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Ion trap (IT) mass analysers are able to trap ions in a three-dimensional electrical field. The ion 
trap consists of a ring electrode and end cap electrodes, capable of analysing, isolating and 
retaining specific ions also for fragmentation upon collision with an inert gas in the same device. 
One end cap electrode usually has a hole in it to allow ions to enter the trap. Ions are injected 
axially and to overcome the exit of the ions, their high kinetic energy is dissipated by cooling them 
collisionally, filling the trap with gas molecules. Ions are dynamically stored in a three-
dimensional quadrupole ion storage device by an electric quadrupole field generated by the applied 
RF voltage. The RF voltage can be scanned to eject successive mass-to-charge ratios from the trap 
to the detector. The discovery of the mass selective instability mode transformed the ion trap from 
a storage device into a powerful instrument capable of sequential ejection of selected or all ions 
out of the trapping cell to a detector. 
Orbitrap mass analyzer was invented by Alexander Makarov. It consists of a spindle-shape central 
electrode surrounded by a pair of bell-shaped outer electrodes. The Orbitrap employs electric fields 
to capture and confine ions. Stable ion trajectories rotate around an axial central electrode with 
harmonic oscillations along it (Figure 1.8). The frequency of these harmonic oscillations along the 
z-axis depends only on the ion mass-to charge ratio m/z. Two split halves of the outer electrode of 
the orbitrap detect the image current produced by the oscillating ions. By Fast Fourier 
Transformation (FFT) of the image current, the instrument obtains the frequencies of these axial 
oscillations and therefore the m/z of the ions. 
 
Figure 1.8: Orbitrap mass analyser 
1.3.1 Tandem Mass Spectrometry 
The power of mass spectrometry can be significantly increased by employing methods of tandem 
mass spectrometry (MS/MS) from which we obtain structural information about a compound by 
fragmenting specific sample ions inside the mass spectrometer and identifying the fragment ions. 
Instruments for tandem mass spectrometry are classified as tandem in space or tandem in time. 
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Tandem in space means that ion selection, ion fragmentation and fragments analysis, are events 
that occur in different regions of the spectrometer, while in tandem in time instruments, the three 
steps of analysis occur in the same region of the spectrometer, but in different times. 
Tandem mass spectrometry uses two stages of mass analysis, the first one to pre-select a precursor 
or parent ion and the second to analyse fragments or daughter ions. These are separated by a 
collision cell into which an inert gas (e.g. nitrogen, argon, and helium) is admitted to collide with 
the selected ions causing the fragmentation. This process is known as Collision Induced 
Dissociation (CID). In elastic collisions between the precursor ion with a high translational energy 
and a neutral target gas cause the conversion of part of the translational energy into internal energy 
of the ion, leading to subsequent decomposition. 
The collisions can break several bonds along the backbone (NH-CαH, CαH-CO and CO-NH) 
originating different fragment ions. Each bond breakage gives rise to two species, one neutral and 
the other one charged, and only the charged species are monitored by the mass spectrometer. Hence 
there are six possible fragment ions for each amino acid residue and these are labelled with the a, 
b, and c ions having the charge retained on the N-terminal fragment, and the x, y and z ions having 
the charge on the C-terminal fragment (Figure 1.9). The most probable fragmentation event occur 
at level of peptide CO-NH bonds, giving rise to the b and the y ion series, characterised by the 
charge retention on the N or C terminus, respectively. 
 
Figure 1.9: Peptides fragmentation scheme. 
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1.4 Protein Identification 
Data obtained by MS/MS spectra provide information about amino acid sequence of peptides, and 
are crucial for univocal protein identification.  
Data provided from an LC-MS/MS analysis, i.e. molecular weight and fragmentation spectra of 
the main abundant ions occurring in the starting mixture, are included in a peak list, entered into 
Mascot software, using the option MS/MS Ion Search and are employed to consult protein 
databases. This software, indeed, by miming the hydrolysis experiment, calculates the expected 
molecular weight of all peptides theoretically generated by each protein present in the database, 
according to protease specificity and possible chemical modifications occurring. An algorithm 
compares the experimental mass values obtained as m/z by MS and MS/MS analyses, with the 
theoretical mass values generated by Mascot on the basis of protein sequences, each match is 
associated to a probability score of identification. The score s is defined as: s= 10*log(P), where 
P is the probability that the coincidence of observed mass values with the theoretical ones is a 
random event; then, lower P value correspond to a higher possibility of identification. Only the 
identifications with a score higher of a score threshold chosen by the software, according to the 
type of mass spectrometer used, its accuracy and resolution and other experimental conditions, 
such as database consulted for the identification, are considerate significant. 
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1.5 Aim of the PhD Thesis 
The protein traffic and the molecular mechanisms involved in the transport of each individual 
protein towards a specific destination are of crucial importance for normal cellular physiology. 
The knowledge of how the protein trafficking processes occur in vivo and how it is impaired in 
pathological conditions might lead to the identification of new therapeutic targets.  
In this perspective, my PhD project is focused on the investigation of molecular mechanisms 
involved in traffic processes both in physiological and in psthological conditions by using 
proteomic approaches. The role that a specific protein plays in intra- and extra-cellular processes 
is clarified by the identification of its molecular partners.  
In addition to proteomics approach, a study of protein conformational stability of amyloidogenic 
protein variants by employing complementary proteolysis approach coupled with mass 
spectrometry (LC-MS), has been performed to clarify the effect of single point mutations in the 
development of protein misfolding/mistrafficking diseases.   
The description of the work has been structured as follows: 
 Chapter 2: The investigation of molecular mechanisms impaired in Wilson disease.
The work was addressed to the study of molecular pathways impaired in Wilson disease comparing 
wild type ATP7B and the mutant ATP7B interactomes. The differences occurred between the two 
set of ATP7B interacting proteins was allowed the identification of new molecular targets for a 
possible therapeutic treatment of Wilson. 
 Chapter 3: The investigation of molecular mechanisms impaired in Pompe disease.
This study was focused on the investigation of the intracellular pathways controlling GAA protein 
traffic in physiological condition and on the internalization process of rhGAA protein in order to 
elucidate the fate of recombinant protein once got into the cell by proteomics approaches. The 
identification of intracellular factors regulating the traffic of GAA protein, involved in Pompe 
disease, might unravel the cell processes impaired in presence of GAA mutant causative of this 
disorder. Moreover, the description of uptake pathway followed by recombinant GAA (rhGAA), 
used in enzyme replacement therapy (ERT) of Pompe disease, has been useful to shed light on 
why only low amount of protein correctly reaching the right destination leading inefficacy ERT in 
numerous cases. 
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 Chapter 4: The investigation of molecular mechanisms impaired in Amyloidosis.
This study was addressed to add knowledge to the molecular mechanisms by which amyloidogenic 
mutations impair Apolipoprotein AI (AApoAI) protein stability and native conformation.  
The last part of research project was focused on the development of new proteomic strategy based 
on decellularization of human fat biopsies coupled with mass spectrometry analysis (LC-MS/MS) 
for a correct typing of amyloid deposits extracted from adipose tissue of patients. Proper amyloid 
typing represents a crucial step in the diagnosis and then in the choice of a specific and 
effectiveness treatment of systemic amyloidosis. 
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2 Chapter 2 – Investigation of Molecular Mechanisms Impaired in 
Wilson Disease 
2.1 Introduction 
2.1.1 The Role of Cu-Transporting ATPases in Copper Homeostasis 
Copper is a micronutrient that plays an essential role in human metabolism. It is a cofactor of key 
metabolic enzymes, which are involved in cellular respiration, neurotransmitter biosynthesis, 
radical detoxification, iron metabolism, and many other physiological processes [1]. Numerous 
dietary foods are rich in copper (shellfish, chocolate, nuts, raw kale, seeds, mushrooms and 
legumes) that is absorbed primarily through the intestinal mucosa and this process is regulated by 
copper intake. In the serum, newly absorbed copper is transported to the liver bound to two 
proteins: albumin and transcuprein. Most of the copper is taken up by the liver, central organ of 
copper homeostasis and is primarily responsible for the export of excess copper out of the body 
(Figure 2.1). In hepatocytes, most of the copper is incorporated into ceruloplasmin in the trans-
Golgi network (TGN), which is then secreted into the blood [2][3]. 
 
Figure 2.1: Scheme of physiology of copper homeostatis. 
In human, copper is in the oxidized Cu(II) form, then it is reduced to Cu(I) by one or more 
metalloreductases upon entry into the cell and reoxidized when exiting the cell [1][4]. 
Although copper is essential for human health, in amounts that exceed cellular needs is highly 
toxic leading to cellular oxidative damage, production of reactive oxygen species (ROS) that can 
have devastating effects, including DNA and RNA damage and oxidation of proteins and lipids 
[2][5]. Therefore, the level of copper in the body must be kept under tight control. The organisms 
have evolved an elaborated network of molecular mechanisms in order to maintain homeostatic 
balance of copper. These mechanisms involve an intricate balance between uptake, distribution 
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and utilization, storage and detoxification, and efflux pathways for copper. The breakdown of these 
mechanisms leads to Cu imbalance that is a crucial factor in the etiology and pathology of several 
neurodegenerative diseases [2]. 
Several proteins, called metallochaperones, are involved in intracellular copper uptake and 
translocation. Copper uptake into cells is mediated by the high-affinity copper transporter Ctr1; 
once internalized, the copper may be delivered by CCS to Cu/Zn-SOD1, or alternatively 
transferred by COX17 within the mitochondrial intermembrane space for metallation and 
assembly of cytochrome C oxidase, or, chaperoned by ATOX1 to the copper-ATPases (Figure 2.2) 
[2]. 
 
Figure 2.2: Schematic representation of intracellular pathways of copper traffic. 
Several physiological processes depend on the proper and timely transport of copper by a family 
of proteins, known as "Copper-transporting P-type ATPases" (Cu-ATPases). ATP7A and ATP7B 
enzymes belong to Cu-ATPases family, and have a key role for the regulation and maintenance of 
homeostatic balance of intracellular copper.  
Cu-ATPases are polytopic membrane proteins that translocate copper from the cytosol across 
cellular membranes using the energy of ATP hydrolysis. This transport process is essential to 
reduce the intracellular copper concentration and to contribute to homeostatic control of copper in 
the body. In addition to their homeostatic function, Cu-ATPases perform important physiological 
functions delivering copper into the secretory pathway where the Cu ion is incorporated into 
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ATP7B protein is a Cu-transporting P-type ATPase, which translocates copper from the cytosol 
across cellular membranes using the energy of ATP hydrolysis. 
The N-terminal domain regulates Cu-ATPase activity and contains six repetitive sequences, each 
harboring the sequence motif GMT/HCxxCxxxIE. Each of these repeats forms a subdomain with 
a single metal binding site CxxC, where the two Cys residues, coordinate copper in the reduced 
Cu(I) form. The total stoichiometry is six copper ions per N-terminal domain. 
By analogy with other P-type ATPases, the catalytic activity of ATP7B is mediated through 
coordinated action of the A-domain, containing conserved TGE motif, essential for enzymatic 
function of P-type ATPases and the ATP-binding domain. The latter consists of two portions: N-
domain and P-domain that includes the site of catalytic phosphorylation and highly conserved 
DKTG motif. D1027 residue in DKTG motif is presumed to be the target of phosphorylation by 
the gamma-phosphate of ATP. Indeed, mutation of this aspartic acid residue in ATP7B completely 
prevents formation of an acylphosphate intermediate during hydrolysis process [1][3]. 
Copper translocation process by P-type ATPases occurs through a general cycling model involving 
several stages in which ATP hydrolysis drives translocation of the Cu(I) ion (Figure 2.4). 
The stages involved in copper translocation are: 
1. Binding of the Cu(I) ion to the MBD  
2. Binding of ATP to the N-domain 
3. After ATP binding to the N-domain, conformational changes take place that bring the 
ATP binding site within the N-domain in close proximity to the P-domain This could 
potentially promote ATP binding, phosphorylation of the P-domain and ADP release. 
4. Translocation of the Cu(I) ion 
5. The translocation stimulates the dephosphorylation of the P-domain mediated by intrinsic 
phosphatase activity, in which the A-domain plays a key role. 
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Figure 2.4: Schematic representation of Cu-ATPase catalytic cycle. 
ATP7B is abundantly expressed in hepatocytes and localises within the trans-Golgi compartment. 
It is involved in cuproenzyme biosynthesis and is essential for homeostatic regulation of cellular 
copper. Under basal copper levels, ATP7B resides at the TGN, where copper is incorporated into 
cuproenzymes such as ceruloplasmin (CP), a ferroxidase that is subsequently secreted into the 
blood. 
In response to elevated copper level, ATP7B binds Cu(I) ions and moves within cytoplasmic 
vesicles from TGN towards canalicular area of hepatocytes. Recent study demonstrated that 
ATP7B reaches lysosomes and imports Cu into their lumen. ATP7B enables lysosomes to undergo 
exocytosis through the interaction with p62 subunit of dynactin that allows lysosome translocation 
toward the canalicular surface of hepatocytes (Figure 2.5). Moreover, the activation of lysosomal 
exocytosis stimulates both the delivery of ATP7B to the canalicular membrane domains and the 
release of excess Cu into the bile indicating that ATP7B-containing lysosomes and lysosomal 
exocytosis have a key role in copper homeostasis [6]. When copper levels decrease, ATP7B is 
endocytosed and cycles back to the TGN [2]. 
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Figure 2.5: ATP7B protein trafficking in hepatocyte. 
The malfunction of the ATP7B protein, correlated to the presence of mutations in the 
corresponding gene, which are often associated with genetic disorders, such as Wilson's disease, 
involves both a homeostatic balance disorder, resulting in accumulation of intracellular copper, 
and dysfunctions at the level of different cuproenzymes. 
2.1.3 Wilson Disease 
Wilson disease (WD) is an autosomal recessive disorder characterised by defective copper 
excretion, with an estimated incidence between 1:30 000 and 1:100 000; worldwide the 
heterozygous carrier rate is approximately 1:100. Almost 300 mutations in ATP7B that are 
associated with WD development have been described. In contrast to Menkes disease, relatively 
few small insertions/deletions and splice site mutations have been identified in patients affected 
by WD; in fact, almost 60% of all identified WD-causing mutations are missense mutations. The 
most prevalent mutations are H1069Q in Europe and North America, and R778L in southeast Asia 
[3]. Several ATP7B mutations, including H1069Q and R778L, result in protein product, which, 
although still functional, remain in the endoplasmic reticulum, presumably because misfolded 
[7][8], or is trapped in cytoplasmic clusters not reaching Cu excretion sites. This mislocalization 
leads to toxic accumulation of copper primarily in the liver of WD patients, but also in other 
organs, such as brain, kidney, cornea. 
Clinical features of WD include hepatic abnormalities (cirrhosis and chronic hepatitis), 
neurological defects (parkinsonian features), and psychiatric symptoms (personality changes, 
depression, psychosis). In some severe cases, patients present fulminant liver failures. A 
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characteristic feature of patients with WD is the Kayser–Fleischer ring, a deposition of copper in 
the Descemet membrane visible as a gold-brown ring around the periphery of the cornea [9]. 
In addition, serum levels of the cuproenzyme ceruloplasmin are often found greatly reduced in 
WD patients as a result of rapid degradation of the copper-free form of ceruloplasmin [3]. 
2.1.4 Treatment of Wilson Disease 
The therapeutic goal in WD patients is to maintain normal copper homeostasis. In most 
circumstances, this can be accomplished with a number of different oral chelating agents, such as 
D-Penicillamine, Trientin, Tetrathiomolybdate. Penicillamine has been shown to effectively 
ameliorate hepatic and neuropsychiatric signs and symptoms in most patients and to prevent the 
onset of disease in asymptomatic individuals. Patients show a rapid and dramatic response within 
the first few months of penicillamine treatment, but poor compliance may result in an acute 
neurological deterioration, presumably secondary to rapid changes in copper distribution with the 
central nervous system. The measurement of urinary copper excretion can be a useful sign of initial 
response to the treatment. Although it is effective, penicillamine is toxic, gives hypersensitivity 
reactions, might induce bone marrow suppression and the development of autoimmune disease, 
and patients must be monitored during treatment. 
Trientine and tetrathiomolybdate are alternative drugs with distinct mechanisms of action that may 
be also used with similar effectiveness. 
Dietary restriction is reasonable suggested to patients that they avoid foods with an abundance of 
copper (shellfish, chocolate, nuts, and legumes).  
In general, these treatment options are very effective; however, if treatment is ineffective, or in 
circumstances of fulminant liver failure, liver transplantation remains the only cure [9]. 
2.1.5 Aim of the Project 
Although the most frequent ATP7B mutants potentially are able to transport Cu, they cannot reach 
the Cu excretion sites to remove excess Cu from hepatocytes. ER retention of ATP7B mutants, 
such as ATP7B(H1069Q), occurs because the mutation destabilizes the native structure which is 
recognized as defective and directed toward the ER-associated protein degradation (ERAD) 
pathway.  
This project, carried out in collaboration with the research group of Dr. Roman Polishchuk of 
TIGEM (Telethon Institute of Genetics and Medicine), was focused on the investigation of 
molecular mechanisms impaired in Wilson disease (WD). In order to evaluate which molecular 
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pathways result altered by expression of ATP7B mutants, a comparison between the interactomes 
of the wild type protein and the mutant ATP7B(H1069Q) was performed by functional proteomic 
approach. This latter lead to the identification of molecular pathways crucial for the recovery of 
partially or fully active ATP7B(H1069Q) mutant from the ER to the appropriate functional 
compartment(s). These pathways would be also targets for drugs in new therapies applicable for 
the majority of Wilson disease patients. 
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2.2 Materials and Methods 
2.2.1 Materials 
All chemicals for electrophoresis, 30% Acrylamide Bis-acrylamide solution, 
Tetramethylethylenediamine (TEMED), sodium dodecylsulfate (SDS), Ammonium Persulphate 
(APS), Tris-Glicine-SDS (TGS), Tris-HCl and the mixture of protein standards of known 
molecular weight (total blue) were from BIO-RAD. 
In addition, Triton X-100, “BioRad Protein Assay” kit and bovine serum albumine (BSA) used in 
Bradford assay were purchased from BIO-RAD. 
Protease inhibitors (Complete mini EDTA-free) were ROCHE. 
The Colloidal Coomassie Blue Brilliant was PIERCE. 
Beads for pre-cleaning and immunoprecipitation (Sepharose Protein-A), dithiothreitol (DTT), 
trypsin, sodium chloride (NaCl), ethylenediaminetetraacetic acid (EDTA), glycerol, NP-40 
detergent, trifluoroacetic acid (TFA) and acetonitrile (ACN) LC-MS Grade were SIGMA-
ALDRICH products. 
The iodoacetoamide (IAM) and ammonium bicarbonate (AMBIC) were from FLUKA. Formic 
acid (HCOOH) and acetonitrile HPLC Grade were Baker products. 
The antibodies anti-GFP and the HepG2 transfected cells were provided by our collaborators of 
TIGEM. 
2.2.2 Methods 
2.2.2.1 Cell Lysis and Protein Quantification 
Protein extracts were prepared starting from HepG2 cells grown in presence of 100μM CuSO4 and 
infected with GFP-ATP7B(WT), GFP-ATP7B(H1069Q) and GFP. This latter constitutes the 
control. 
Lysis buffer composition was: 
 20mM Tris HCl pH=8 
 150mM NaCl  
 1mM EDTA pH=8 
 10% glycerol 
 0.5% NP-40  
 0.5% Triton X-100 
 1 mini pill of protease inhibitor for 10 mL of lysis buffer 
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A ratio of 1:5 (v/v) pellet/buffer was used for lysis of each cell pellet. After buffer addition, pellets 
were left for 10 minutes in ice, and successively shacked and agitated on the wheel at 4°C for 30 
minutes. Finally, the suspensions were centrifuged for 15 minutes at 13200 rpm in order to separate 
protein extracts from debris.  
Bradford assays were carried out for a quantitative evaluation of protein extracts. Bovine serum 
albumin (BSA) was used as standard for the calibration curve construction, obtained by reporting 
the absorbance measurements at 595 nm in function of concentrations of BSA standard solutions. 
The total protein concentrations defined by Bradford protein assay are reported in Table 2.1. 
Table 2.1: Total protein concentration from Bradford assay. 
 
 
Total protein concentration 
HepG2 expressing GFP-ATP7B(WT) 10.6 μg/μL, (11.8mg total protein) 
HepG2 expressing GFP -ATP7B(H1069Q) 8 μg/μL, (8.8mg total protein) 
HepG2 expressing empty-GFP (control) 9.7 μg/μL, (10.7mg total protein) 
2.2.2.2 Isolation of Protein Complexes by Immunoprecipitation 
7 mg of protein extract from each HepG2 protein pellet were subjected to the immunoprecipitation 
procedure. As first step, every cell extract was pre-cleared in order to remove unspecific proteins 
adsorbed on beads by incubating protein extracts with Sepharose beads Protein-A (20μL of slurry 
resin per mg of protein extract), previously conditioned in lysis buffer, for 3h at 4°C on the wheel.  
Pre-cleaned extracts were then incubated with specific anti-GFP antibody (policlonal mouse) (2.5 
μg of antibody per mg of protein extract), over-night at 4°C on the wheel. 
Finally, the samples were transferred in new tubes and incubated with beads Protein-A (40µL of 
slurry resin per mg of protein extract) for 4h at 4°C under gently agitation on the wheel in order to 
capture antigen-antibody complexes. The unbound proteins were then removed, and the beads 
were repetitively washed with lysis buffer containing either low (150mM) or high (300mM) NaCl 
concentrations, in order to remove unspecific proteins. Proteins retained were eluted by using 
Laemli Buffer (100mM Tris HCl pH=6.8, 4% SDS, 20% glycerol, bromophenol blue) for 10 min 
at 99°C in thermomixer. 
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2.2.2.3 Preparative SDS-PAGE 
100mM DTT (dithiothreitol) was added to each samples following 10 minutes of boiling at 99°C. 
Sample and control eluates were loaded on a 16x16 cm, polyacrylamide gel gradient 6%-15% 
SDS-PAGE fractionation. The electrophoretic run was performed at initial voltage of 200 V. 
The gel was stained by Colloidal Blue Comassie over-night and the excess of dye was removed 
by extensive washing with deionized water. 
2.2.2.4 Hydrolysis in situ 
After electrophoresis and staining, the whole lanes were cute in several bands by scalpel, chopped 
and placed in tubes. The bands were bleached by ACN, removed following agitation with vortex 
and fast centrifugation; then, 50μl of NH4HCO3 (AMBIC) 50mM, pH 8 was added and left few 
minutes for the gel pieces rehydration. These alternative washings were repeated until the complete 
destaining of gel bands. 
Protein bands were treated with 60μL of 10mM DTT in 50mM NH4HCO3, for 45 min at 56°C to 
reduce cysteine residues. At the end of the reduction, the bands were first dehydrated with ACN 
and then rehydrated with 60μL 50mM NH4HCO3, containing 55mM iodoacetamide for the 
alkylation reaction. This latter was carried out in the dark at room temperature for 30 minutes. The 
excess of reagent was finally removed by washing with ACN 50mM/NH4HCO3 as previously 
described. 
The dehydrated gel bands were then treated with 10μL of 10ng/μL trypsin solution in 50mM 
NH4HCO3 pH=8 at 4°C, for 1h. Finally, a supplemental volume of 50mM NH4HCO3 was added 
to cover the gel bands and samples were placed over-night at 37°C. 
At the end of hydrolysis, samples were centrifuged at 13200 rpm for few seconds and the 
supernatants were collected and placed in tube. Each sample was acidified by 20% trifluoroacetic 
acid. Then the remaining gel pieces were shrunk with 50μL of acetonitrile, in order to extract any 
peptides still present in the gel. The extracts were joined to the respective supernatants, previously 
removed. A second extraction was performed adding 20μL of HCOOH 0,2% followed by ACN to 
gel bands and the surnatants recovered and joined to respective peptide mixtures. The obtained 
mixtures were dried by a Speed-Vac system. 
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2.2.2.5 LC-MS/MS Analysis 
Each peptide mixture was re-suspended in 10μL of 0.2% HCOOH, and analyzed by nano-
chromatography tandem mass spectrometry (MS/MS) on a CHIP MS Ion Trap XCT Ultra (Agilent 
Technologies, Palo Alto, CA). 
After loading, the peptide mixture was first concentrated and desalinated in the reverse-phase pre-
column working at a flow rate of 4L/min with 0.1% formic acid as eluent. Each peptide sample 
was then fractionated on a C18 reverse-phase capillary column (C18 EasyColumn ID=75 m, 
L=43 mm, Agilent Technologies) working at a flow rate of 200nL/min, with a gradient of eluent 
B (0,2% formic acid, 95% acetonitrile LC-MS Grade) and eluent A (0,2% formic acid, 2% 
acetonitrile LC-MS Grade) from 5 to 60% in 50 mins.  
Peptide analysis was performed using data-dependent acquisition (DDA) of one MS scan (mass 
range from 400 to 2000 m/z) followed by MS/MS scans of the three most abundant ions in each 
MS scan, obtained by CID (Collision Induced Fragmentation) fragmentation in the ion trap. 
2.2.2.6 Proteins Identification 
Raw data from nano-LC-MS/MS analyses were processed and converted in .mgf files to be 
introduced into the MASCOT software (Matrix Science Boston, USA) to search a non-redundant 
protein database. Both peptide mass data and the data obtained by fragmentation spectra were 
included in the peak list for protein identification. 
The research was done by setting the following parameters: 
 Database: NCBI 
 Taxonomy: Homo sapiens 
 Enzyme: Trypsin 
 Fixed modification: carbamidomethyl (C) 
 Variable modification: oxidation (M), pyro-Glu (N-term Q),   pyrocarbamidomethyl 
(N-term C) 
 Peptide tolerance: 600 ppm 
 MS/MS tolerance: ± 0,6 Da 
 Ions charge: +2, +3 
 Instrument: ESI-TRAP 
It has also been used the software ExPASy Blast Form to assign to each protein a code that 
uniquely identify each sequence in the annotated database UniProt KB.
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2.3 Results 
The investigation of molecular mechanism involving ATP7B(WT) and ATP7B(H1069Q) protein 
trafficking was carried out by the identification of protein partners interacting with both GFP 
tagged proteins expressed in HepG2 cells.  
HepG2 cells expressing GFP-ATP7B(WT), GFP-ATP7B(H1069Q) and GFP (control) were 
lysated as reported in Methods paragraph 2.2.2.1 and 7 mg of each protein extract 
immunoprecipited as reported in 2.2.2.2 section. 
Proteins specifically retained by ATP7B-GFP proteins or by GFP (control) were eluted in 
denaturing conditions and individual proteins were fractionated by SDS-PAGE. 30 Protein bands 
were excised from the gel (Figure 2.6), digested in situ with trypsin and the resulting peptide 
mixtures were directly analyzed by nano-chromatography tandem mass spectrometry (MS/MS) on 
a CHIP MS Ion Trap XCT Ultra (Agilent Technologies, Palo Alto, CA). 
Since the samples were fractionated by one-dimensional electrophoresis, a low-resolution 
technique, each band might contain more than one protein. Therefore, the identification of all 
proteins required the employment of tandem mass spectrometry associated with reverse phase 
liquid chromatography (nanoLC-MS/MS) methodologies for the analyses of complex peptide 
mixtures as those obtained by in situ hydrolysis of each band. 
The data obtained by mass spectrometry analyses, which included both the m/z ratios of intact 
peptides and the correspondent ions (peak lists), were inserted in the MS/MS Ion Search option of 
Mascot software, leading to proteins identification. 
Unambiguous protein identification is achieved by a large number of peptides, with scores 
exceeding the minimum confidence threshold suggested by Mascot, that allows a high percentage 
of sequence coverage. The peptide scores are determined by the quality of the fragmentation 
spectra in terms of signal/ noise ratio, the accuracy of the m/z values and consequently by the 
number of signals that could be assigned to the expected amino acid sequences present in the 
databases, and, finally, the size of the database in which the search is performed. 
The databases used for the ATP7B interacting protein identification was NCBI, which has the 
advantage to be continuously updated, although suffers from redundancy problems. Once 
identified, all proteins have been associated to UniProt database code. 
The lists of ATP7B(WT) and ATP7B(H1069Q) putative interactors (Table 2.2) were obtained by 
subtracting the proteins identified in the control (IP GFP) to those identified in IP ATP7B(WT) 
and ATP7B(H1069Q) samples. For each protein, the molecular weight, the total number of 
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identified peptides (in parentheses those with a score higher than the reliability threshold defined 
by Mascot), the UniProt code, the gene name, keywords for GO Biological process are also 
reported. 
 
Figure 2.6: SDS-PAGE of the immunoprecipitated samples from HepG2 cells expressing 1. GFP-ATP7B(WT), 2. 
GFP-ATP7B(H1069Q) and 3. GFP (control). M represents a mixture of known molecular weight proteins used as 
standards. 
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Table 2.2: Putative ATP7B(WT) and ATP7B(H1069Q) protein partners. Protein name, gene name, number of 
peptides in both experiments, in parenthesis those with scores above the threshold UniProt code and GO Biological 
Process are reported. 
MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
>250 
Cation-independent 
mannose-6-phosphate 
receptor 
IGF2R 2(1) - P11717 
Signal 
transduction 
Myosin-10 MYH10 27(11) 37(11) P35580 
Actin 
filament-
based 
movement 
Myosin-14 MYH14 5(1) 8(1) Q7Z406 
Actin 
filament-
based 
movement 
Copper-transporting 
ATPase 2 
ATP7B 35(21) 27(14) P35670 
Cellular 
copper ion 
homeostasis 
Eukaryotic translation 
initiation factor 3 subunit 
A 
EIF3A 8(2) 6(2) Q14152 Translation 
150-100 
Tight junction protein 
ZO-2 
TJP2 8(5) 12(4) Q9UDY2 
Hippo 
signaling 
Vigilin HDLBP 7(2) 9(5) Q00341 
Lipid 
transport 
1-phosphatidylinositol 
4,5-bisphosphate 
phosphodiesterase 
gamma-1 
PLCG1 - 3(1) P19174 
Activation of 
MAPKK 
activity 
Large proline-rich 
protein BAG6 
BAG6 3(1) - P46379 
Protein 
stabilization 
Protein transport protein 
Sec31A 
SEC31A 4(2) 4(3) O94979 
ER to Golgi 
vesicle-
mediated 
transport 
Hypoxia up-regulated 
protein 1 
HYOU1 9(2) 15(6) Q9Y4L1 
ER to Golgi 
vesicle-
mediated 
transport 
LIM domain only protein 
7 
LMO7 4(2) - Q8WWI1 
Regulation of 
signaling 
Ubiquitin-associated 
protein 2-like 
UBAP2L 4(2) 5(2) Q14157 
Regulation of 
gene 
expression 
Ubiquitin-associated 
protein 2 
UBAP2 3(1) - Q5T6F2 
Regulation of 
gene 
expression 
Cullin-associated 
NEDD8-dissociated 
protein 1 
CAND1 8(2) 9(4) Q86VP6 
Protein 
ubiquitination 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
150-100 
Ubiquitin conjugation 
factor E4 A 
UBE4A - 2(1) Q14139 
Ubl 
conjugation 
pathway 
Cell cycle and apoptosis 
regulator protein 2 
CCAR2 6(2) - Q8N163 Transcription 
Kinesin-1 heavy chain KIF5B 12(7) 9(4) P33176 
Vesicle 
transport 
along 
microtubule 
Importin-5 IPO5 11(6) 11(6) O00410 
Protein 
transport 
Poly [ADP-ribose] 
polymerase 1 
PARP1 5(3) 3(2) P09874 Transcription 
Protein transport protein 
Sec24C 
SEC24C 3(1) - P53992 
ER to Golgi 
vesicle-
mediated 
transport 
100 
General vesicular 
transport factor p115 
USO1 9(3) 6(1) O60763 
ER to Golgi 
vesicle-
mediated 
transport 
Heat shock protein 105 
kDa 
HSPH1 6(3) 6(4) Q92598 
Chaperone 
mediated 
protein 
folding 
5'-3' exoribonuclease 2 XRN2 3(2) - Q9H0D6 
Regulation of 
transcription 
Transferrin receptor 
protein 1 
TFRC 4(1) - P02786 
Cellular iron 
ion 
homeostasis 
Alpha-actinin-1 ACTN1 7(5) 7(5) P12814 
Actin 
filament 
organization 
Eukaryotic translation 
initiation factor 4 gamma 
2 
EIF4G2 2(2) - P78344 
Translation 
regulation 
Pyridoxal-dep 
decarboxylase domain-
containing p. 1 
PDXDC1 8(2) 4(2) Q6P996 
Carboxylic 
acid 
metabolic 
process 
Conserved oligomeric 
Golgi complex subunit 5 
COG5 2(1) - Q9UP83 
ER to Golgi 
vesicle-
mediated 
transport 
DNA replication 
licensing factor MCM3 
MCM3 - 6(3) P25205 
DNA 
replication 
Heat shock 70 kDa 
protein 4L 
HSPA4L - 2(2) O95757 
Unfolded 
protein 
binding 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
100 
Dynamin-2 DNM2 - 4(2) P50570 Endocytosis 
26S proteasome non-
ATPase regulatory 
subunit 2 
PSMD2 - 3(1) Q13200 
MAPK 
cascade 
Rho GTPase-activating 
protein 18 
ARHGAP18 - 4(2) Q8N392 
Signal 
transduction 
E3 UFM1-protein ligase 
1 
UFL1 - 5(1) O94874 
Ubl 
conjugation 
pathway 
Interleukin enhancer-
binding factor 3 
ILF3 - 7(3) Q12906 Transcription 
Calnexin CANX - 7(5) P27824 
Unfolded 
protein 
binding 
DNA replication 
licensing factor MCM6 
MCM6 - 4(1) Q14566 
DNA 
replication 
Methionine--tRNA 
ligase, cytoplasmic 
MARS - 7(4) P56192 
Protein 
biosynthesis 
100-75 
Mitochondrial inner 
membrane protein 
IMMT 4(2) 7(4) Q16891 
Mitochondria
l calcium ion 
homeostasis 
DNA replication 
licensing factor MCM7 
MCM7 6(2) 9(3) P33993 
DNA 
replication 
6-phosphofructokinase, 
liver type 
PFKL - 3(3) P17858 Glycolysis 
Polyadenylate-binding 
protein 4 
PABPC4 - 8(3) Q13310 Translation 
ORF protein ORF - 8(6) Q7KYM9 
mRNA 
splicing 
Thimet oligopeptidase THOP1 - 2(1) P52888 
Peptide 
metabolic 
process 
Long-chain-fatty-acid--
CoA ligase 4 
ACSL4 - 10(4) O60488 
Lipid 
metabolism 
Lysine--tRNA ligase KARS - 8(3) Q15046 
Protein 
biosynthesis 
Eukaryotic translation 
initiation factor 4B 
EIF4B 3(2) 3(2) P23588 
Protein 
biosynthesis 
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit 
NDUFS1 7(2) 6(2) P28331 
Mitochondria
l electron 
transport 
Sec1 family domain-
containing protein 1 
SCFD1 9(6) 2(1) Q8WVM8 
ER-Golgi 
transport 
Sorting nexin-1 SNX1 - 3(1) Q13596 
Protein 
transport 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
100-75 
Annexin A6 ANXA6 10(3) 2(1) P08133 
Ion 
transmembra
ne transport 
Transmembrane protein 
214 
TMEM214 4(2) 3(1) Q6NUQ4 Apoptosis 
75 
Arginine--tRNA ligase, 
cytoplasmic 
RARS 4(2) 4(2) P54136 
Protein 
biosynthesis 
ATP-dependent Clp 
protease ATP-binding 
subunit clpX-like 
CLPX 5(2) - O76031 
Chaperone 
mediated 
protein 
folding 
EH domain-containing 
protein 1 
EHD1 3(1) - Q9H4M9 
Intracellular 
protein 
transport 
Pyruvate kinase 
isozymes M1/M2 
PKM - 4(1) P14618 Glycolysis 
Asparagine--tRNA 
ligase, cytoplasmic 
NARS - 3(1) O43776 
Protein 
biosynthesis 
EH domain-containing 
protein 4 
EHD4 - 3(2) Q9H223 
Regulation of 
endocytosis 
Dihydrolipoyllysine-
residue acetyltransferase 
component of pyruvate 
dehydrogenase complex, 
mitochondrial 
DLAT - 3(1) P10515 
Glucose 
metabolism 
Phenylalanine--tRNA 
ligase beta subunit 
FARSB - 6(4) Q9NSD9 Translation 
Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit 1 
RPN1 - 8(5) P04843 
Cellular 
protein 
modification 
process 
Inositol-3-phosphate 
synthase 1 
ISYNA1 3(1) - Q9NPH2 
Lipid 
metabolism 
75-50 
Glucose-6-phosphate 
isomerase 
GPI 10(6) 9(4) P06744 Glycolysis 
T-complex protein 1 
subunit delta 
CCT4 8(5) 12(4) P50991 
Chaperone 
mediated 
protein 
folding 
Importin subunit alpha-2 KPNA2 6(2) 5(1) P52292 
Protein 
transport 
Serine--tRNA ligase, 
cytoplasmic 
SARS 4(2) 3(2) P49591 
Protein 
biosynthesis 
Hydroxymethylglutaryl-
CoA synthase, 
cytoplasmic 
HMGCS1 8(4) 7(6) Q01581 
Lipid 
metabolism 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
75-50 
Inosine-5'-
monophosphate 
dehydrogenase 2 
IMPDH2 9(2) 6(4) P12268 
Purine 
biosynthesis 
T-complex protein 1 
subunit epsilon 
CCT5 - 6(3) P48643 
Chaperone 
mediated 
protein 
folding 
T-complex protein 1 
subunit beta 
CCT2 - 8(4) P78371 
Chaperone 
mediated 
protein 
folding 
tRNA-splicing ligase 
RtcB homolog 
RTCB - 2(1) Q9Y3I0 
tRNA 
processing 
DnaJ homolog subfamily 
C member 7 
DNAJC7 - 2(1) Q99615 
Protein 
folding 
Coiled-coil domain-
containing protein 47 
CCDC47 - 3(1) Q96A33 
ER overload 
response 
Beta-1-syntrophin SNTB1 - 3(1) Q13884 
Muscle 
contraction 
Aldehyde 
dehydrogenase, 
mitochondrial 
ALDH2 2(2) 4(2) P05091 
carbohydrate 
metabolic 
process 
50-37 
Serpin H1 SERPINH1 2(2) 3(3) P50454 
Stress 
response 
Rab GDP dissociation 
inhibitor beta 
GDI2 5(2) 6(1) P50395 
Vesicle-
mediated 
transport 
Synaptic vesicle 
membrane protein VAT-
1 homolog 
VAT1 4(2) 7(3) Q99536 
Regulation of 
mitochondrial 
fusion 
Hydroxysteroid 
dehydrogenase-like 
protein 2 
HSDL2 3(2) 2(2) Q6YN16 
Oxidation-
reduction 
process 
Ribonucleoside-
diphosphate reductase 
subunit M2 
RRM2 2(2) - P31350 
DNA 
replication 
Erlin-1 ERLIN1 2(2) 3(2) O75477 
Lipid 
metabolism 
Annexin A11 ANXA11 - 2(1) P50995 Cell cycle 
26S proteasome non-
ATPase regulatory 
subunit 13 
PSMD13 - 5(2) Q9UNM6 
MAPK 
cascade 
Protein DDI1 homolog 2 DDI2 - 2(1) Q5TDH0 Proteolysis 
Hsp90 co-chaperone 
Cdc37 
CDC37 - 3(1) Q16543 
Protein 
folding 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
50-37 
Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
UQCRC1 - 4(1) P31930 
Oxidation-
reduction 
process 
Thioredoxin domain-
containing protein 5 
TXNDC5 - 5(2) Q8NBS9 
Response to 
endoplasmic 
reticulum 
stress 
Lymphokine-activated 
killer T-cell-originated 
protein kinase 
PBK - 2(2) Q96KB5 
Regulation of 
stress-
activated 
MAPK 
cascade 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
PGD - 6(3) P52209 
Oxidation-
reduction 
process 
Alpha-aminoadipic 
semialdehyde 
dehydrogenase 
 
ALDH7A1 - 4(2) P49419 
Oxidation-
reduction 
process 
Aldehyde dehydrogenase 
X, mitochondrial 
ALDH1B1 - 4(2) P30837 
Oxidation-
reduction 
process 
DnaJ homolog subfamily 
B member 1 
DNAJB1 3(2) 3(1) P25685 
Chaperone 
mediated 
protein 
folding 
37 
Ubiquitin fusion 
degradation protein 1 
homolog 
UFD1L 3(2) 5(3) Q92890 
Ubl 
conjugation 
pathway 
26S proteasome non-
ATPase regulatory 
subunit 7 
PSMD7 - 2(2) P51665 
MAPK 
cascade 
Nucleophosmin NPM1 - 2(1) P06748 
Response to 
stress 
Proteasome activator 
complex subunit 1 
PSME1 - 8(3) Q06323 
MAPK 
cascade 
Ubiquitin thioesterase 
OTUB1 
OTUB1 - 2(1) Q96FW1 
Ubl 
conjugation 
pathway 
Proteasome activator 
complex subunit 2 
PSME2 - 5(2) Q9UL46 
MAPK 
cascade 
Ubiquitin carboxyl-
terminal hydrolase 
isozyme L3 
UCHL3 - 2(2) P15374 
Ubl 
conjugation 
pathway 
PDZ and LIM domain 
protein 1 
PDLIM1 5(3) 4(2) O00151 
Regulation of 
transcription 
37-25 
Voltage-dependent 
anion-selective channel 
protein 1 
VDAC1 6(5) 6(5) P21796 Ion transport 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
37-25 
Receptor of activated 
protein C kinase 1 
RACK1 11(5) - P63244 
Regulation of 
protein 
localization 
ATP synthase subunit 
gamma, mitochondrial 
ATP5C1 3(2) - P36542 Ion transport 
60S ribosomal protein L7 RPL7 8(2) - P18124 Translation 
ADP/ATP translocase 3 SLC25A6 7(2) - P12236 Transport 
60S ribosomal protein 
L7a 
RPL7A 8(4) - P62424 Translation 
Signal recognition 
particle receptor subunit 
beta 
SRPRB 5(3) - Q9Y5M8 
Signal 
transduction 
Estradiol 17-beta-
dehydrogenase 8 
HSD17B8 2(2) - Q92506 
Lipid 
metabolism 
Proteasome subunit 
alpha type-1 
PSMA1 4(2) 6(3) P25786 
Protein 
polyubiquitin
ation 
Vesicle-associated 
membrane protein-
associated protein B/C 
VAPB 3(2) - O95292 
ER to Golgi 
vesicle-
mediated 
transport 
60S ribosomal protein L8 RPL8 3(2) 4(2) P62917 Translation 
Glutathione S-transferase 
omega-1 
GSTO1 6(2) - P78417 
Oxidation-
reduction 
process 
Proteasome subunit 
alpha type-7 
PSMA7 6(3) 4(3) O14818 
Protein 
polyubiquitin
ation 
Tumor protein D54 TPD52L2 4(3) 3(2) O43399 
Regulation of 
cell 
proliferation 
Proteasome subunit 
alpha type-6 
PSMA6 4(3) 4(3) P60900 
Protein 
polyubiquitin
ation 
14-3-3 protein theta YWHAQ 2(2) - P27348 
Signal 
transduction 
14-3-3 protein eta YWHAH 2(2) - Q04917 
Intracellular 
protein 
transport 
Proteasome subunit 
alpha type-3 
PSMA3 4(3) 3(2) P25788 
Protein 
polyubiquitin
ation 
Phosphoglycerate mutase 
1 
PGAM1 4(2) 5(2) P18669 Glycolysis 
B-cell receptor-
associated protein 31 
BCAP31 2(2) - P51572 
ER-Golgi 
transport 
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MW 
(kDa) 
Protein name Gene 
Peptides 
in WT 
Peptides 
in H1069Q 
UniProt 
code 
GO 
Biological 
Process 
37-25 
Ran-specific GTPase-
activating protein 
RANBP1 2(2) - P43487 
Signal 
transduction 
Ras-related protein Rab-
5C 
RAB5C 4(3) 2(2) P51148 
Protein 
transport 
Vesicle-trafficking 
protein SEC22b 
SEC22B 3(3) 3(2) O75396 
ER-Golgi 
transport 
Eukaryotic translation 
initiation factor 6 
EIF6 3(2) 2(2) P56537 
Protein 
biosynthesis 
40S ribosomal protein S9 RPS9 4(1) - P46781 
Protein 
biosynthesis 
Superoxide dismutase 
[Mn], mitochondrial 
SOD2 2(1) - P04179 
Oxidation-
reduction 
process 
Apoptosis regulator 
BAX 
BAX 4(2) 4(2) Q07812 Apoptosis 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 4 
NDUFB4 3(2) - O95168 
Oxidation-
reduction 
process 
NADH 
dehydrogenase[ubiquino
ne]1 alpha subcomplex 
subunit 2 
NDUFA2 2(2) - O43678 
Oxidation-
reduction 
process 
15-10 
Peptidyl-prolyl-cis-trans 
isomerase FKBP1A 
FKBP1A - 3(3) P62942 
Protein 
folding 
COX5B protein COX5B - 3(2) Q6FHJ9 
Unfolded 
protein 
binding 
D-dopachrome 
decarboxylase 
DDT - 2(1) P30046 
Melanin 
biosynthesis 
Protein transport protein 
Sec61 subunit beta 
SEC61B - 2(1) P60468 
Ubl 
conjugation 
pathway 
Glutaredoxin-1 GLRX - 2(1) P35754 
Cell redox 
homeostasis 
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proteins) have been identified as common putative partners of both ATP7B(WT) and 
ATP7B(H1069Q) proteins suggesting that the mutant protein retains roughly native 
threedimensional structure and then the ability to bind many interactors of wild type protein. 
Common interactors include essentially enzymes involved in lipid metabolism, glycolysis pathway 
and mitochondrial processes. The presence of the latter might be attributed to the existence of a 
smaller isoform of ATP7B (140kDa), localised in mitochondria, where it participates or assists to 
Cu- dependent processes taking place in this organelle [10]. 
Differential proteomic experiments carried out in Long-Evans Cinnamon (LEC) rats, an animal 
model of WD, demonstrated that the excess of Cu induces mitochondrial injury and carbohydrate 
metabolism disorders affecting the expression levels of several enzymes involved in these 
processes [11]. 
GO analysis of Biological processes indicated that specific binding partners of ATP7B(WT) were 
enriched in “intracellular trafficking” category (Figure 2.10). Among this latter, the Vesicle-
associated membrane protein-associated protein B/C (VAPB), the B-cell receptor-associated 
protein 31 (BCAP31) and the Protein transport protein Sec24C (SEC24C), component of the 
COPII coat, that covers ER-derived vesicles, are involved in transport of new synthesized proteins 
from ER to the Golgi complex [12][13][14]. 
Also other putative ATP7B(WT) interactors, the 14-3-3 proteins, such as YWHAH and YWHAQ, 
play a key role in intracellular protein transport. Recent studies demonstrated that 14-3-3 facilitates 
SAC1 protein transport from the endoplasmic reticulum by stimulating the packaging of SAC1 
into COPII vesicles. This process involves the interaction of SEC24C with 14-3-3 [15]. All these 
data support the hypothesis that ATP7B translocates from ER to Golgi stacks through COPII 
vesicles traffic. The absence of these proteins among the variant interactors suggests that the traffic 
of mutant is impaired at level of the exit from ER and the entrance to Golgi. 
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functions as a scaffold/anchoring protein. Within this context, RACK1 is thought to promote 
efficient intracellular signaling through accurate and highly reproducible spatial and temporal 
compartmentalization of binding partners. RACK1 function is critical for many proteins 
physiological activities, as the correct localization of other plasma membrane proteins, such as 
ABCB4 [23] and the chloride channel CFTR [24]. RACK1 regulates the apical localization of the 
CFTR protein through the interaction with protein kinase C (PKCε) and Na+/H+ exchanger 
regulatory factor (NHERF1), two proteins essential for the activity of the ion channel. Figure 2.12 
shows a hypothetical model of the RACK1 role for CFTR apical localization. RACK1 interacts 
with activated PKCε and NHERF1. The PKCε-RACK1-NHERF1 complex binds tubulin through 
other NHERF1 molecules. In this scenario, RACK1 works as an anchor to localize thin molecular 
machinery at apical region of epithelial cell. Down regulation of RACK1 reduces the apical 
localization of CFTR, indicating a role for a RACK1 in regulating the residency of CFTR at the 
cell surface [24]. 
Interestingly RACK1 is absent among ATP7B(H1069Q), suggesting that the interaction with 
ATP7B might play crucial for the correct localisation of the protein. It is possible that the absence 
of this interaction might depend either by the retention of ATP7B variant in the ER or by the 
conformation changes occurring in the ATP7B mutant. In order to deeply investigate the role of 
RACK1 in ATP7B trafficking, RACK1 siRNA experiment has been carried out. Silencing 
RACK1, ATP7B(WT) is retained in the ER thus confirming the importance of the interaction for 
the correct localization of the protein. 
 
Figure 2.12: Hypothetical model of an epithelial RACK1 proteome for the apical localization of CFTR. 
All these ATP7B(WT) specific interactors could assist the biological role of ATP7B in copper 
transport along the path from the ER/Golgi, where the protein is synthesized and subsequently 
uploaded copper, towards the plasma membrane where the excess copper is ejected from the cell. 
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Notably, many non-ATPase regulatory subunits interacting with ATP7B mutant are associated to 
MAPK activating pathways. These latter have recently been shown to affect proteostasis of 
proteins such as cystic fibrosis transmembrane conductance regulator (CFTR) [25] and to regulate 
the expression of ER quality control/degradation genes [26]. 
Among mutant protein partners, p38 (MAPK14) and its activators PLCG1 and PBK were 
identified, indicating a specific activation of stress kinase pathways.  
Proteomic data are coherent with a comparative transcriptomic analysis carried out by microarrays 
on mRNA extracted from cell expressing ATP7B(WT) and mutant that revealed significative 
differences in expressed genes. Gene ontology analysis of these data indicated enrichment in genes 
that regulate cell death and response to stress (Figure 2.14). Additional bioinformatics analysis 
with String tool revealed that more than 100 gene altered in presence of ATP7B(H1069Q) 
mutation form a network enriched in “response to stress” (Figure 2.14). Several genes in this 
network (SQSTM1-TXNIP-IL6R-FOSL1-MAP2K6-NET1) operate in signaling pathways 
mediated by two pro-apoptotic stress kinases: p38 MAPK and JNK. These data are in agreement 
with the results obtained from functional proteomic analyses. 
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Figure 2.15: HepG2 cells were infected with ATP7BWT-GFP or ATP7BH1069Q-GFP and analyzed with Western 
blot. Phosphorylated forms of p38 or JNK increased in cells expressing the ATP7BH1069Q mutant, while overall 
amounts of p38 or JNK remained similar in wild type-expressing and mutant-expressing cells. 
To test whether deactivating the p38 and JNK pathways facilitates ATP7B(H1069Q) export from 
the ER, the activity of p38 and JNK was suppressed first by using specific chemical inhibitors, 
SB202190 (SB90) and SP600125 (SP125), and then by RNA interference. Neither p38 and JNK 
inhibitor (added for 24 hours) affected ATP7B(WT), but both reduced ATP7B(H1069Q) within 
the ER and improved the delivery of the mutant to the Golgi (Figure 2.16 panel B). The RNA 
interference gave same results. In control experiments the ERK inhibitor failed to correct the 
mutant from the ER to the Golgi indicating that only p38 and JNK branches of the MAPK signaling 
cascade are involved in mutant retention in the ER. 
Following inhibition of p38 and JNK, the mutant moves from ER to vesicles and PM in response 
to copper overload, showing a localization compatible with ATP7B(WT) (Figure 2.16). These data 
suggested that SB90 and SP125, respectively p38 and JNK inhibitors, might act as molecular 
chaperones promoting ATP7B mutant to escape from ER quality control, and leading to a right 
cell collocation of protein. 
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Figure 2.16: Suppression of p38 and JNK corrects localization and trafficking of ATP7B(H1069Q) mutant in hepatic 
cells. (A) HepG2 cells were infected with Ad-ATP7B(WT)-GFP or Ad-ATP7B(H1069Q)-GFP, incubated overnight 
with 200 µM BCS, and fixed or incubated for an additional 2 hours with 100 µM CuSO4. In response to Cu, 
ATP7B(WT) (left column) traffics from the Golgi (arrowheads in upper panels) to the PM and vesicles (arrows in 
lower panels), while ATP7B(H1069Q) (second column) is retained in the ER under both low-Cu and high-Cu 
conditions. p38 or JNK inhibitors were added to the cells 24 hours before fixation (as indicated in the corresponding 
panels). Fixed cells were then labelled for TGN46 and visualized under a confocal microscope. Both p38 and JNK 
inhibitors corrected ATP7B(H1069Q) from the ER to the Golgi (arrowheads in upper panels) under low-Cu conditions 
and to the PM and vesicles (arrows in lower panels) upon Cu exposure. (B) Cells were treated as in (A). The percentage 
of cells (average ± standard deviation, n =10 fields) with ATP7B signal in the ER, Golgi, or PM/vesicles was 
calculated. Both p38 and JNK inhibitors reduced the percentage of cells exhibiting ATP7B(H1069Q) in the ER 
independently from the Cu levels and increased the number of cells in which ATP7B was corrected to the Golgi under 
low-Cu conditions and to the PM and vesicles upon Cu stimulation. 
Once the mutant has reached the membrane, its ability to excrete copper from the cell were also 
investigated by ICP-MS analysis. The quantization of intracellular Cu revealed that the treatment 
with p38 or JNK inhibitors caused a significant decay of the intracellular copper levels, confirming 
that the mutant following inhibition of p38 and JNK not only reaches the correct location to plasma 
membrane, but there it works properly eliminating the excess of copper from the cell (Figure 2.17) 
[27]. 
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2.5 Conclusions 
In conclusion, proteomic and transcriptomic analyses revealed that the molecular mechanisms 
causative of Wilson disease triggered by the presence of ATP7B(H1069Q) is the retention of 
mutant protein in the ER compartment, due by its partial misfolding. This conformational change 
affects interactions occurring between ATP7B and several proteins controlling protein trafficking 
and translocation from ER to PM, which is impaired in the presence of mutant. On the other hand, 
the conformational instability of ATP7B(H1069Q) induces a strong stress response in the cell, 
with the activation of both protein degradation and apoptotic pathways.  
In particular, the activation of p38 and JNK pathways has been associated to the disease onset and 
development [28]. Surprisingly, by inhibiting these two pathways, the mutant is redirect out from 
the ER to the secretory pathway, subtracting the protein to degradation and leading to the restoring 
the right copper level in the cell.  
All together, the results of present research suggest that p38 and JNK might represent two new 
attractive targets for novel therapeutic strategies in the cure of Wilson disease’s patients. 
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3 Chapter 3 – Investigation of Molecular Mechanisms Impaired in 
Pompe Disease 
3.1 Introduction 
3.1.1 Lysosomes and Lysosomal Enzymes 
Lysosomes are subcellular organelles that break down and recycle a wide range of complex 
substrates, including glycosaminoglycans, sphingolipids, glycogen, and several proteins. Their 
catabolic function is performed through the concerted action of approximately 60 different acidic 
hydrolases belonging to different protein families, such as glucosidases, sulfatases, peptidases, 
phosphatases, lipases, and nucleases. Lysosomal catabolic function depends on direct interaction 
between enzymes and substrates in the lysosomal lumen [1]. Lysosomal enzymes are synthesized 
in the endoplasmic reticulum (ER), where they adopt their native conformations and reach the 
lysosomes via specialized pathways. The most of these hydrolases are targeted to lysosomes 
through the addition of mannose-6-phosphate (M6P) residues onto the oligosaccharide moieties of 
the enzymes, a modification that occurs in the late Golgi compartment, and through the M6P 
receptor (MPR) pathway [2]. Some specific enzymes do not depend on MPR for lysosomal 
delivery, such as β-glucocerebrosidase, which is transported to lysosomes by lysosomal integral 
membrane protein 2 (LIMP-2) [3]. 
Substrates are translocated to lysosomes through different paths: specific endocytic mechanisms, 
such as phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, and clathrin and caveolin-independent endocytosis, are preferentially exploited 
according to the nature of the cargo. Intracellular materials are transported to the lysosomes mainly 
through autophagy, a process that delivers cytoplasmic components and organelles to lysosomal 
degradation and recycling (Figure 3.1). 
The biological role of lysosomal hydrolases is crucial for the cell survival: the total or partial lack 
of their enzymatic activity causes intra-lysosomal accumulation of undegraded substrates and 
abnormalities of several cellular pathways. Mutations in the genes that encode lysosomal enzymes 
are responsible for genetic diseases, called Lysosomal Storage Diseases [1]. 
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Figure 3.1: Overview of cellular trafficking to the lysosome and autolysosome. Lysosomal proteins reach the 
lysosome directly, via the trans-Golgi network (TGN), or indirectly by way of the plasma membrane. In the direct 
pathway, upon trafficking to the TGN, some oligosaccharide side chains acquire the mannose-6-phosphate (M6P) 
recognition marker. Enzymes with this modification are recognized by cation-dependent and cation-independent M6P 
receptors (M6PRs) in the TGN, mediating their sorting into the endosome–lysosome pathway. M6P-tagged molecules 
that escape M6PR recognition in the TGN are transported to the cell surface and secreted into the extracellular fluid. 
Secreted M6P-labeled proteins are recognized by M6PR on the extracellular plasma membrane and are delivered to 
the lysosome by receptor-mediated endocytosis. 
3.1.2 Lysosomal Storage Diseases 
Lysosomal storage diseases (LSDs) are a group of more than 50 rare inherited metabolic disorders 
caused by mutations in genes encoding soluble acidic hydrolases, integral membrane proteins, 
activator and transporter proteins that are essential for lysosomal functions. These genetic 
mutations result in the impairment of one or more functions of lysosomes. Indeed, the missense 
mutations may cause protein retention in the endoplasmic reticulum, often followed by 
degradation; analogously, other alterations in post-translational modification, such as an abnormal 
glycosylation might induce mistrafficking of the mutant protein through the Golgi apparatus, trans-
Golgi network (TGN), and to the lysosomes [1][4]. Functional deficiencies in lysosomal proteins 
trigger pathogenetic cascades that lead to intra-lysosomal accumulation of undegraded substrates 
in multiple tissues and organs (Figure 3.2). The accumulation of specific substrates in lysosomal 
compartment affects several cellular functions with mechanisms that include the activation of 
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receptors by a non-physiological over accumulation of ligands, the modulation of receptor 
responses and signal transduction cascades, the activation of an inflammatory response, the altered 
intracellular traffic of vesicles, of membranes and membrane-bound protein, the alteration of 
related to the autophagy [5]. 
The clinical consequences affect different organs with visceral, ocular, haematological, skeletal, 
or neurological manifestations, and with phenotypes overlapping among different disorders. 
Symptoms may emerge at variable ages, in some cases starting in utero or during the new-born 
period, or becoming evident in late adulthood. In general, the diseases progress and evolve over 
the time. 
The lysosomal storage diseases are generally classified by the nature of the accumulated substrates. 
Some examples of LSDs are listed in Table 3.1 [1][5]. 
 
Figure 3.2: Cascade of events underlying the pathogenesis of LSDs.
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Table 3.1: Some examples of Lysosomal Storage Diseases. 
Disease Defective protein Storage materials Major symptoms 
Pompe Acid α-glucosidase Glycogen 
Cardiomyopathy, cardiomegaly, 
severe hypotonia, limb-girdle 
weakness, muscle weakness, 
respiratory dysfunction 
Fabry α-Galactosidase A 
Globotriaosylceramide, 
Galabiosylceramide, 
Globotriaosylsphingosine 
Painful paresthesias, angiokeratoma, 
renal disease, cardiomyopathy and 
stroke. There is no neuronal 
involvement.  
Multiple 
Sulfatase 
Deficiency 
Formylglycine-
generating enzyme 
Heparan sulphate, Dermatan 
sulphate, Chondroitin-4- and -
6-sulphates, Sulpholipids 
Neurologic symptoms prevail. In 
addition, patients have attenuated 
signs of mucopolysaccharidosis like 
hepatomegaly, dysostosis multiplex 
and coarse facial features.  
Gaucher 
Acid β-
Glucosidase 
Glucosylceramide, 
Glucosylsphingosine 
Type 1: Dysfunction of liver, spleen 
and bone marrow. Symptoms involve 
hepatosplenomegaly, 
thrombocytopenia, skeletal 
deformations and bone fractures. 
There is no nervous system 
involvement. 
Type 2: In addition to visceral 
symptoms, patients have severe 
neurologic involvement. Brain 
biopsies show extensive neuronal 
death. 
Type 3: intermediate symptoms 
between type 1 and 2. 
Niemann–Pick 
A and B 
Sphingomyelinase 
Sphingomyelin, Cholesterol, 
Bismonoacylglycerophosphate, 
Glucosylceramide, 
Lactosylceramide, 
Globotriaosylceramide, 
Globotetraosylceramide 
Hepatosplenomegaly and rapid 
progressive neurodegeneration. 
3.1.3 Pompe Disease 
Pompe Disease (PD), also known as glycogen type II storage disease (GSDII) or acid maltase 
deficiency, is a rare disorder of glycogen metabolism with an estimated frequency of 1 in 40,000 
live births. PD is an autosomal recessive disease, occurring when an individual inherits two alleles, 
one from each parent, mutated in the gene encoding acid α-1,4-glucosidase (GAA), which maps 
on the long arm of chromosome 17 (location q25.2-q25.3) [6]. 
Lysosomal acid α-glucosidase (GAA, acid maltase) is an exo- 1,4- and -1,6-α-glucosidase that 
hydrolyzes glycogen to glucose in lysosome (Figure 3.3). 
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Figure 3.3: Enzymatic degradation of glycosidic bonds by acid α- glucosidase. 
More than 450 mutations in GAA have been reported in individuals affected by PD, leading to both 
a partial deficiency of the enzymatic function or to the complete absence of the active protein [7]. 
Furthermore, the GAA protein undergoes complex post-translational modifications trafficking 
from ER towards lysosomes, including glycosylation and proteolytic maturation (Figure 3.5) [8]. 
In several PD forms, many abnormalities might occur along this pathway, thus affecting the 
availability of an opportune amount of active enzyme at level of lysosome [1][7]. 
GAA is synthesized as precursor with an amino-terminal signal peptide for co-translational 
transport into the endoplasmic reticulum lumen, where it is N-glycosylated at seven glycosylation 
sites, resulting in a glycosylated precursor of 110-kDa. The 110-kDa precursor, containing N-
linked carbohydrate groups modified with mannose-6-phosphate, after the transport through the 
Golgi complex and targeting to the endosome/lysosome, is proteolytically processed at the amino 
terminus, resulting in a 95-kDa intermediate with a sequence beginning at amino acid 122. Than 
95-kDa intermediate is proteolytically processed to a 76-kDa form, at the carboxyterminal. The 
76-kDa form is then proteolytically processed at the amino terminus at amino acid 204 to give the 
70-kDa mature form (Figure 3.4). 
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Figure 3.4: Model for the maturation of GAA protein. 
Proteolytic processing appears to be required for GAA enzymatic activity. Indeed, the 76/70-kDa 
species have a 7-10 times higher affinity for glycogen compared to the 110-kDa precursor [8]. The 
identities of the proteases involved in the maturation of GAA are still unknown. 
Genetic mutation affecting the activity of acid alpha-glucosidase leads to metabolic disorder, 
defined Pompe Disease, responsible for abnormal intra-lysosomal glycogen storage with 
subsequent extensive damage of muscles. 
The age of onset, the organ involvement, and the rate of disease progression are heterogeneous. 
According to the clinical manifestations, PD is divided into two wide categories: infantile and late-
onset forms. The infantile form includes classic and non-classic variants. Classic infantile disease 
is a rapidly progressive disorder manifesting with cardiomegaly, hypotonia, or mild hepatomegaly 
that leads to death for cardiorespiratory failure within the first year of life. In the non-classic 
infantile form, the symptoms appear early, but the disease shows a slower progression and less 
severe cardiomyopathy [9]. All the infantile forms show a complete or near-complete GAA 
deficiency [10]. The late-onset forms include childhood, juvenile, and adult-onset variants. Both 
childhood and juvenile diseases appear any time after infancy with mild or no cardiac involvement. 
In the adult form, the presence of a residual enzymatic activity leads to a late-onset, occurring 
between the second and sixth decade of life. A slow progressive skeletal muscle myopathy 
constitutes the main manifestation of the late-onset form, and it is often associated to a proximal 
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muscle weakness with a massive involvement of respiratory muscles: indeed, respiratory failure is 
the principal cause of significant morbidity and mortality in this form. 
In Pompe Disease, the glycogen accumulation in lysosomes promoted by muscle activity 
associated to the lack of the enzymatic degradation, triggers the breaking of lysosomes, with the 
consequent release of potentially toxic substances into the cytosol and the degenerations of skeletal 
muscle (Figure 3.5). 
Unlike the other cells, in skeletal muscles of PD patients, the enlarged lysosomes are found in a 
limited inter-myofibrillar space, which facilitates the physical disruption of the lysosomal 
membrane, leading to the loss of myofibrillar material and the complete destruction of the fiber 
[11]. 
 
Figure 3.5: Representation of a normal muscle fiber (left) and a fiber muscle affected by PD (right). 
3.1.4 Possible Therapies in LSDs 
Until about two decades ago, the treatment of LSDs was based on multidisciplinary palliative 
therapies. In the last 25 years, the advances in knowledge of LSD pathophysiology and the 
improvement of highly innovative technologies have led to the development of several therapeutic 
approaches. Most of them have been designed to increase the enzymatic residual activity, such as: 
hematopoietic stem cell transplantation (HSCT), gene therapy (GT), pharmacological chaperone 
therapy (PCT), therapy based on substrate reduction (SRT) and enzyme replacement therapy 
(ERT), [1][12]. 
3.1.4.1 Hematopoietic Stem Cell Transplantation 
Hematopoietic stem cell transplantation (HSCT) has been the first therapeutic approach for the 
treatment of LSDs in which hematopoietic stem cells derived from a healthy donor are used as 
therapeutic agents [12]. The bone marrow has been traditionally used as source of cells to be 
transplanted for this procedure. However, in recent years, many patients have been treated with 
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umbilical cord blood transplants from uncorrelated donors, thus achieving a quick and easy access 
to transplantation [12]. This approach has a dual effect: both repopulate specific tissues and secrete 
functional lysosomal hydrolases in the extracellular space and into blood circulation. The enzyme 
secreted by transplanted cells is taken up by the recipient host cells thus cross-correcting the 
enzymatic defect. This approach is not effective for all LSD forms [1]. 
3.1.4.2 Gene Therapy 
Gene therapy (GT) is a therapeutic aimed to restore the defective enzyme activity by delivering a 
wild-type copy of the defective gene in patients’ cells and tissues by using viral vectors as carriers 
[1]. LSDs are monogenic disorders and then constitute excellent candidates for gene therapy, 
because, in principle, it is possible to cure the disease by correcting the gene defect. In addition, 
small increases in enzymatic activity (<10%) may be sufficient to produce clinical benefit and 
phenotypic correction of LSDs. 
The GT, when applicable, constitutes the best therapeutic approach, which allows the long-term 
expression of the native protein in patients affected by serious forms of disease, for which the 
alternative ERT would be a commercially not advantageous. 
Although GT is a promising approach for LSDs treatment, the main limitation is the safety in the 
employment of viral vectors, for their potential pathogenic nature and the possibility to integrate 
into the host genome in uncontrolled way.  
Besides the well-known technical difficulties in the GT set up, other strong limitations in the 
employment of GT concern: 1) the choice of the suitable vector to get the best possible correction 
in specific organs and tissues, 2) the doses to be used, 3) the risk of an unexpected immune reaction 
against the enzyme produced by GT, which may be recognized as an “exogenous” protein by 
immune system [12]. 
3.1.4.3 Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT) is considered the standard of care for several LSDs. This 
approach is based on periodic intravenous infusions of human recombinant enzyme, produced and 
purified on a large scale from various sources by recombinant DNA techniques. Once injected, the 
recombinant enzymes are internalized by cells and directed to the lysosomal compartment, where 
they have to compensate for the defective enzyme dysfunction. 
ERT is an excellent example of how progress in the field of lysosomal biology stimulated the 
development of novel therapeutic approaches. The logic behind ERT evolved from pivotal studies 
on the molecular mechanisms implicated in the sorting of newly synthesized lysosomal enzymes 
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by way of the M6P and MPR pathways. These studies have shown that lysosomal hydrolases have 
on their structure some markers, namely mannose or mannose-6-phosphate, which they are 
recognized by specific receptors in the cell, which direct the enzyme to the lysosomal 
compartment, where it must perform its function. The mannose or mannose-6-phosphate receptors 
are also expressed on the plasma membrane. Thus, the recombinant lysosomal enzymes produced 
and purified in the laboratory can be "captured" by the cells, and following the path of the 
endocytic route, be properly transported to lysosomes (Figure 3.6) [13]. 
 
Figure 3.6: Recombinant enzymes are recognized by receptors on the cell surface and transported to lysosomes. 
Since 2006, Pompe disease is treated with Myozyme (alglucosidase alfa). The human recombinant 
enzyme GAA (rhGAA) is produced biotechnologically and administered intravenously in the form 
of a precursor of 110 kDa containing groups of mannose-6-phosphate, which allow the enzyme to 
bind to the receptor on the cell surface. 
The first clinical tests with rhGAA have shown the benefits of ERT in patients with Pompe disease, 
but the treatment is not a cure because only a few patients showed significant improvements in 
motor function. The effectiveness of treatment is high in the early stages of diagnosis. 
3.1.4.4 Pharmacological Chaperone Therapy 
Pharmacological Chaperone Therapy (PCT) is a therapy based on the employment of drugs 
developed to stabilise native conformation of proteins containing missense mutations that alter the 
native folding, and allowing them to escaping the degradation. Indeed, misfolded proteins 
recognized by the quality control systems of the endoplasmic reticulum (ER) might be retained in 
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the ER, or abnormally glycosylated and mistrafficked or degraded by proteasome. Therefore, in 
many diseases associated to misfolding, the loss of function is not often due to a reduced catalytic 
activity, but rather to aberrant protein degradation or to inappropriate trafficking. Following 
interacting with mutant proteins, molecular ligands with pharmacological chaperones activity, 
allow the stabilization of protein native conformation, enhance their stability, and restoring the 
correct trafficking. As a result, the mutant protein reaches the lysosomes and its enzymatic activity 
is partially rescued (Figure 3.7) [1]. 
 
Figure 3.7: Missense mutations in lysosomal enzymes alter their three-dimensional conformation. Thus they are 
recognized and degraded by the cell. Pharmacological chaperones can interact physically with the mutant protein 
allowing their correct conformation and reaching the lysosomes. 
At present, some iminosugars are used as pharmacological chaperones: 1-deoxynojirimycin 
(DNJ), its derivative N-alkylated butyl-deoxynojirimycin (NB-DNJ) (Figure 3.8) [14]. 
 
Figure 3.8: Known iminosugars as pharmacological chaperones. 
Molecular chaperones have several advantages for LSDs treatment: 1) they can be administrated 
orally, allowing a non-invasive treatment; 2) they are not immunogenic and do not need to be taken 
up by cells through receptor mannose-6-phosphate, whose function can be compromise in some 
of LSDs. In addition, these small molecules diffuse freely across cellular membranes and reach 
different tissues and systems in therapeutic concentrations. 
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The real limitations in this therapeutic approach concern its feasibility, because the treatment is 
effective only in patients carrying few mutations, mostly located in specific structural domains of 
the enzyme [12]. 
In addition to PCT, other approaches based on the employment of proteostasis regulators have 
been proposed for the LSDs treatment. This small-molecules class acts at different levels on the 
so-called cell proteostasis, a complex network of processes that controls protein synthesis, folding, 
trafficking, aggregation, and degradation. This approach, however, is not so employed because it 
is still at early stage of testing [1]. 
3.1.4.5 Substrate Reduction Therapy 
Substrate reduction therapy (SRT) is based on inhibition of specific steps in the biosynthetic 
pathways of substrates to restore the equilibrium between the synthesis of substrates and their 
degradation by lysosomal enzymes. This task is generally accomplished by using small-molecule 
enzyme inhibitors involved in substrate biosynthesis [1]. 
3.1.5 Aim of the Project 
Although the biochemistry and genetics of PD are well characterized, the cellular mechanisms 
involving GAA protein and how glycogen storage leads to muscles atrophy remain poorly 
understood. 
This project was focused on the investigation of the intracellular pathways controlling GAA traffic 
by the identification of protein partners associated to the enzyme on the route from ER to 
lysosomes. Similarly, the uptake pathway of recombinant GAA (rhGAA), used in ERT, was also 
studied in order to define the fate of recombinant protein once got into the cell. 
The identification of intracellular factors regulating the traffic of endogenous GAA might shed 
light on cellular processes impaired in the presence of GAA mutant causative of Pompe Disease. 
Moreover, the description of the cellular route(s) followed by rhGAA is useful to understand why 
a low amount of protein correctly reaching the lysosomes leading inefficacy ERT in several cases. 
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3.2 Materials and Methods 
3.2.1 Materials 
All chemicals for electrophoresis, 30% Acrylamide Bis-acrylamide solution, 
Tetramethylethylenediamine (TEMED), sodium dodecylsulfate (SDS), Ammonium Persulphate 
(APS), Tris-Glicine-SDS (TGS), Tris-HCl and the mixture of molecular known weight proteins 
(total blue) used as standard were from BIO-RAD. 
In addition, from BIO-RAD were purchased chemicals and devices for Western Blot: Trans-Blot 
Turbo Transfer Pack, Tween 20, PBS and nonfat dry milk used for blocking solution, Triton X-
100, as well as the “BioRad Protein Assay” kit and bovine serum albumine (BSA) employed in 
Bradford assay. 
Protease inhibitors (Complete mini EDTA-free) were ROCHE. Reagents for ECL, photographic 
plates and ECL anti-mouse and anti-rabbit were purchased from GE HEALTHCARE. The 
Colloidal Coomassie Blue Brilliant was PIERCE. 
Dithiothreitol (DTT), trypsin, sodium chloride (NaCl), potassium chloride (KCl), trifluoroacetic 
acid (TFA) and acetonitrile (ACN) LC-MS Grade were SIGMA-ALDRICH products. 
Beads for pre-cleaning and immunoprecipitation (Dynabeads protein G) were from Invitrogen. 
The iodoacetoamide (IAM) and ammonium bicarbonate (AMBIC) are from FLUKA. Formic acid 
(HCOOH) and acetonitrile HPLC Grade were Baker products.  
Anti-GSN primary antibody was a SIGMA-ALDRICH product. Anti-TPM3 primary antibody was 
provided by PROTEIN-TECH. MYO1C primary antibody was a SANTA CRUZ product. Anti -
GAL primary antibody is a NOVUS BIOLOGICALS product. The antibodies anti-GAA and anti-
MYO6 were provided by collaborators of TIGEM (Telethon Institute of Genetics and Medicine). 
3.2.2 Methods 
3.2.2.1 Cell Lysis and Protein Quantification 
The present project was carried out in collaboration with Prof. Giancarlo Parenti's research group 
of TIGEM, that provided human fibroblasts and anti-GAA and anti-MYO6 antibodies.  
Protein extracts were prepared starting from normal fibroblasts expressing wt-GAA, fibroblasts 
from PD patient biopsy not expressing GAA, fibroblasts from the same patient but incubated for 
two and six hours with the recombinant enzyme (concentration of 50 ng/mL) named Myozyme. 
This latter was expressed in Chinese hamster ovary cells (CHO) and used as a drug in the 
enzymatic replacement therapy. 
CHAPTER 3 – INVESTIGATION OF MOLECULAR MECHANISMS IMPAIRED IN POMPE DISEASE – MATERIALS AND METHODS 
Page 75 of 152 
Lysis buffer composition was: 
 50mM Tris HCl pH=6.5 
 150mM NaCl 
 0.1% Triton X-100 
 2.5mM KCl 
 1 mini pill of protease inhibitor for 10 mL of lysis buffer 
A ratio of 1:5 (v/v) pellet/buffer was used for lysis of each cell pellet. After buffer addition, pellets 
were left for 10 minutes in ice, and successively shacked on the wheel at 4°C for 30 minutes. 
Finally, the suspensions were centrifuged for 30 minutes at 13000 rpm in order to separate protein 
extracts from debris.  
Bradford assays were carried out for a quantitative evaluation of protein extracts (Table 3.2).  
Bovine serum albumin (BSA) was used as standard for the calibration curve construction, obtained 
by reporting the absorbance measurements at 595 nm in function of concentrations of BSA 
standard solutions. 
Table 3.2: Total protein concentration from Bradford assay. 
Experiments Total protein concentration 
Endogenous GAA 9.8µg/µL, (6mg of total proteins) 
rh-GAA, sample treated for 2h 6.5 μg/μL, (3.8mg total protein) 
rh-GAA, control untreated (2h) 6.4 μg/μL, (3.6mg total protein) 
rh-GAA, sample treated for 6h 3.6 μg/μL, (6.7mg total protein) 
rh-GAA, control untreated (6h) 4.8 μg/μL, (4.6mg total protein) 
3.2.2.2 Isolation of Protein Complexes by Immunoprecipitation 
Proteins extract from different fibroblast preparations (normal, PD, and PD treated with Myozyme) 
were subjected to the immunoprecipitation procedure. 
As first step, cell extracts were pre-cleared in order to remove unspecific proteins adsorbed on 
beads. Pre-cleaning was performed by incubating protein extracts with Dynabeads Protein-G 
(25μL of slurry resin per mg of protein extract), previously conditioned in lysis buffer, for 3h at 
4°C on the wheel.  
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Pre-cleaned extracts were then incubated with specific antibody anti-GAA (policlonal rabbit) (2μg 
of antibody per mg of protein extract), over-night at 4°C on the wheel. 
Finally, the samples were transferred in new tubes and incubated with Dynabeads Protein-G (50μL 
of slurry resin per mg of protein extract), for 3h at 4°C under gently agitation on the wheel in order 
to capture antigen-antibody complexes.  
The unbound proteins were then removed, and the beads were repetitively washed with lysis buffer 
containing either low (150mM) or high (300mM) NaCl concentrations, in order to remove 
unspecific proteins. Proteins retained were eluted by using Laemli Buffer (100mM Tris HCl 
pH=6,8, 4% SDS, 20% glycerol, bromophenol blue) for 10 min at 99°C in thermomixer. Beads 
employed in the pre-cleaning steps were treated in parallel with the same procedure, and the eluted 
proteins constituted the negative control. 
3.2.2.3 Preparative SDS-PAGE 
100mM DTT (dithiothreitol) was added to each samples following 10 minutes of boiling at 99°C. 
Sample and control eluates were loaded on a 16x16 cm, 10% polyacrylamide gel for mono-
dimensional SDS-PAGE fractionation. The electrophoretic runs were performed at initial voltage 
of 200 V. 
The gels were stained by Colloidal Blue Comassie over-night and the excess of dye was removed 
by extensive washing with deionized water. 
3.2.2.4 Hydrolysis in situ 
Refer to Chapter 2, section 2.2.2.4. 
3.2.2.5 LC-MS/MS analysis 
Each peptide mixture was resuspended in 12μL of 0,2% HCOOH, and analyzed by LC-MS/MS, 
using a system LTQ Orbitrap XL (Thermo Fisher) equipped with a nano-HPLC. After loading, the 
peptide mixture was first concentrated and desalinated in the pre-column (C18 EasyColumn 
L=2cm, 5μm, ID=100m, Thermo Fisher Scientific). Each peptide sample was then fractionated 
on a C18 reverse-phase capillary column (C18 EasyColumn L=10cm, ID=75μm, 3μm, Thermo 
Fisher Scientific) working at a flow rate of 300nL/min, with a gradient of eluent B (0,2% formic 
acid, 95% acetonitrile LC-MS Grade) and eluent A (0,2% formic acid, 2% acetonitrile LC-MS 
Grade) from 5 to 60% in 70 mins. 
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Peptide analysis was performed using data-dependent acquisition (DDA) of one MS scan (mass 
range from 400 to 1800 m/z) followed by MS/MS scans of the five most abundant ions in each 
MS scan, obtained by CID (Collision Induced Fragmentation) fragmentation in the ion trap. 
3.2.2.6 Proteins Identification 
Raw data from nano-LC-MS/MS analyses were processed and converted in .mgf files to be 
introduced into the MASCOT software (Matrix Science Boston, USA) to search a non-redundant 
protein database. Both peptide mass data and the data obtained by fragmentation spectra were 
included in the peak list for protein identification. 
The research was done by setting the following parameters: 
 Database: NCBI 
 Taxonomy: Homo sapiens 
 Enzyme: Trypsin 
 Fixed modification: carbamidomethyl (C) 
 Variable modification: oxidation (M), pyro-Glu (N-term Q), pyrocarbamidomethyl (N-
term C) 
 Peptide tolerance: 10 ppm 
 MS/MS tolerance: ± 0,6 Da 
 Ions charge: +2, +3 
 Instrument: ESI-FTICR 
It has also been used the software ExPASy Blast Form to assign to each protein a code that 
uniquely identify each sequence in the annotated database UniProt KB. 
3.2.2.7 Co-Immunoprecipitation and Western Blotting Experiments 
Co-immunoprecipitation (Co-IP) experiments were carried out in order to verify the physiological 
interaction between endogenous GAA and several potential interacting proteins among those 
identified by functional proteomic approach. These GAA putative interactors are: Gelsolin (GSN), 
Unconventional myosin-IC (MYO1C), Unconventional myosin-VI (MYO6), Tropomyosin alpha-
3 chain (TPM3). 
The protocol used for the Co-IP was the same employed for the preparative IP (refer to section 
3.2.2.2), although Co-IP experiments were carried out on lower protein amounts (800g).  
The ratio antibody / total protein extract was: 2µg of antibody per mg protein extract. This 
condition was used for each Co-IP experiment. 
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Finally, eluates from IP, controls and 100µg of total extract (INPUT) were diluted in Loading 
Buffer, with the addition of 100mM DTT (dithiothreitol), boiled for 10 minutes at 99°C and 
fractionated by SDS-PAGE into a 10% Acrylamide Bis gel (size 10x10 cm and thickness of 1,5 
mm). 
Proteins separated by SDS-PAGE were then electro-transferred to nitrocellulose membranes with 
Trans-Blot Turbo Blotting system for mini-gel. Membranes were stained with Ponceau Red (0,1% 
solution in 1% acetic acid) to visualise the effective transfer of the proteins. After destaining in 1x 
PBS  (1mM sodium phosphate, 15mM NaCl, pH 7.4) the membranes were immersed in a blocking 
solution, consisting of 5% nonfat dry milk in 1x PBS for 1h at room temperature, on a shaking 
plate. Then, membranes were incubated with specific primary antibody (Table 3.3), diluted in 1% 
nonfat dry milk in 1x PBS, 0,1% Tween20.  
Table 3.3: Primary antibodies dilutions employed for Western blot assays. 
Antibody Ratio 
I antibody 
Incubation 
condition 
Anti-GAA (rabbit) 1/2000 2 hours, rt 
Anti-GSN (mouse) 1/500 2 hours, rt 
Anti-TPM3 (rabbit) 1/1000 Over night, 4°C 
Anti-MYO6 (rabbit) 1/750 Over night, 4°C 
Anti-MYO1C (rabbit) 1/500 Over night, 4°C 
The incubation with primary antibodies was followed by three washes with 1x PBS and 0,1% 
Tween20 (washing solution) and then by 45 minutes incubation with the II antibody (1/5000) at 
room temperature, in a solution of 1% nonfat dry milk in 1x PBS, 0,1% Tween20. The II antibody 
is covalently conjugated to the horseradish peroxidase (HRP), an enzyme that, in presence of 
hydrogen peroxide (H2O2), oxidizes its chemiluminescent substrate, luminol, to acid 3-
amminoftalic with concomitant emission of light, which is impressed on a photographic plate. 
Following three washes to remove the excess of II antibody, the enzymatic development was 
carried out by using an ECL kit consisting of luminol and H2O2. 
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3.3 Results 
The investigation of molecular mechanism involving GAA trafficking was carried out by 
functional proteomic approach. The identification of protein partners interacting with endogenous 
GAA in normal and PD fibroblasts allowed us to describe the route followed by GAA from ER to 
lysosomes. This led to formulate a hypothesis on where this route is interrupted when mutants of 
GAA causative of Pompe Disease occur. By using the same approach, the traffic of recombinant 
protein (rhGAA) from outside the cell to lysosomes was also investigated. The final aim of the 
project was to unravel the cellular processes involving GAA at molecular level in order to 
understand the defects in the physiological traffic towards its natural sub-cellular compartment 
where the enzyme exerts its biological function. All the information collected during this study 
will be useful to develop new protocols or to improve existing procedures to correct the aberrant 
traffic, providing more effective therapies against Pompe Disease. 
3.3.1 Investigation of Wild Type GAA Interactome 
The investigation of wild type GAA interactome was carried out using normal human fibroblasts, 
provided by our co-workers from Professor Parenti’s laboratory. 
Fibroblasts were lysated as reported above and 6 mg of total protein extract were 
immunoprecipitated by using anti-GAA antibody. In order to remove false positive interactors 
(proteins with affinity for the matrix, magnetic beads derivatised with protein G), total cellular 
extract was pre-cleared by preliminary incubation with magnetic beads in the absence of specific 
antibodies. Proteins retained by the beads during the pre-cleaning step were eluted and employed 
as control. 
The pre-cleared extract was, then, incubated first with anti-GAA antibody over night and then for 
2 hours with the Dynabeads derivatized with the G protein; the supernatant containing all the 
unbound proteins was then discarded and the beads retaining the immunoprecipited proteins were 
extensively washed with lysis buffer.  
Finally, proteins specifically bound to the antibody (GAA containing complexes) or to the beads 
(control) were eluted in denaturing conditions (Laemli buffer) and the individual proteins 
fractionated by SDS-PAGE and stained by colloidal blue coomassie (Figure 3.9). 33 protein bands 
for the control and sample lanes were excised from the gel, digested in situ with trypsin and the 
resulting peptide mixtures were directly analyzed by LC-MS/MS, using a LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher) equipped with a nano-HPLC. 
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Table 3.4: List of putative GAA protein partners. Protein name, gene name, number of identified peptides, in 
parentheses those with scores above the threshold, UniProt code and the key words for GO Molecular Functions and 
Biological Process of the identified protein are reported. In bold are reported the identification parameters of GAA 
(the bait). 
MW 
(kDa) 
Protein name Gene Peptides 
UniProt 
code 
GO Molecular 
Function 
GO Biological 
Process 
> 250 Plectin PLEC 10(3) Q15149 
Structural 
constituent of 
muscle 
Hemidesmosome 
assembly 
150-100 
Unconventional 
myosin-VI 
MYO6 3(1) Q9UM54 Actin Binding 
Actin filament-
based movement 
Unconventional 
myosin-Ic 
MYO1C 22(11) O00159 
Microfilament 
motor activity 
Actin filament-
based movement 
Unconventional 
myosin-Ib 
MYO1B 7(5) O43795 
Actin-dependent 
ATPase activity 
Actin filament-
based movement 
100 
Lysosomal alpha-
glucosidase 
GAA 6(4) P10253 
alpha-1,4-
glucosidase 
activity 
Glucose 
metabolic 
process 
100-75 
Gelsolin GSN 16(8) P06396 
Actin and Myosin 
II Binding 
Actin filament 
polymerization 
Unconventional 
myosin-Id 
MYO1D 8(6) O94832 
Actin filament 
binding 
Actin filament-
based movement 
75-50 Coronin-1C CORO1C 5(3) Q9ULV4 
Actin filament 
binding 
Actin cytoskeleton 
organization 
50-37 Tropomodulin-3 TMOD3 4(2) Q9NYL9 
Tropomyosin 
binding 
Actin cytoskeleton 
organization 
37-25 
Tropomyosin alpha-
1 chain 
TPM1 18(9) P09493 Actin binding 
Actin cytoskeleton 
organization 
Tropomyosin alpha-
4 chain 
TPM4 14(11) P67936 
Actin filament 
binding 
Actin filament 
organization 
Tropomyosin alpha-
3 chain 
TPM3 10(8) P06753 
Actin filament 
binding 
Actin filament 
organization 
Tropomyosin beta 
chain 
TPM2 4(2) P07951 Actin binding 
Actin filament 
organization 
20-15 
60S ribosomal 
protein L12 
RPL12 2(2) P30050 rRNA binding Translation 
As shown by the Gene Ontology categories (Molecular Functions and Biological Process), almost 
all the GAA interactors belong to the actin cytoskeleton, including Gelsolin (GSN) and 
tropomyosin (TPM) or are involved in protein trafficking, such as unconventional myosins. 
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Figure 3.17: SDS-PAGE of the immunoprecipitated samples from fibroblasts treated with Myozyme for 2h (left) and 
for 6h (right). Lanes indicated with "IP UT" are the controls (untreated), while the ones indicated with "IP T" are the 
samples (treated). M represents a mixture of known molecular weight proteins used as standards. 
The list of rhGAA putative interactors (Table 3.5) was obtained by discording the proteins 
identified in both in the sample and in the control (IP UT) and considering those only occurring in 
sample (IP T). 
Table 3.5: Putative rhGAA protein partners identified at 2h and 6 h of incubation. Protein name, gene name, number of 
identified peptides in both experiments, in parentheses those with scores above the threshold, UniProt code and GO 
Biological process are reported. 
MW 
(kDa) 
Protein Gene 
Peptides 
2h 
Peptides 
6h 
UniProt 
code 
GO Biological 
Process 
> 250  
Filamin-B FLNB 14 (5) - O75369 
Actin cytoskeleton 
organization 
Neuroblast 
differentiation-
associated protein 
AHNAK 
AHNAK 10 (7) - Q09666 
Protein 
oligomerization 
250-150 
Myosin-10 MYH10 38 (28) - P35580 
Actin filament-based 
movement 
Ras GTPase-
activating-like protein 
IQGAP1 
IQGAP1 16 (6) - P46940 Signal transduction 
Clathrin heavy chain 
1 
CLTC 2 (1) - Q00610 
Intracellular protein 
transport 
150-100 
Lysosomal alpha-
glucosidase 
GAA 7 (5) 10 (7) P10253 
Glucose metabolic 
process 
Unconventional 
myosin-Ic 
MYO1C 20 (10) 10 (6) O00159 Protein transport 
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MW 
(kDa) 
Protein Gene 
Peptides 
2h 
Peptides 
6h 
UniProt 
code 
GO Biological 
Process 
150-100 
Unconventional 
myosin-Id 
MYO1D 7 (3) 6 (2) O94832 
Early endosome to 
recycling endosome 
transport 
Major vault protein MVP 14 (5) - Q14764 Protein transport 
Unconventional 
myosin-Ib 
MYO1B 5 (2) - O43795 
Post-Golgi vesicle-
mediated transport 
Cytospin-A SPECC1L 6 (4) - Q69YQ0 
Actin cytoskeleton 
organization 
Liprin-alpha-1 PPFIA1 4 (2) - Q13136 Signal transduction 
SERPINB SERPINB3 - 9 (4) P29508 Autocrine signaling 
ProteinS100-A8 S100A8 - 7 (6) P05109 Apoptotic process 
Protein S100-A9 S100A9 - 5 (5) P06702 Apoptotic process 
Protein S100-A7 S100A7 - 4 (4) P31151 
Innate immune 
response 
Protein-glutamine 
gamma-
glutamyltransferase K 
TGM1 - 6 (2) P22735 
Keratinocyte 
differentiation 
Alpha-2-
macroglobulin-like 
protein 1 
A2ML1 - 5 (1) A8K2U0 
Regulation of 
endopeptidase activity 
Protein POF1B POF1B - 3 (3) Q8WVV4 
Organization of 
epithelial monolayers 
Serpin B12 SERPINB12 - 4 (2) Q96P63 
Negative regulation of 
protein catabolic 
process 
100 
Lysosomal alpha-
glucosidase 
GAA 13 (9) 8 (5) P10253 
Glucose metabolic 
process 
Endoplasmin HSP90B1 11 (9) - P14625 
ER-associated 
ubiquitin-dependent 
protein catabolic 
process 
Protein phosphatase 1 
regulatory subunit 
12A 
PPP1R12A 2 (2) - O14974 
Cellular response to 
drug 
Phostensin PPP1R18 13 (7) - Q6NYC8 
Target protein 
phosphatase 1 to F-
actin cytoskeleton 
Actin filament-
associated protein1 
AFAP1 6 (3) - Q8N556 
Regulation of 
cytoskeleton 
organization 
Ribosome-binding 
protein1 
RRBP1 3 (2) - Q9P2E9 Translation 
Dynamin-2 DNM2 3 (2) - P50570 Endocytosis 
100-75 
Lysosomal alpha-
glucosidase 
GAA 4 (2) 7 (5) P10253 
Glucose metabolic 
process 
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MW 
(kDa) 
Protein Gene 
Peptides 
2h 
Peptides 
6h 
UniProt 
code 
GO Biological 
Process 
100-75 
ATP-dependent 6-
phosphofructokinase, 
liver type 
PFKL 7 (6) - P17858 Glycolytic process 
Protein-glutamine 
gamma-
glutamyltransferase 2 
TGM2 - 3 (1) P21980 
Apoptotic cell 
clearance 
75 
Moesin MSN 19 (10) - P26038 
Positive regulation of 
early endosome to late 
endosome transport 
Stress-70 protein, 
mitochondrial 
HSPA9 12 (5) - P38646 Protein folding 
*Glycine-tRNA 
ligase 
GARS 13 (7) - P41250 
tRNA aminoacylation 
for protein translation 
Synaptopodin-2 SYNPO2 6 (2) - Q9UMS6 
Positive regulation of 
actin filament bundle 
assembly 
Annexin A6 ANXA6 5 (3) - P08133 
Protein 
homooligomerization 
Transforming growth 
factor-beta-induced 
protein ig-h3 
TGFBI 4 (2) - Q15582 Cell adhesion 
75-50 
Lysosomal alpha-
glucosidase 
GAA 4 (3) 7 (6) P10253 
Glucose metabolic 
process 
5'-nucleotidase NT5E 2 (2) 7 (4) P21589 
Negative regulation of 
inflammatory response 
Palladin PALLD 11 (7) - Q8WX93 
actin cytoskeleton 
organization 
PDZ and LIM 
domain protein 5 
PDLIM5 6 (2) - Q96HC4 
Cell growth involved 
in cardiac muscle cell 
development 
Dihydropyrimidinase-
related protein 2 
DPYSL2 2 (2) - Q16555 
Cytoskeleton 
organization 
T-complex protein 1 
subunit alpha 
TCP1 6 (3) - P17987 Protein folding 
Prolyl 4-hydroxylase 
subunit alpha-1 
P4HA1 5 (3) - P13674 
Collagen fibril 
organization 
Ser/thr-protein 
phosphatase 2A 65 
kDa regulatory sub 
A 
PPP2R1A 5 (1) - P30153 Apoptotic process 
Prolyl 4-
hydroxylase sub -2 
P4HA2 2 (2) - O15460 
oxidation-reduction 
process 
Pyruvate kinase 
PKM 
PKM 6 (4) - P14618 Glycolytic process 
Protein disulfide-
isomerase 
P4HB 6 (3) - P07237 
Cell redox 
homeostasis 
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MW 
(kDa) 
Protein Gene 
Peptides 
2h 
Peptides 
6h 
UniProt 
code 
GO Biological 
Process 
75-50 
Methylcrotonoyl-
CoA carboxylase 
beta chain, 
mitochondrial 
CCC2 3 (2) - Q9HCC0 
Biotin metabolic 
process 
50 
Coronin-1C CORO1C 18 (8) - Q9ULV4 
Actin cytoskeleton 
organization 
Alpha-enolase ENO1 10 (7) - P06733 Glycolytic process 
Protein disulfide-
isomerase A6 
PDIA6 5 (4) - Q15084 
Cell redox 
homeostasis 
Protein disulfide-
isomerase A3 
PDIA3 7 (4) - P30101 
Cell redox 
homeostasis 
Fascin FSCN1 6 (4) - Q16658 
actin cytoskeleton 
organization 
Ca/calmodulin-
dependent protein 
kinase type II sub 
delta 
CAMK2D 4 (4) - Q13557 Calcium ion transport 
Protein-lysine 6-
oxidase 
LOX 5 (2) - P28300 
Oxidation-reduction 
process 
Septin-11 SEPT11 3 (3) - Q9NVA2 Cell cycle 
37-25 
Synaptic vesicle 
membrane protein 
VAT-1 homolog 
VAT1 3 (2) - Q99536 
Calcium-regulated 
keratinocyte activation 
Perilipin-3 PLIN3 2 (2) - O60664 
Vesicle-mediated 
transport 
Phosphoglycerate 
kinase1 
PGK1 7 (7) - P00558 Glycolytic process 
F-actin-capping 
protein sub -1 
CAPZA1 2 (2) 2 (1) P52907 
Barbed-end actin 
filament capping 
PDZ and LIM 
domain protein 1 
PDLIM1 15 (13) - O00151 
Regulation of 
transcription 
Annexin A1 ANXA1 7 (6) - P04083 
Actin cytoskeleton 
reorganization 
Annexin A2 ANXA2 8 (5) - P07355 
Protein targeting to 
plasma membrane 
60S acidic 
ribosomal protein 
P0 
RPLP0 4 (4) - P05388 Translation 
Ser/thr-protein 
phosphatase  
PP1- catalytic sub 
PPP1CA 6 (4) - P62136 
Glycogen metabolic 
process 
Tropomyosin alpha-
4 chain 
TPM4 5 (4) - P67936 
Actin filament 
organization 
EF-hand domain-
containing protein 
D2 
EFHD2 3 (2) - Q96C19 
Cadherin binding 
involved in cell-cell 
adhesion 
CHAPTER 3 – INVESTIGATION OF MOLECULAR MECHANISMS IMPAIRED IN POMPE DISEASE – RESULTS 
Page 91 of 152 
MW 
(kDa) 
Protein Gene 
Peptides 
2h 
Peptides 
6h 
UniProt 
code 
GO Biological 
Process 
37-25 
Coatomer subunit 
delta 
ARCN1 - 2(1) P48444 
Intracellular protein 
transport 
25-20 
Triosephosphate 
isomerase 
TPI1 10 (5) - P60174 Glycolytic process 
Alpha-crystallin B 
chain 
CRYAB 4 (2) - P02511 Protein folding 
Proteasome subunit 
beta type-6 
PSMB6 - 4 (4) P28072 
Protein 
polyubiquitination 
Proteasome subunit 
beta type-5 
PSMB5 - 5 (3) P28074 
Protein 
polyubiquitination 
20-15 
40S ribosomal 
protein S18 
RPS18 3 (2) 5 (4) P62269 Translation 
Heat shock protein 
beta-1 
HSPB1 5 (2) - P04792 
Regulation of 
apoptotic process 
40S ribosomal 
proteinS13 
RPS13 3 (2) - P62277 Translation 
Peptidyl-prolyl cis-
trans isomerase A 
PPIA 3 (2) - P62937 Protein folding 
40S ribosomal 
proteinS25 
RPS25 2 (2) - P62851 Translation 
15-10 
Histone H4 HIST1H4A - 5(5) P62805 
Transcription 
regulation 
Fatty acid-binding 
protein, epidermal 
FABP5 - 6 (2) Q01469 
Lipid metabolic 
process 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) 
subunit gamma-12 
GNG12 - 4 (1) Q9UBI6 Signal transduction 
Calmodulin-like 
protein5 
CALML5 - 3 (1) Q9NZT1 Signal transduction 
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3.4 Discussion 
Pompe disease (PD) is an inherited disorder caused by mutation the acid alpha-glucosidase (GAA) 
gene, mapped to the long arm of chromosome 17 (location 17q25.2-q25.3). As autosomal recessive 
disorder, PD only occurs when an individual inherits two mutant alleles, one from each parent. To 
date, almost 300 distinct GAA mutations have been identified, although not all are considered 
pathogenic [15]. 
In general, genotype-phenotype correlation is not well understood and significant clinical 
heterogeneity exists among patients with similar or identical mutations. One exception is the 
presence of two null mutations, resulting in a complete absence of the GAA enzyme activity. This 
genotype results in very early disease onset during infancy and severe, rapid disease progression. 
More studies, however, are needed in order to better understand genotype-phenotype relations, 
because the molecular basis underlying the cellular abnormalities of PD are still not clear. It is 
supposed that aberrant protein-protein interactions occurring in the presence of GAA variants may 
contribute to the loss of function by affecting GAA regular trafficking and cation independent-
mannose-6-phosphate receptor (CI-MPR) distribution in PD. 
The investigation of GAA interactome allowed us to shed light on the physiological steps of GAA 
traffic from endoplasmic reticulum to lysosomes and to understand the key role of some of these 
interactions in physiological conditions, when the enzyme localizes in the expected cell 
compartments. 
Once the route followed by native GAA was characterised, the attention focused to the 
investigation of both mutant GAA enzyme trafficking and the route followed by the recombinant 
enzyme rhGAA used during the enzyme replace therapy (ERT) in PD fibroblasts not expressing 
GAA. The aim of this study was the definition of molecular mechanisms involved in protein 
internalization thus to speculate about the low rescue of GAA biological function in many ERTs. 
The identification of proteins contacting rhGAA following its internalization, has allowed us to 
obtain information about the route followed by rhGAA from the entrance into the cell until its 
localization in lysosomes or other cell organelles. 
Bioinformatic analysis with Cytoscape tool was performed in order to highlight unique and 
common interactors between wild type GAA and rhGAA proteins. A graphical representation of 
the molecular interactions networks for GAA, rhGAA at 2 and 6 hours of incubation is shown in 
Figure 3.18. The presence of several common interactors between endogenous GAA and rhGAA, 
suggests that the route followed inside the cell from both proteins is partially overlapped. 
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Figure 3.18: Graphical representation of protein interaction networks specific for endogenous GAA in green, rhGAA 
(2h) in pink, rhGAA (6h) in light blue, and those in common in yellow, obtained by using Cytoscape software. 
3.4.1 Investigation of Wild Type GAA Interactome 
The investigation of wild type GAA interactome in normal fibroblasts led to the identification of 
12 putative interacting proteins, classified according to the main biological function by using Gene 
Ontology, STRING and/or information reported in literature (Figure 3.19).  
A large number of GAA protein partners belongs to the family of actin interacting protein, such as 
gelsolin (GSN), several tropomyosins (TPM) and unconventional myosins; these latter are actin-
based motor molecules involved in intracellular movements.  
Bioinformatic analysis with STRING tool revealed that the identified proteins belong to the so-
called “cytoskeleton based processes” network (Figure 3.20). 
These results strongly suggest that the GAA fate is strictly connected to cellular processes 
concerning the rearrangement of cytoskeleton and protein traffic.  
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Among identified GAA interactors some proteins belong to the unconventional myosin family, 
such as Myo1B, Myo1C, Myo1D, Myo6. 
It is known that Unconventional myosins are a superfamily of actin-based molecular motors 
playing several roles including intracellular vesicle trafficking, mechanical supports, force sensing 
and transmission. Unconventional myosins are able to bind to specific cargoes including proteins 
and lipid vesicles by their variable neck and tail domains (Figure 3.21) [16]. Co-IP experiments 
indicated that interactions occurred between GAA protein partners and specific GAA isoforms. 
These data were also supported by recent literature reports and allowed us to define the individual 
step of GAA journey from ER to lysosomes. 
 
Figure 3.19: Functional classification of GAA putative interactors. 
 
 
 
 
 
 
Figure 3.20: “Cytoskeleton based processes” obtained by analyzing all GAA interactome by String software. The 
interaction among all proteins belonging to the present network are indicated with different color code. 
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Figure 3.21: Unconventional Myosin along actin cytoskeleton. 
Among all unconventional myosin identified as GAA interactors, Myo1C captured our attention 
because it has been found to be involved in the exocytosis of Glucose Transporter 4 (GLUT4), a 
glycoprotein that maintains glucose homeostasis by regulating protein translocation. In muscle and 
adipocytes, insulin stimulates the glucose uptake by activating the signalling for the translocation 
of GLUT4 from intracellular membranes to the cell periphery [17]. The translocation of GLUT4 
occurs on actin cytoskeleton and its rapid movement along linear tracks is mediated by Myo1C 
motor, which was found to be associated to GLUT4 vesicles and its presence was demonstrated to 
be essential for the terminal events of GLUT4 vesicle exocytosis [18]. Other GAA interacting 
proteins affect GLUT4 transport process: Tropomodulin-3 (TPMOD3) and Tropomyosin 3 
(TPM3). TPMOD3 is a pointed-end actin-capping protein, which promotes the insulin-dependent 
GLUT4 translocation and exocytosis through an actin remodelling [19]. 
By co-immunoprecipitation experiment and western blot analysis, we demonstrated that Myo1C 
interacts with the GAA 110kDa precursor (Figure 3.12). This data suggests that the interaction 
between GAA and Myo1C (and probably TPMOD3) occur at the earliest phase of enzyme 
translocation, prior to the beginning of the proteolytic processing. The complex involving Myo1C 
and TPMOD3 might favour the movement of the GAA precursor from ER lumen to the Golgi 
apparatus, along actin cytoskeleton, in a process similar that involving GLUT4. The 100kDa GAA 
precursor interacts also with TPM3, as demonstrated by co-IP. TPM3, as well as TPM1, TPM2, 
and TPM4, belongs to tropomyosin family, actin-associated proteins that can form head-to-tail 
polymers along the major groove of F-actin. Different actin–tropomyosin interactions support a 
wide range of contractile and transport processes, each driven by either a specific member of the 
non-muscle myosin-2 family or an unconventional myosin. 
TPM3 is reported to affect GLUT4 trafficking to the plasma membrane by balancing the amount 
of cortical F-actin that can interact with various myosin isoforms. Consistent with this, Tpm3.1 
containing actin filaments promotes the engagement of non-muscle myosin-IIA (MyoIIA), 
generating a contractile force that may promote vesicle penetrance of the cortical mesh. 
Simultaneously TPM3.1 acts as Myo1C antagonist inhibiting its interaction with actin by 
competing with Myo1C for binding to actin filaments [20]. Consequently, the balance between 
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TPM3.1-containing and TPM3.1-free actin filaments determines the efficiency of movement of 
GLUT4 through the cortical actin network to plasma membrane (Figure 3.22) [21]. 
The interaction of GAA with both proteins suggests that they contribute to protein translocation 
along actin filaments as well as for GLUT4 traffic. Both proteins interact with the longest GAA 
form, suggesting that these competitive interactions occur at the earliest phase of enzyme 
translocation, prior or alternatively to the beginning of the proteolytic processing. 
 
Figure 3.22: Schematic representation of how the balance between Tpm3.1/MyoIIA and Tpm3.1-free/Myo1c actin 
filament populations may determine the efficiency of movement and/or fusion of GLUT4 vesicles with the plasma 
membrane. 
Differently, the first product of proteolytic maturation, the 95kDa isoform, was found to interact 
with Gelsolin (GSN), a calcium-, pH- and lipid-dependent actin severing and capping protein: its 
main function is to regulate the assembly of the actin cytoskeleton. GSN is composed of six 
conserved domains (S1–6) that have four distinct actin-binding sites, within S1, S2, S4 and S6. 
The increase of intracellular Ca2+ concentration induces conformational changes in GSN structure 
that allows the severing process to proceed. After severing, GSN is bound to the newly formed 
actin + end (barbed end) of one of the two shorter filaments. Further uncapping of actin filaments 
requires binding of gelsolin to phosphatidylinositol lipids (PPIs). This process exposes the barbed 
end for polymerization (Figure 3.23) [22][23][24]. 
 
Figure 3.23: Schematic model for GSN binding, severing, and capping of an actin filament. Left, Gelsolin in the 
process of Ca2+ activation. Severing occurs when sufficient actin-actin bonds are broken. Right, the terminal actin in 
each strand is capped by GSN. PIP2 induces Gelsolin to dissociate from the ends in a process called uncapping. 
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In addition, it was demonstrated that at low pH values, within the physiologically normal range, 
Gelsolin binds lipids in the absence of PPI becoming partially embedded in lipid vesicles and 
simultaneously vesicle-bound Gelsolin is also able to bind actin filaments [22]. 
Previous studies showed the Gelsolin involvement in Minute Virus of Mice (MVM)-induced actin-
network remodelling and vesicular egress. Gelsolin activity is indispensable not only to trim actin 
filaments but also to drive virus export from perinuclear region to the periphery of infected cells. 
The delivery is mediated by vesicles bearing protein markers of lysosomes and/or late endosomes, 
suggesting that GSN may play a role in the assembly, loading, and/or trafficking of these vesicles 
[25]. 
These previous data suggest that, following the beginning of maturation process and formation of 
95 kDa intermediate, the GAA might translocate by moving in vesicles along actin cytoskeleton 
associated to GSN, as confirmed in vivo by Proximity Ligand Assay (Figure 3.14). 
Myo1B is involved in the traffic of cargo along the endocytic pathway, regulating the formation of 
post-Golgi carriers by modulation of actin assembly at trans-Golgi network (TGN). In this region, 
moreover, Myo1B co-localized with CI-mannose-6-phosphate receptor (CI-MPR) that carries 
cargos from TGN to sorting endosomes, transports lysosomal enzymes to lysosomes and recycles 
back to TGN. It was demonstrated that Myo1B expression regulates the cellular distribution and 
TGN exit of CI-MPR. Indeed, the depletion of Myo1B inhibits CI-MPR the delivery of lysosomal 
hydrolases is affected, as demonstrated for β–hexosaminidase, one of the lysosomal enzymes [26]. 
The interaction between GAA and Myo1B might have a potential role, even indirectly, in GAA 
trafficking from TGN to lysosomes. 
Another identified unconventional myosin among GAA interactors was Myo6, a multifunctional 
motor protein involved in a wide variety of intracellular processes including cargo sorting and 
membrane delivery in the endocytic pathway, Golgi network organization and exocytosis along 
actin cytoskeleton [27]. Previous studies demonstrated that Myo6 participates to preliminary 
phases of autophagy, by mediating the delivery of endocytic cargo to autophagosomes and 
facilitating the autophagosome maturation and fusion with the lysosomes [28]. 
Autophagy is the major intracellular degradation system by which cytoplasmic materials are 
delivered to and degraded in the lysosome, contributing to the maintenance of cellular homeostasis 
in physiological conditions. A crucial step in this degradation pathway is the fusion of the double-
membrane autophagosomes with lysosomes, where they deliver their contents for degradation. 
Myo6 plays an important role in this process; indeed its lack leads to an accumulation of 
autophagosomes due to a lysosomal fusion defect [28]. 
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Co-immunoprecipitation and western blot analysis showed that Myo6 interacts selectively with 
the 70 kDa mature form of GAA (Figure 3.12). 
The functional proteomic approach employed for identification of GAA interactome, showed that 
that the enzyme interacts with actin cytoskeleton associated proteins, such as several 
unconventional myosins, tropomyosins, tropomodulins and gelsolin. In addition, co-IP 
experiments and western blot assays allowed to identify which GAA isoform interacts with each 
protein partners. 
On the basis of all these data and considering that GAA maturation occurs in specific cell 
compartments, it is possible to speculate about the route and the proteins accompanying GAA in 
the path from the endoplasmic reticulum to lysosomes (Figure 3.24). 
 
Figure 3.24: Representation of how GAA traffic from ER to lysosomes might occur in presence of confirmed protein 
partners. 
Myo1C and TPM3 interact with the GAA 110 kDa precursor, existing in ER lumen and as 
demonstrated for GLU4 trafficking, it is possible to hypothesize that these interactions are 
alternative to one another. The exit of 95 kDa GAA isoform from TGN might involve GSN, a 
protein controlling actin polymerization and that might have a key role in the early stages of GAA 
trafficking toward lysosomes. Intact this does not occur in presence of L552P-GAA variant. The 
loss of interaction with GSN might lead to consequent accumulation of the variant in ER, from 
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where it is redirected towards degradation by ER quality control machine. In order to validate this 
hypothesis, immunofluorescence experiments are still in progress and the creation of a mouse 
knock out for GNS for functional studies in vivo. The occurrence of the interaction between GSN 
and α-galactosidase A, another lysosomal enzyme involved in Fabry disease confirms the 
cruciality of this protein in the general traffic process of many enzymes that have to be addressed 
to lysosomes. If this hypothesis will be confirmed by further experiments, the restoring of 
interaction with GSN might constitute a target for the development of broad-spectrum therapies 
for LSDs. 
Finally, the delivery of GAA to lysosomes might be controlled by Myo6, as demonstrated by its 
interaction with the 70 kDa active form of GAA, localised specifically in lysososmes.  
3.4.2 Investigation of rhGAA Interactome 
Proteomics analysis was carried out in PD fibroblasts treated for 2 and 6 hours with exogenous 
recombinant enzyme rhGAA, Myozyme drug. Putative interactors were classified according to 
their main biological function (Figure 3.25-26). 
 
Figure 3.25: Functional classification of rhGAA putative interactors identified at 2 hours of treatment with Myozyme. 
 
 
Figure 3.26: Functional classification of rhGAA putative interactors identified at 6 hours of treatment with Myozyme. 
After 2 hours of treatment, several proteins involved in vesicular trafficking processes within 
endocytic pathway, i.e. Clathrin heavy chain 1 and Dynamin-2 have been identified, as well as a 
rhGAA interactors at 6 hours 
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large number of proteins involved in actin cytoskeleton rearrangement and polymerization, a 
process essential for the internalisation of exogenous molecules. 
Endocytosis is the process through which the cell incorporates external macromolecules by 
invaginations of plasma membrane, resulting in the production of vesicles able to fuse with 
endosomes and inserting into the endo-lysosomal membrane system. Endocytosis also regulates 
the recycling of plasma membrane lipids and trafficking proteins, and the uptake or degradation 
of cell-surface receptors [29]. 
In the endocytosis mediated by Clathrin-coated vesicles (CCVs) (Figure 3.27), the vesicles 
assemble at the plasma membrane, select the load, invaginate and then are detached. Moving into 
the cell, the vesicle lose their coat and, once uncoated, they fuse with the early endosome to deliver 
their content [29][30]. 
 
Figure 3.27: Role of Dynamin in Clathrin-coated vesicles formation. 
In mammals, endocytosis process involves actin cytoskeleton, whose recruitment at the nascent 
vesicle favours the formation and internalization of most of the "coated pits" and mature vesicles 
through the development of dynamic polar filamentous structures (F-actin), which form an 
important part of the cytoskeleton. F-actin associates with numerous proteins that regulate the 
rapidity of assembly and disassembly promoting both the closing and movement of the vesicle 
through an effect called "comet-like tail" whose driving force is related to hydrolysis of ATP 
(Figure 3.28). Dynamin, a GTPase that mediates plasma membrane fission during clathrin-
mediated endocytosis through the energy generated from the hydrolysis of GTP, acts on the 
generation, length and regularity of the movement of comet tails that move the intracellular 
vesicles [31]. 
 
Figure 3.28: The effect of “comet-like tail” of actin in the formation and movement of coated clathrin vesicles. 
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Dynamin is both involved at an early stage of endocytosis, by promoting the detachment of the 
vesicles from plasma membrane, and in a later stage by participating in the assembly of proteins 
involved in actin polymerization and "comet tail" generation [32]. 
Many protein partners play an important role in cytoskeleton organization, such as Palladin 
(PALLD), Myosin-10 (MYH10), Filamin-B (FLNB), Cytospin-A (SPECC1L), Fascin (FSCN1), 
Actin filament-associated protein (AFAP1), Ras GTPase-activating-like protein IQGAP1 
(IQGAP1). In addition, Moesin (MSN), a member of the Ezrin protein family, has been found to 
act as linkers between the plasma membrane and the cytoskeleton, playing an important role in 
connections of major cytoskeletal structures to the plasma membrane [33]. 
These proteins have been identified at 2 hours of treatment, but not at 6 hours, suggesting that 
cytoskeleton reorganization is crucial for the first phase of internalisation. 
Moreover, at shorter time of incubation, several members of Annexins family, Annexin-1 -2 and -
6 were found among rhGAA protein partners. 
Annexins are calcium- and phospholipid-binding proteins that have multiple roles in membrane 
traffic. In endocytosis, Annexins play a role increasing the efficiency of internalization process 
from plasma membrane regulated by calcium [34]. 
Previous studies showed that Annexins 2 and 6 interact with both mu1 and mu2 subunits of clathrin 
assembly proteins complex AP-2. The mu2 subunit is mainly involved in trafficking events at 
plasma membrane, and mu1 controls movements of vesicles between internal compartments in the 
endocytic pathway. These components of Annexin family might act a level of both processes, 
controlling the entrance of rhGAA and its translocation inside the cell. In contrast, Annexin 1 is 
only involved in trafficking between intracellular compartments [35]. 
Annexin 2 has also been found to interact with the large protein AHNAK, another rhGAA partner 
at 2 hours of treatment. Recruiting AHNAK, Annexin 2 might play the role of scaffold protein 
linking plasma membrane domains with the actin polymerization machinery [36]. In addition, 
when Annexin 2 localized at early endosomes, it exerts an essential role in multi vesicular 
endosome/bodies (MVBs) formation. MVBs are also known as endocytic carrier vesicles and 
transport material from early to late endosomes. The so-called early MVBs have few internal 
vesicles and still contain recycling proteins such as transferrin receptor, while late MVBs have 
accumulated more internal vesicles and recycling proteins have been largely removed. Given the 
ability of Annexin 2 to interact with actin, its effects on MVB formation could be mediated through 
the actin cytoskeleton. Annexin 2 plays a role in regulating the morphology of the early endosome 
such that its depletion can affect both stable vacuole/MVB formation and efficiency of recycling. 
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Also Annexin 1 was found associated with MVBs. It can mediate inward vesiculation and might 
act in closing the invagination and/or vesicle scission. 
Annexin 6 has been localized to many places throughout the cell including the plasma membrane 
and late endosomes, where plays a role in endosome–lysosome fusion (Figure 3.29) [34]. 
 
Figure 3.29: Possible sites of action of Annexins on the endocytic pathway. 
Among rhGAA interactors there is Perilipin-3, also called TIP47. It is a 47kDa protein, that binds 
selectively to the cytoplasmic domains of cation-independent and cation-dependent Mannose 6-
phosphate receptors (MPRs). TIP47 is present in cytosol and on endosomes and it is necessary for 
MPR transport from endosomes to the trans–Golgi network. MPRs transport newly synthesized 
lysosomal hydrolases from the Golgi to prelysosomes and then return to the Golgi for another 
round of transport. In order to escape lysosomal degradation, MPR would need to be retrieved 
from this prelysosomal compartment. TIP47 binds to MPR cytoplasmic domains and thereby 
triggers their efficient inclusion into newly forming transport vesicles departing from endosomes 
[37]. 
Moreover, studies have demonstrated that Dynamin has a role in late endosome dynamics and 
trafficking of the CI-MPR. It could be involved in the recycling of CI-MPR from endosomes to 
CHAPTER 3 – INVESTIGATION OF MOLECULAR MECHANISMS IMPAIRED IN POMPE DISEASE – DISCUSSION 
Page 103 of 152 
the TGN, probably by playing a crucial role in the generation of recycling vesicles from tubular 
processes of endosomes [38]. 
Among the identified cytoskeleton proteins there are some unconventional myosins, Myo1B, 
Myo1C, Myo1D, involved in vesicle trafficking already present in endogenous GAA partners list. 
These interactions suggest that once rhGAA is internalized into the cell, the route to reach 
lysosomes is partially superimposable to the endogenous GAA pathway. 
The above described proteins have been found as putative interactors of recombinant enzyme in 
the treatment for two hours. Their involvement in processes ranging from the formation of vesicles 
at plasma membrane, until the fusion of late endosomes into lysosomes suggests the path that 
rhGAA already accomplished in two hours by enzyme administration to reach to final fate, the 
lysosome, where the enzyme plays its physiological function. 
The rhGAA interactors involved in the early phase of endocytic pathway and found at 2 hours of 
incubation with Myozyme drug, are absent at longer time of treatment. This suggests that after six 
hours the internalization process is almost complete. 
Although it has been shown that following treatment with rhGAA, the formation of its mature 
forms takes place in a manner similar to the endogenous GAA, often the enzyme activity achieved 
is lower than the expected. The data obtained in these experiments might suggest a hypothesis to 
explain this partial failure. 
As shown in the chart pie (Figure 3.25), 11% of rhGAA interactors are ER proteins, such as several 
PDIs and Heat shock protein beta-1, suggesting that a portion of recombinant enzyme reaches also 
this compartment, implying a not complete transport of rhGAA to lysosomes. The identification 
of Endoplasmin, a protein that operates in the endoplasmic reticulum associated to the quality 
control and degradation machinery (ERAD), suggests that the fate of a portion of rhGAA might 
be addressed to degradation. 
The identification of Proteasome subunit beta type-6 e Proteasome subunit beta type-5, at 6 hours 
of Myozyme treatment, confirms the previously hypothesis. Indeed, the ubiquitin-proteasome 
pathway is one of the systems employed by eukaryotic cells to accomplish the turnover of proteins 
and to degrade defective or damaged proteins. The retro-traslocation of an amount of internalised 
enzyme toward the ER and proteasome where it will take place the partial degradation of Myozyme 
could explain the unsatisfactory yield of rhGAA in terms of the total effectiveness in the ERT. 
In addition, after longer treatment time, among the rhGAA interactors there are some proteins 
belonging to S100 family: Protein S100-A7, Protein S100-A8 and Protein S100-A9. These proteins 
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are defined “calgranulins”, reflecting their calcium-binding properties and high expression in 
granulocytes. Little is known about their biological function, but it has been demonstrated that 
S100-A8 and S100-A9 levels increase in cellular stress conditions and are often strongly expressed 
in inflamed tissues. These proteins are also associated with the activation of apoptotic processes 
that may contribute to lowering of ERT efficacy [39]. 
All together these data suggest the possible pathways followed by rhGAA, as described by the 
known functions and cell localization of its protein partners (Figure 3.30). 
 
Figure 3.30: Hypotheses of rhGAA uptake pathways followed by Myozyme in PD fibroblasts. 
In fibroblasts, the rhGAA uptake begins from the Myozyme recognition by mannose-6-phosphate 
receptor localized on the plasma membrane. The internalization process occurs through a clathrin-
mediated mechanism, in which the plasma membrane invaginates and subsequent detachment of 
coated vesicle reaches completeness through Dynamin, Annexin 6 and actin activities. The largest 
amount of vesicles reaches the early endosomes, and the fusion with the late endosomes involves 
several annexins. The mannose-6-phosphate receptor is recycled to trans-Golgi by TIP47. This 
step might be the same by means an amount of internalized rhGAA retrotranslocates to the ER. At 
present, no other information is available to confirm this hypothesis or better describe how a 
portion of rhGGA may contact ER resident enzymes, such as Endoplasmin and several PDIs. Once 
in the ER, this amount of rhGAA does not pass the quality control and then it is addressed to the 
proteasome degradation. Further investigations, including co-IP experiments for each relevant 
rhGAA interactor, will be performed in order to confirm and support our hypothesis about rhGAA 
uptake process and its routes once internalized in the cell, and to define the maturation process 
steps of exogenous protein once internalized. 
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3.5 Conclusions 
Proteomics results have showed that, in physiological condition, endogenous GAA interacts with 
different cytoskeleton proteins and in particular, the interactions are isoforms specific, suggesting 
that they might occur at different step during the traffic of GAA from endoplasmatic reticulum to 
lysososmes. 
Gelsolin, a validated GAA protein partner, has a key role in the early stages of GAA trafficking 
resulting a potential target for definition of new therapeutic strategy in Pompe disease. 
Moreover, proteomics experiments carried out in PD fibroblasts treated for 2 and 6 hours with 
rhGAA have provided information about both early steps of internalization process and the route 
followed by the Myozyme towards lysosomes. Furthermore, our data suggest that the only partial 
effectiveness of rhGAA observed in patients treated with Enzyme Replace Therapy might be 
explained considering that an amount of internalized protein is destined to degradation. 
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4 Chapter 4 –Investigation of Molecular Mechanisms Impaired in 
Amyloidosis 
4.1 Introduction 
4.1.1 Protein Misfolding Diseases: Amyloidosis 
The amyloidoses are a large group of diseases caused by extracellular deposition of insoluble 
protein aggregates, called amyloid, derives from misfolding of several precursor proteins that 
aggregate in highly ordered abnormal cross β-sheet conformation. 
In the cell, the folding process of a newly synthesized protein occurs through a rapid sequence of 
conformational changes. According to the folding energy landscape theory, the process follows a 
funnel-like pathway in which the conformational intermediates progressively merge into a final 
species (Figure 4.1) [1]. 
 
Figure 4.1:The process of protein folding: the unfolded polypeptide enters a funnel-like pathway in which the 
conformational intermediates become progressively more organized, resulting in the most stable native state. In this 
state, there is a minimum of free energy, which results from the balance between the level of enthalpy, the internal 
energy that in folded protein is mainly determined by the kind and number of intramolecular bonds, and the level of 
conformational entropy, the level of randomness of the polypeptide in solution. 
The folding process is subjected to a quality control by molecular chaperones and protease 
machinery. 
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Misfolded proteins are either rescued by chaperones or eliminated by the ubiquitin-proteasome 
system or lysosome-mediated autophagy [2]. These mechanisms are normally sufficient to prevent 
the accumulation of misfolded proteins, but under certain pathological conditions, the system of 
intracellular quality control appears to be incapable of recognizing and removing dangerous 
misfolded proteins. 
Once the folding process has been completed and the native proteins overcome the ER quality 
control, they are addressed to intra o extra-cellular places where accomplish their biological 
functions. All native proteins remain in dynamic equilibrium with a partially unfolded state, which 
is favourited in presence of genetic mutation and or in presence of abnormal environmental 
conditions. 
These pathological conditions are known as protein misfolding diseases (or protein 
conformational disease) because the pathological protein undergoes structural changes that trigger 
self-association, aggregation and tissue deposition, causing severe functional impairment [3]. 
These structures are defined as amyloid fibrils (or amyloid plaques) when they accumulate in the 
extracellular space, whereas the term “intracellular inclusions” has been suggested as more 
appropriate when fibrils accumulate inside the cell [4]. 
The molecular mechanisms involved in fibrillogenesis, are not clear yet. The knowledge of how 
protein aggregation process occurs requires the characterization of the conformational changes and 
of oligomeric structures adopted by the polypeptide chain during the process.  
The identification of residues and/or regions of the amino acidic sequence that promote the 
aggregation is also determinant for the comprehension of the process and for the perspective of 
the development of new therapeutic strategies. 
It is known that the formation of amyloid fibrils is a polymerization nucleation-dependent process 
(Figure 4.2). The time course of the conversion of a peptide or protein into its fibrillar form 
typically includes a lag phase, the rate-limiting step, followed by a rapid exponential growth 
phase. The lag phase represents the time required to form“nuclei”. Once a critical nucleus has been 
generated, it represents a “seed” which accelerates the growth of fibril with very fast kinetics. Any 
available monomers in the amyloidogenic conformation quickly become trapped in the fibril. As 
in other processes dependent on a nucleation step, the addition of preformed fibrillar species to a 
sample protein under aggregation conditions (seeding) determines the shortening of the lag phase 
[1][5]. 
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Figure 4.2: Kinetics of amyloid fibril formation: the process is described by a sigmoidal curve. The blue line indicates 
the formation of amyloid fibrils, beginning from a solution of monomeric proteins, which may temporarily assume an 
amyloidogenic conformation. Following rate-limiting step (lag phase) aggregate growth proceeds rapidly by further 
addition of monomers to form larger polymers (plateau phase). The red line represents a similar condition in which 
preformed fibrils are added, thus making the lag phase much shorter. 
As mentioned before, the occurrence of specific environmental conditions, the achievement of a 
higher local concentration, the interaction with extracellular matrix might synergistically induce 
the deposition of amyloid plaques. 
Both in vivo and in vitro fibrils when stained by Congo red give rise to a specific apple-green 
birefringence under a polarized light microscope; this flurescence is so specific that constitutes the 
preliminary method for amyloidosis diagnosis. The presence of rigid, non-branching fibrils is also 
detectable by electron microscopy and atomic force microscopy (Figure 4.3) [1]. 
All amyloid deposits contain an amount of heparansulfate and dermatan sulphate proteoglycans 
and glycosaminoglycan chains, some of which are strongly bound to the fibrils. These glycan 
molecules may contribute to amyloid fibrillogenesis as well as the stabilization of fibril structure. 
Heparansulfate proteoglycans are components of the extracellular matrix, as well as perlecan, 
laminin, entactin, and collagen IV. These molecules can have a scaffold role, facilitating the initial 
phase of fibril nucleation, and could have a targeting role in the localization of amyloid deposits 
in tissue. Ubiquitous components of amyloid deposits are the glycoprotein Serum Amyloid P 
component (SAP) and other proteins, such as Apolipoprotein E and Apolipoprotein A-IV, which 
are considered as amyloid protein signatures [1][6]. 
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Table 4.1: The most common amyloid proteins, their pathogenic precursors, distribution and type of amyloidosis. 
AMYLOID 
PROTEIN 
PRECURSOR DISTRIBUTION TYPE 
AΒ 
Aβ protein precursor Localized 
Localized 
Acquired 
Hereditary 
APRP 
 
Prion protein Localized 
Localized 
Acquired 
Hereditary 
ABRI ABri protein precursor Localized or systemic Hereditary 
ACYS Cystatin C Systemic Hereditary 
AΒ2M β 2-microglobulin Systemic Acquired 
AL 
Immunoglobulin light 
chain 
Systemic or localized Acquired 
AA Serum amyloid A Systemic Acquired 
ATTR 
Transthyretin Systemic 
Systemic 
Hereditary 
Acquired 
AAPOAI Apolipoprotein A-I Systemic Hereditary 
AAPOAII Apolipoprotein A-II Systemic Hereditary 
AGEL Gelsolin Systemic Hereditary 
ALYS Lysozyme Systemic Hereditary 
AFIB Fibrinogen A α-chain Systemic Hereditary 
4.1.2 Examples of Systemic Amyloidosis: Clinical Features, Diagnosis and Therapies 
AL amyloidosis – Immunoglobulin light chain (AL) amyloidosis is characterized by a clonal 
population of bone marrow plasma cells that produces a monoclonal light chain of lambda or kappa 
type as either an intact molecule or a fragment. Light chain kappa or lambda fibrils accumulate in 
tissues and interfere with organs function [7]. 
AL amyloidosis is the most commonly diagnosed form of cardiac amyloidosis. One or many 
organs may be involved: heart, kidneys, liver, peripheral and autonomic nervous systems and soft 
tissues [8]. Clinical features depend on organs involved, but can include restrictive 
cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and 
atypical multiple myeloma [7]. 
The chemotherapy is used for the treatment of AL amyloidosis. In addition, most patients with 
cardiac AL amyloidosis receive a cyclic combination of the alkylating agent cyclophosphamide, 
the proteasome inhibitor bortezomib and dexamethasone [7][8]. 
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ATTR amyloidosis – Transthyretin (TTR) is homo-tetrameric plasma protein produced almost 
exclusively by the liver, but also in small amounts within the choroid plexus andretina. Its 
physiological function is transportation of retinol-binding protein and thyroxine. Normal TTR 
(ATTRwt) is an inherently amyloidogenic protein. ATTRwt amyloidosis is almost exclusively a 
disease that affects elderly individuals (more than 70 years of age) with a 10-fold male 
predominance. In most patients, the heart is the only vital organ that is clinically affected, but 
carpal tunnel syndrome is common and may precede the development of cardiac symptoms by 10 
years [8]. 
Hereditary ATTR amyloidosis is usually associated with a single amino acid substitution caused 
by a point mutation in the TTR gene. Amyloidogenic TTR variants are less stable than their wild-
type counterpart, underlying their increased propensity to form amyloid fibrils. To date, more than 
120 point mutations in TTR gene have been identified, most of which are associated with 
amyloidosis. The most common mutations causative of hereditary ATTR amyloidosis are 
Val30Met, Thr60Ala, Ser77Tyr and Val122Ile, and their occurrence is strongly dependent by 
geographical area. 
So far the prevalent therapeutic treatment for ATTR amyloidosis include liver or heart 
transplantation in the cases of significant cardiac involvement from either ATTRwt or ATTR 
variant. In these last years several alternative therapeutic methods addressed to the synthesis of 
molecules able to stabilize TTR tetramer, or to inhibit hepatic synthesis of both wild-type and 
variant TTR, or to inihibit/destroy fibril formation have been developed to tackle TTR amyloidosis  
[8][9]. 
AApoAI amyloidosis - Apolipoprotein A-I (ApoAI) is the main component of high density 
lipoproteins (HDL) and is mostly involved in the removal of cholesterol from peripheral tissues 
and its transfer, via the plasma, to the liver, where it is either recycled back to plasma as a 
component of newly formed lipoproteins, or excreted from the body via bile [10].  
ApoAI amyloidosis can be present as a non-hereditary form with wild-type protein deposits in 
atherosclerotic plaques or as a hereditary form with the variant protein depositing more 
systemically in specific target organs, depending by the nature and localization of mutation [11]. 
For example, L75P-AApoAI amyloidosis is characterized by preferential accumulation of fibrils 
in the kidneys and liver, while fibrils from L174S-AApoAI occur preferentially in the heart, skin, 
testes and larynx [12][13]. 
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Patients affected by hereditary ApoAI amyloidosis typically present hypertension, proteinuria, and 
renal impairment and frequently develop extensive visceral deposits that affect the liver, spleen, 
and kidneys, with occasional involvement of the nerves, larynx, and gastrointestinal tract [14]. 
4.1.3 About Amyloidosis Diagnosis Issues 
Regarding the therapeutic strategies, an accurate definition of amyloid type is a crucial step in the 
diagnosis of systemic amyloidosis since the amyloid type dictates the therapy [15]. In fact, a 
precise identification of the amyloid fibril protein is essential for administration of appropriate 
therapy underlined by the fact that AL amyloidosis is treated with systemic chemotherapy, which 
is not efficacious and may have deleterious effects in other forms of systemic amyloidosis [16]. 
Proteomic analysis of amyloid deposits provides a chemical characterization of fibrillar 
constituents, representing a complementary strategy to genetic sequencing and 
immunohistochemistry analysis. However, there are ambiguous cases, in which more than one 
potentially amyloidogenic protein is found within the patient’s biopsy and an accurate diagnosis 
becomes challenging [17]. Typical examples are those in which both light chains and transthyretin 
are detected. This problem is becoming more common in aged individuals suffering of monoclonal 
gammopathies associated to a high secretion of monoclonal light chains: in several cases the 
amyloid plaques contain both proteins, the precursor of AL amyloid and the ATTR, leading 
ambiguous the diagnosed of amyloidosis [18]. Indeed, a recent study showed that up to 20% of 
patients with ATTR amyloidosis have an incidental monoclonal protein in serum or urine [19]. In 
addition, the increasing use of fine needle aspiration fat biopsies aggravates the issue for 
unambiguous typing of amyloid. Fine needle fat aspiration has the advantages to be a safe, simple 
and non-invasive technique to extract accumulated amyloid from tissue. The disadvantage is that 
the proteome of fine needle aspiration biopsy typically contains more than one potential amyloid 
fibril protein, thus complicating the achievement of a proper diagnosis. 
4.1.4 Apolipoprotein A-I: From Physiological Function to Amyloid Fibrils Formation 
ApoAI plays a critical role in lipid metabolism [20], both in delivering cholesterol to steroidogenic 
tissues and in transporting it from the periphery to liver for catabolism in reverse cholesterol 
transport. High density lipoproteins (HDL) particles containing ApoAI are antiatherogenic and 
protect against atherogenesis via reverse cholesterol transport and play an important role in 
antiinflammatory and antithrombotic response [21]. 
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ApoAI protein is synthesized by the liver and the small intestine; the mature form of 243 amino 
acids (28 kDa) is secreted in the plasma, where it is either associated to lipids, or in a lipid-free 
state (5-10%) [11][22]. 
More than 50 ApoAI variants have been identified, and about half of them are associated with 
HDL reduced levels [11].  
To date, 19 mutations are known to be associated with hereditary AApoAI amyloidosis (Table 
4.2). Most of the mutants are generated by single point mutations, but deletions or 
deletions/insertions have also been described [23][24]. For these variants, amyloid fibrils isolated 
ex vivo were found to be mainly constituted by 90-100 residues long N-terminal fragments of 
ApoAI. Thus, ApoAI variants represent the precursors of N-terminal fibrillogenic fragments, 
which show a high propensity to aggregate. 
Most of mutations are present within the N- terminal portion of the protein that is eventually found 
in fibrils (inside mutations). Other mutations occur in positions located outside this region of the 
polypeptide sequence (outside mutations) [14][25]. 
Table 4.2: The mutations occurring in ApoAI sequence, associated to amyloid pathology. The affected organs or 
tissues are also indicated. 
OUTSIDE 
MUTATIONS 
INVOLVED ORGAN 
OR TISSUE 
ΔL107 Circulatory sistem 
A154 frameshift Kidneys 
H155M 
frameshift 
Kidneys 
L170P Larynx 
R173P Kidneys, skin, heart, larynx 
L174S Skin, testes, heart, larynx 
A175P Larynx, testes 
L178H Larynx, skin, heart, nerves 
 
  
INSIDE 
MUTATIONS 
INVOLVED ORGAN 
OR TISSUE 
G26R Kidneys, liver, peripheral 
nerves, GI tract 
E34K Kidneys, liver 
W50R Kidneys, liver, GI tract 
L60R Kidneys, liver, testes, heart 
L64P Kidneys, liver 
Δ60-71+ VT INS Liver 
Δ70-72 Kidneys, liver, choroid 
F71Y Liver, palate 
N74K frameshift Kidneys, uterus, ovaries, pelvic 
lymph nodes, GI tract 
L75P Kidneys, liver, testes 
L90P Skin, heart, larynx 
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The structures proposed for ApoAI as lipid bound or lipid-free protein are different. In the absence 
of lipids, ApoAI assumes a compact four-helix bundle structure. In the lipid-bound form ApoAI 
exists as a dimer. It known that Δ(185-243)ApoAI C-terminally truncated forms a dimer composed 
of two antiparallel molecules adopting a semi-circular conformation, with a diameter comparable 
to that of HDL particle. The structure is stabilized by two symmetric four-helix bundles at the 
opposite ends of the dimer (Figure 4.4) [26]. 
 
Figure 4.4: Locations of the AApoAI mutations in the structure of free ApoAI. (A) X-ray crystal structure ofC-
terminally truncated human lipid-free Δ (185–243) ApoAI with the sites of all known AApoAI mutations mapped The 
structure is a crystallographic dimer stabilized by two symmetry-related four-helix bundles. (B) Proposed structure of 
lipid-free ApoAI monomer. 
Recently, a model has been proposed, prompting that AApoAI mutations perturb one of the 4 
predicted hot spots of the protein (14–22, 53–58, 69–72 and 227–232), with consequent full-length 
protein aggregation via the N-terminal region. Consequently, the proteolytic cleavage at the 
exposed loop (83–100) occurs and the N-terminal fibrillogenic polypeptide is released (Figure 4.5) 
[26]. The latter has been found to be the main protein constituent of ex-vivo fibrils [27]. It has 
been assumed that perturbation in the hot spots is one of the prerequisite for AApoAI misfolding, 
even though other factors may influence this process [26]. 
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Figure 4.5: Proposed pathway of ApoAI misfolding in amyloidosis. (A) The presence of a mutation in ApoAI reduces 
its affinity for lipid and promotes the shift from HDL-bound to lipid-poor/free monomeric ApoAI. Once dissociated 
from HDL, ApoAI forms a four-helix bundle containing residues 1–184 (helix ribbon) followed by the partially 
unstructured C-terminal residues 185–243 (thin line) containing the primary lipid-binding site. Four predicted amyloid 
hot spots are color-coded. The single point mutations may perturb the native structure in these hot spots and allow β-
aggregation. This leads to the formation of the protease-resistant amyloid core in the first 75 residues containing N-
terminal amyloid hot spots (in blue, teal and green) (B). In the parallel in-register β -sheet predicted for ApoAI, each 
hot spot (color-coded) stacks in register against its counterparts from the adjacent molecules. At about pH 7, the β-
breaking EKETEG residues 76–81 probably impede the amyloid core propagation towards the C-terminus and hamper 
the in-register stacking of the similarly charged groups. As a result, amyloid core stops at residues 76–81, leading to 
protein cleavage shortly there after. This explains why amyloid core in the patient-derived AApoAI deposits contains 
residue segments 1–83 to 1–100 (C). (D) At low pH, partial protonation of the adjacent Glu is expected to diminish 
the β -breaking potential of the EKETEG motif. This facilitates the β -sheet propagation towards the C-terminus and 
the formation of fibrils containing full-length ApoAI, such as those found in atherosclerotic plaques. In the resulting 
parallel in-register β -sheet structure, different hot spots within the molecule act in synergy (D), whereas similar 
secondary structural elements from different molecules (in different shades of gray) (E) are stacked in register. 
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4.1.5 Aims of the Project 
In the field of systemic amyloidosis, the present research project was focused on two main goals: 
1. The investigation of the effects of “inside mutation” L75P and the “outside mutation” 
L174S on AApoAI propensity to undergo an amyloidogenic pathway in order to elucidate 
the effect of two different mutation on the protein stability. To this end, a complementary 
proteolysis approach, coupled with mass spectrometry (LC-MS), was performed. 
This project was carried out in collaboration with Professor Renata Piccoli and Professor Daria 
Maria Monti of University of Naples Federico II. 
2. The development of an innovative proteomic strategy for typing amyloid deposits. The 
procedure is based on methodologies of tissues decellularization addressed to an 
unambiguous identification by mass spectrometry (LC-MS/MS) of the fibrillogenic 
protein. 
This research activity has been carried out at Wolfson Drug Discovery Unit, Centre for 
Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London (Royal 
Free Campus), London, UK, during the last year of my PhD course, under supervision of Professor 
Vittorio Bellotti. 
 
CHAPTER 4 –INVESTIGATION OF MOLECULAR MECHANISMS IMPAIRED IN AMYLOIDOSIS 
 INVESTIGATION OF APOAI CONFORMATIONAL PERTURBATIONS IN HEREDITARY AMYLOIDOSIS 
Page 120 of 152 
4.2 Investigation of ApoAI Conformational Perturbations in Hereditary 
Amyloidosis 
4.2.1 Materials and Methods 
4.2.1.1 Materials 
Trifluoroacetic acid (TFA), trypsin, chymotrypsin, endoproteinase Glu-C used for proteolysis 
experiments were SIGMA- ALDRICH products. 
Tris-HCl used to solubilize ApoAI protein was provided by BIO-RAD. 
Formic acid and acetonitrile HPLC Grade used for LC/MS analysis were Baker products. 
Professor D.M. Monti research group of University of Naples “Federico II” provided the 
recombinant his-tagged ApoAI proteins: wild-type, L75P, L174S ApoAI. 
4.2.1.2 Methods 
Complementary proteolysis experiments were carried out by using 0.4 mg/mL solutions of 
proteins in presence of trypsin (E:S= 1:8000), chymotrypsin (E:S= 1:8000), and endoproteinase 
Glu-C (E:S= 1:10000) in 50mM Tris-HCl, pH 7.4.  
The proteolysis experiments were carried out at 37°C and monitored on a time-course basis by 
sampling the peptide mixture at 15 and 30 minutes and blocking the reactions with 2% 
trifluoroacetic acid (TFA). 
Peptide mixtures were analyzed by liquid chromatography-mass spectrometry (LC–MS) onto a 
QuattroMicro LC- MS system (Micromass, Waters) interfaced with a 1100 HPLC (Agilent 
Technologies, Palo Alto, CA). Peptide mixtures from the different proteolysis experiments were 
fractionated by reverse-phase HPLC on a Phenomenex Jupiter C18 column (250 mm × 2.1 mm, 
300 Å pore size) and eluted by using a step gradient from 5% to 60% of solvent B (5% formic acid 
and 0.05% TFA in acetonitrile) over 60 min and from 60% to 95% in 5 min (solvent A 5% formic 
acid and 0.05% TFA in water). The flow rate was 200 μL/min and directly introduced in the mass 
spectrometer ESI source. Horse heart myoglobin was used as standard to calibrate the instrument 
(average molecular mass 16,951.5 Da) at 5 scans/s. 
4.2.2 Results and Discussion 
The aim of this study was to clarify the different impacts of two single point mutations, L75P and 
L174S, on ApoAI conformational stability by complementary proteolysis approach coupled with 
mass spectrometry identification of cleavage sites (LC–MS) [28]. 
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Complementary proteolysis refers to limited proteolysis experiments carried out in conditions able 
to give rise to a single proteolytic event on the protein, which originates two “complementary” 
peptides. In these conditions, flexible and exposed regions will be preferentially hydrolysed 
instead of buried or rigid regions. Further cleavages occurring on the two complementary peptides 
are not considered informative for conformational analysis. By using an array of proteolytic 
enzymes with different specificity, it has been possible to discriminate exposed regions from the 
regions not accessible to proteases. Conformational changes induced by mutations and affecting 
protein topology were monitored by the appearance of preferential cleavage sites located in 
exposed and flexible regions of the proteins, which become more susceptible to proteolysis 
[29][30]. 
Complementary proteolysis experiments were performed on the three proteins, wild-type, L75P-, 
L174S-ApoAI by using three proteases: trypsin, chymotrypsin and endoprotease Glu-C, as 
conformational probes. The reactions were carried out in parallel using the same enzyme:substrate 
ratio and were monitored on a time-course basis by sampling the incubation mixture after 15 and 
30 minutes of hydrolysis. Following this time course approach, primary and secondary cleavage 
sites, always occurring as a single proteolytic event, were only defined on kinetic basis.  
Peptide mixtures were analyzed by liquid chromatography-mass spectrometry (LC-MS) onto a 
QuattroMicro LC- MS system (Micromass, Waters) interfaced with a 1100 HPLC (Agilent 
Technologies, Palo Alto, CA). 
The LC-MS profiles showed that both variants were more susceptible to proteases than the wild-
type protein, as demonstrated by the higher number of peptides released at the same hydrolysis 
time (Figures 4.7- 4.9). This observation suggests that both AApoAI variants are more flexible 
and/or less structured than the wild-type protein. 
Molecular weight (MW) of intact proteins and complementary peptides originated by proteolysis 
with the relative MW are shown in Tables 4.3- 4.5. 
Recombinant proteins have been expressed with a His tag stretch at N-terminus (Figure 4.6) and 
the molecular weights expected for each one are following reported: wild type ApoAI 29798.5 Da, 
L75P- AApoAI 29782.5, and L174S- AApoAI 29772.4. 
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HIS- WT ApoAI  
  1 MHHHHHHGLV PRGSIDDPPQ SPWDRVKDLA TVYVDVLKDS GRDYVSQFEG SALGKQLNLK LLDNWDSVTS TFSKLREQLG  
 81 PVTQEFWDNL EKETEGLRQE MSKDLEEVKA KVQPYLDDFQ KKWQEEMELY RQKVEPLRAE LQEGARQKLH ELQEKLSPLG  
161 EEMRDRARAH VDALRTHLAP YSDELRQRLA ARLEALKENG GARLAEYHAK ATEHLSTLSE KAKPALEDLR QGLLPVLESF  
241 KVSFLSALEE YTKKLNTQ 
HIS- L75P ApoAI  
  1 MHHHHHHGLV PRGSIDDPPQ SPWDRVKDLA TVYVDVLKDS GRDYVSQFEG SALGKQLNLK LLDNWDSVTS TFSKLREQLG  
 81 PVTQEFWDNP EKETEGLRQE MSKDLEEVKA KVQPYLDDFQ KKWQEEMELY RQKVEPLRAE LQEGARQKLH ELQEKLSPLG  
161 EEMRDRARAH VDALRTHLAP YSDELRQRLA ARLEALKENG GARLAEYHAK ATEHLSTLSE KAKPALEDLR QGLLPVLESF  
241 KVSFLSALEE YTKKLNTQ 
HIS- L174S ApoAI 
  1 MHHHHHHGLV PRGSIDDPPQ SPWDRVKDLA TVYVDVLKDS GRDYVSQFEG SALGKQLNLK LLDNWDSVTS TFSKLREQLG  
 81 PVTQEFWDNL EKETEGLRQE MSKDLEEVKA KVQPYLDDFQ KKWQEEMELY RQKVEPLRAE LQEGARQKLH ELQEKLSPLG  
161 EEMRDRARAH VDALRTHLAP YSDELRQRSA ARLEALKENG GARLAEYHAK ATEHLSTLSE KAKPALEDLR QGLLPVLESF 
241 KVSFLSALEE YTKKLNTQ 
Figure 4.6: Sequences of His-tagged wild-type, L75P-, L174S- AApoAI. His-tag stretch at N-terminus is in black. 
The amino acid substitutions in L75P and L174S variants are reported in bold. 
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Figure 4.7: Chromatographic profiles (30 min) of proteolysis experiments of wild type, L75P, L174S ApoAI in 
presence of trypsin 1/8000. 
L75P ApoAI  
L174S ApoAI 
WT ApoAI 
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Table 4.3: Wild type, L75P, L174S ApoAI proteolytic cleavages carried out by using trypsin. Peptides released, 
retention time (RT), observed and theoretic MW (Da), cleveage types are reported. 
ApoAI 
Peptides 
released 
RT (min) Experimental MW (Da)  Theoretic MWAV (Da)  Cleavages 
Wild-type 
1-4 
5-243 
20.00 
66.83 
1494.0±0.01 
28322±1.98 
1494.70 
28321.83 
Primary 
1-131 
132-243 
67.68 
56.18 
17102.25±3.82 
12715.93±0.86 
17101.08 
12715.45 
Primary 
1-133 
134-243 
67.68 
56.18 
17357.59±2.22 
12459.71 ±1.61 
17357.38 
12459.15 
Secondary 
1-188 
189-243 
65.81 
57.97 
23630.38+1.78 
6188.03± 1.5 
23628.46 
6188.07 
Secondary 
1-243 65.81 29799.0 ±1.79 29798.5 - 
L75P 
1-4 
5-243  
20.00 
61.38 
1494.1±0.02 
28305.63±3.22 
1494.70 
28305.79 Primary 
1-96 
97-243 
59.08 
55.84 
12749.80±3.08 
17050.25±2.33 
12751.15 
17049.33 Secondary 
1-188 
189-243 
59.93 
58.06 
23614.30±2.79 
6188.21±0.71 
23612.42 
6188.71 Primary 
1-243 60.70 29783±1.5 29782.5 - 
L174S 
1-4 
5-243  
19.90 
67.09 
1494.84±0.02 
28295.98±2.37 
1494.70 
28295.75 Primary 
1-188 
189-243 
66.23 
58.06 
23603.91±2.58 
6188.06±0.28 
23602.38 
6188.07 Secondary 
1-153 
154-243 
67.09 
56.78 
19747.81±1.35 
10044.52±0.41 
19747.10 
10043.35 Primary 
1-243 66.23 29772.29±1.98 29772.4 - 
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Figure 4.8: Chromatographic profiles (30 min) of proteolysis experiments of wild type, L75P, L174S ApoAI in 
presence of chymotrypsin 1/8000. 
WT ApoAI 
L75P ApoAI 
L174S ApoAI 
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Table 4.4: Wild type, L75P, L174S ApoAI proteolytic cleavages carried out by using chymotrypsin. Peptides 
released, retention time (RT), observed and theoretic MW (Da), cleveage type are reported. 
ApoAI 
Peptides 
released 
RT (min) Experimental MW (Da)  Theoretic MWAV (Da)  Cleavages 
Wild-type 
1-8 
9-243 
29.44 
63.93 
2675.13±0.29 
27142.75±2.37 
2674.94 
27141.59 
Primary 
1-18 
19-243 
36.85 
63.51 
3836.14±0.16 
25981.38±3.28 
3836.26 
25980.27 
Secondary 
1-57 
58-243 
54.91 
58.23 
8165.70±1.65 
21652.96±2.63 
8165.05 
21651.48 
Secondary 
1-192 
193-243 
65.47 
57.29 
24106.92±1.26 
5712.45±1.41 
24104.99 
5711.54 
Primary 
1-243 65.47 29800±2.25 29798.5 - 
L75P 
1-8 
9-243 
29.53 
58.31 
2675.03±0.16 
27127.99±1.85 
2674.94 
27125.55 
Primary 
1-18 
19-243 
36.77 
57.72 
3836.19±0.29 
25966.14±2.41 
3836.25 
25964.23 
Primary 
1-57 
58-243 
54.74 
55.50 
8165.92±1.06 
21637.09±1.66 
8165.05 
24635.44 
Primary 
1-192 
193-243 
59.16 
57.29 
24091.81±1.96 
5712.42±0.62 
24088.94 
5711.54 
Primary 
1-243 59.76 29783±1.3 29782.5 - 
L174S 
1-8 
9-243 
29.61 
63.76 
2675.09±0.35 
27115.44±1.94 
2674.94 
27115.51 
Primary 
1-18 
19-243 
37.02 
63.76 
3835.80±0.81 
25955.47±2.31 
3836.26 
25954.19 
Primary 
1-57 
58-243 
54.65 
58.06 
8164.89±1.20 
21627.11±2.13 
8165.05 
21625.40 
Primary 
1-115 
116-243 
67.08 
55.24 
15241.96±1.68 
14552.21±2.13 
15238.96 
14551.49 
Secondary 
1-192 
193-243 
65.30 
57.29 
24079.81±1.87 
5711.44±0.71 
24078.91 
5711.54 
Secondary 
 1-243 65.30 29773±1.4 29772.4 - 
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Figure 4.9: Chromatographic profiles (30 min) of proteolysis experiments of wild type, L75P, L174S ApoAI in 
presence of endoproteinase GluC 1/10000. 
  
WT ApoAI 
L75P ApoAI 
L174S ApoAI 
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Table 4.5: Wild type, L75P, L174S ApoAI proteolytic cleavages carried out by using endoprotease Glu-C. Peptides 
released, retention time (RT), observed and theoretic MW (Da), cleveage type are reported. 
ApoAI 
Peptides 
released 
RT (min) Experimental MW (Da) Theoretic MWAV (Da) Cleavages 
Wild-type 
1-136 
137-243 
67.68 
57.12 
17735.20±2.69 
12079.90±2.75 
17736.80 
12079.73 
Secondary 
1-223 
224-243 
66.66 
45.88 
27484.23±1.84 
2333.39±0.10 
27482.87 
2333.66 
Primary 
1-243 66.66 29799.49±1.8 29798.5 - 
L75P 
1-34 
35-243 
52.69 
63.85 
5674.68±0.73 
24126.94±1.94 
5675.25 
24125.24 
Primary 
1-223 
224-243 
65.21 
48.43 
27466.41±2.16 
2333.28±0.08 
27466.83 
2333.66 
Secondary 
1-243 66.23 29783.88±2.77 29782.5 - 
L174S 
1-34 
35-243 
51.16 
67.85 
5674.57±0.93 
24113.88±1.72 
5675.25 
24115.20 
Primary 
1-136 
137-243 
67.85 
60.44 
17735.55±1.62 
12053.22±0.91 
17736.80 
12053.65 
Secondary 
1-243 68.45 29772.29±1.98 29772.4 - 
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Figure 4.10: Schematic representation of the results obtained from limited proteolysis experiments on wild-type 
ApoAI (upper), L75P-AApoAI (middle) and L174S-AApoAI (lower). Proteolytic sites are designed as primary (filled) 
or secondary sites (empty) on kinetic basis. The R-4 cleavage site was not taken in consideration, as it is located in 
the his-tag peptide sequence occurring in the recombinant proteins. 
The distribution of the proteolytic sites of ApoAI, obtained by trypsin, chymotrypsin and 
endoprotease Glu-C hydrolyses, is shown in Figure 4.10. 
In all the proteins a similar pattern of proteolytic accessibility can be observed, with preferential 
cleavage sites gathering at both the N- and C- terminal regions. 
However, proteolytic cleavages at Y18 and F57 residues occurred much faster in the mutants than 
in wild-type ApoAI and E34 was not recognized in the native protein, suggesting a higher 
flexibility in the N-terminal region of the variants. Moreover, hydrolysis at residues K96 and Y115, 
in L75P- and L174S-AApoAI, respectively, suggests a slight conformational change in the region 
including the putative proteolytic site in AApoAI variants, responsible for the release of the 
fibrillogenic polypeptide. On the contrary, in wild-type ApoAI this region, as reported in the 
crystal structure [31], is in predominantly α-helical structure, which protects the protein from 
proteolytic cleavage. 
Also at C-terminal region, wild-type ApoAI and L75P variant are characterized by a similar 
proteolytic profile, showing accessibility at residues R188, Y192 and E223. The disappearance of 
the E223 cleavage site and the slower kinetic of hydrolysis at level of R188 and Y192 residues in 
the L174S variant suggest that a slight conformational change occurred in this region. 
Further differences in the proteolytic patterns of the three proteins were located in the region 
including the 131–136 sequence that was exposed in the wild-type ApoAI, as demonstrated by 
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cleavages at R131, K133 and E136 sites. On the other hand, this region became completely 
inaccessible in the L75P variant. The conformation in this region changed also in the L174S 
mutant, where E136 was still recognized, but with slow kinetics and the appearance of new 
cleavage sites at R153 and Y166 was detected. It is noteworthy that these cleavages occurred quite 
close to the mutation site 174, indicating that a conformational change occurred, making this 
region less structurated or higher accessible. 
Complementary proteolysis support perfectly the molecular dynamic (MD) simulation carried out 
by our co-workers. 
From the MD simulations it emerged that no significant changes in the overall structure from the 
corresponding crystal structure occurred in wild- type ApoAI, while the two variants show subtle, 
but significant variations. The replacement of L174 with a Ser has only a moderate effect on the 
overall structure of the protein. In fact, in the L174S variant, the serine side chain can be well 
accommodated within the helix 141–180, since it can form a hydrogen bond with the carbonylic 
oxygen of Y170 (Figure 4.11A). On the contrary, the L75P substitution has a stronger destabilizing 
effect, since the presence of Pro breaks helix 70–76 and disturbs the stabilizing hydrophobic 
interactions that play a major role in orienting the helices of the four- segment bundle (Figure 
4.11B). 
 
Figure 4.11: Structural features of AApoAIvariants. A, insight of the structure of helix encompassing residues 141–
180 in wild-typeApoAI (yellow) and in L174S variant (cyan). B, ribbon representation of the helix bundle in proximity 
of L75 in the structure of wild-typeApoAI (yellow) and of L75P variant (green). For sake of clarity, one helix from 
the second chain of the dimer was removed. 
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All these data clearly indicate that the mutations enhance the overall flexibility of the protein and 
both L75P- and L174S-AApoAI variants have an increased exposure of the N-terminal region. In 
particular, L75P-AApoAI shows a lower helical content in correspondence of residues 66–73, 
135–137, 157–160 and 172–177, but it is more structured than both wild-type ApoAI and L174S 
in the regions 125–129 and 140–142. L174S-AApoAI has a lower α-helical content in 
correspondence of residues 107–110, 140–141, but it is more structured in the regions 77–80 and 
158–160.  
These simulation data well fit with the results of far-UV CD spectroscopy measurements showing 
that the wild- type ApoAI and the two amyloidogenic variants were predominantly in an α-helical 
state, with a slightly lower α-helix content of the variants with respect to the wild-type protein 
(Table 4.6). When the proteins were incubated at 37 °C over time, no significant changes in the 
spectra of the wild-type protein were observed; on the contrary, the α-helicity of both variants 
decreased over time accompanied by an increase in β- strand, indicating an alteration of the protein 
native conformation towards an aggregation competent state. 
Table 4.6: α-Helix and β-strand contents (%) for wild-type ApoAI and its amyloidogenic variants, upon incubation 
at 37 °C. Data shown are the means from three independent experiments. The accuracy of the secondary structure 
content estimation is approximately 2% for wild-type ApoAI and 4% for its amyloidogenic variants. 
 
As supposed, the substitution of L75 with proline has a destabilizing effect, as it breaks helix 70–
76. This helix overlaps with one of the three predicted N- terminal amyloid “hot spots”, whose 
perturbation has been recently suggested to be a prerequisite for misfolding [32]. This leads to the 
exposure of hydrophobic residues mainly located in the N-terminal region, as demonstrated by the 
increased intrinsic fluorescence intensity and ANS binding [33], as well as by the exposure of a 
proteolytic site at Y18, belonging to the major hot spot 14–22, as also found for G26R and L178H 
variants [34]. Furthermore, the accessibility of further proteolytic sites at E34 and F57 (the latter 
belonging to the minor hot spot 53–58), both hindered in the native protein, is the consequence of 
the propagation of the local perturbation (helix 70–76) to the other two predicted hot spots and the 
cause of the decreased protein compactness. In fact, DLS measurements of the hydrodynamic 
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diameter carried out by our co-workers [33] demonstrated that the L75P variant is much less 
compact protein with respect to both the wild-type protein and the L174S variant.  
4.2.3 Conclusions 
In conclusion, the investigation of effects L75P and L174S mutations on conformational stability 
of ApoAI contribuited to add knowledge, at a molecular level, to the general mechanism by which 
amyloidogenic mutations determine ApoAI destabilization and a higher propensity to aggragate 
triggering systemic amyloidosis. 
As a response to the occurrence of the “internal” mutation L75P, the protein acquires a “looser” 
structure at the N-terminal domain, with significant alteration of protein conformation and 
compactness, while the “external” mutation L174S is responsible for a less destabilized but more 
flexible structure to which a more pronounced aggregation-competent state is associated [33]. 
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4.3 Development of an Innovative Proteomic Strategy for Typing Amyloid 
Deposits 
4.3.1 Materials and Methods 
4.3.1.1 Materials 
Dithiothreitol (DTT), sodium deoxycholate (SDC), acetonitrile LC-MS, methanol LC-MS, formic 
acid, trifluoroacetic acid (TFA)were provided by SIGMA ALDRICH. Ammonia solution HPLC 
grade (35%) and water LC-MS were Fisher scientific products. Zwittergent (3-16 detergent) was 
provided by Merck Millipore. 
Trypsin Gold Mass Spectrometry Grade was Promega product. 
Sodium chloride, calcium chloride, ethanol (96%), sodium hydroxide were provided by AnalaR 
NORMAPUR.  
ClearVueMountants XYL was Thermo Scientific product. Formal saline solution (10%) was 
provided by CellPath. 
Congo red stain was provided by AMRESCO. 
Mayer's Hematoxylin solution and Scott's Tap Water Substitute solution were Pioneer Research 
Chemicals products. 
Adipose tissue biopsies were provided by National Amyloidosis Centre (NAC), University 
College London, Royal Free Hospital, London, UK. 
4.3.1.2 Methods 
Adipose tissues decellularization - The protocol for the decellularization of adipose tissue was 
carried out through sequential 2 min washing steps with 500mM NaCl; 4% sodium deoxycholate 
(SDC) in the presence of 2mM calcium chloride; Tris-HCl containing 140mM NaCl (TC), 2mM 
calcium chloride, pH 8, respectively. 
All the steps were performedby using a minimal volume of each buffer (500 µL), in a TissueLyser 
instrument set at a frequency of 25Hz. After decellularization the fat became translucent. Both 
non-treated and decellularized fat tissues were directly subjected to trypsin digestion. 
Adipose tissues digestion - Proteins were extracted from adipose tissues by using buffer solution 
(50µL/sample) and by heating at 99 oC for 90 minutes. 
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Buffer composition: 
 10mM TrisHCl pH 8 
 1mM CaCl2 2H2O 
 0.002% Zwittergent 
The samples were allowed to cool, centrifuged at 10,000 rpm for 5 minutes, and sonicated for 60 
minutes at room temperature.  Each sample was treated with 20μL of 4ng/μL trypsin solution and 
incubated overnight at 37 ºC. The digested samples were reduced with dithiothreitol (50µg/sample) 
at 99 ºC for 5 minutes. Finally, the samples were freeze dried, reconstituted in 0.1 % v/v 
trifluoroacetic acid in HPLC grade water (100µL/sample) and 5µLof sample were analysed by 
LC-MS/MS. 
LC-MS/MS analysis - Nanoflow liquid chromatography-electrospray tandem mass spectrometry 
was performed using a Waters nanoACQUITY™ UPLC system (Waters Ltd., Elstree, 
Hertfordshire, UK) coupled to a Thermo Scientific OrbitrapVelos Mass Spectrometer (Thermo 
Electron, Bremen, Germany) operated in the positive ion mode.  Tryptic digests were applied to a 
trap column (180 µm ID x 20 mm bed, 5 µm Symmetry C18 packing; Waters Corporation, 
Massachusetts, USA) and separated on a reverse phase column (100 µm ID x 150 mm bed, 5 µm 
C18 packing; NikkyoTechnos Company Ltd, Tokyo, Japan) using a gradient from5% to 
60 % acetonitrile/water over 44 min. Peptide analysis was performed using data-dependent 
acquisition (DDA) of one MS scan (mass range from 400 to 2000 m/z) followed by MS/MS scans 
of the ten most abundant ions in each MS scan. 
The chromatographic system was washed between each sample using a protocol that includes five 
washes: 10% formic acid; 0.1% TFA; 1% NH3 in 50% MeCN; 80% MeOH and 80% MeCN. A 
control blank run prior to each sample to confirm the absence of any carryover. 
Proteins identification - Instrument control and data acquisition used Thermo Scientific Xcalibur 
Version 2.1. MS data files were analysed using Matrix Science Mascot. Searches were performed 
by setting following parameters: 
 Database: SwissProt 
 Taxonomy: Homo sapiens 
 Enzyme: Trypsin (with 2 missed cleavages) 
 Variable modification: oxidation (M) 
 Peptide tolerance: 10 ppm 
 MS/MS tolerance: ± 0,6 Da 
 Ions charge: +2, +3, +4 
 Instrument: ESI-TRAP 
CHAPTER 4 –INVESTIGATION OF MOLECULAR MECHANISMS IMPAIRED IN AMYLOIDOSIS 
 DEVELOPMENT OF AN INNOVATIVE PROTEOMIC STRATEGY FOR TYPING AMYLOID DEPOSITS 
Page 135 of 152 
Protein identities were expressed in terms of MASCOT score probabilities with a significance 
value set at P<0.05.  
In addition, Mascot output data files were analyzed and validated using Scaffold 4.6.1 (Proteome 
Software). This tool uses a Local False Discovery Rate (LFDR)-based scoring system for peptide 
validation based on a Bayesian approach to confirm peptide probabilities. MS data files were 
queried using both Mascot and X!Tandem algorithms.The likelihood of peptides is calculated on 
parent ion mass accuracy and parent ion delta masses. Proteins identified with 2 assigned peptides, 
protein threshold over the 99 % confidence level, peptide threshold over the 95 % were considered 
significant.  
Congo red staining – Untreated and decellularized adipose tissues (5-10 µm thick sections) were 
attached to the slides and left to dry for 2 hours. After, the slides were placed for 1 minute in box 
containing formalin fixative alcoholic solution (85.5% ethanol and 10%of formal saline solution 
10%) in order to preserve permanently the tissues. Then dried slides were put in a box with 
Mayer’s hematoxylin stain for 10 minutes. This step was carried out in order to stain the nuclei of 
cells. Subsequently a wash was carried out in Scott's tap water solution for 5 minutes. The slides 
were washed with saturated NaCl in 80% ethanol and then with the same solution containing 
Congo red stain for 20 minutes, in order to visualize the amyloid. Finally, tha slide were washed 
in 100% ethanol removing the excess of stain, placed in ClearVuecoverslipper machine (Thermo 
Scientific) and left to dry over-night. The slides were displayed using LEICA DMLB microscope. 
4.3.2 Results and Discussion 
Proper amyloid typing represents a crucial step in the diagnosis and treatment of systemic 
amyloidosis. There are some cases in which more than one potentially amyloidogenic protein may 
be detected and an accurate diagnosis becomes challenging. 
The present study was focused on the development of a methodology based on decellularization 
of human fat biopsies coupled with mass spectrometry analysis (LC-MS/MS) in order to improve 
the specificity of amyloid typing. Adipose tissue biopsies from patients affected by amyloidosis 
were provided by National Amyloidosis Centre at Royal Free Hospital-University College London 
(London, UK). 
The research activity was carried out at the laboratoty of Wolfson Drug Discovery Unit, Centre 
for Amyloidosis and Acute Phase Proteins, University College London (London, UK), where it 
has recently been developed a strategy for the decellularization of a whole amyloidotic mouse 
organ demonstrating that structure and functional properties of amyloid fibrils were maintained 
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within the extracellular space. The procedure included sequential perfusion of water, detergent and 
DNase [35]. 
In this study, a specific protocol addressed to the decellularization of human fat biopsies has been 
set up. Ten cases were analysed. The small size tissue samples permitted to employ few steps of 
sequential washing using a 1/40 ratio for weight of biopsy/buffer volume. The procedure was fast 
and the limited number of washing steps minimized the loss of tissue material and allowed the 
analysis of sample of very limited dimensions. After decellularization, the fat tissues became 
translucent as shown in Figure 4.12. 
Microscopic analysis in bright field demonstrated that the procedure successfully removed the 
cells without affecting the abundant green birefringence in the Congo-red stained material 
observed in the tissue before and after decellularization under cross-polarized light (Figure 4.13). 
 
Figure 4.12: Fat aspirate biopsies pre- and post decellularization. 
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Figure 4.13: Microscopic analysis in bright field and under cross-polarized light of fat tissue before and after 
decellularization. 
Both untreated and decellularized fat biopsies were digested by trypsin and analysed by LC-
MS/MS; the proteins were identified by Mascot search. In addition, Mascot output data files were 
analyzed and validated by the use of Scaffold 4.6.1 tool, which provides information about: 
 Protein identification probability (P) 
 Exclusive Unique Peptide count (EUP): number of unique peptides associated only with 
each protein 
 Total Spectrum count (TS): number of total spectra associated with each protein including 
those shared with other proteins 
The identifications of potentially amyloidogenic proteins pre- and post-decellularization are shown 
in Table 4.7. 
  
Non-treated 
Decellularised 
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Table 4.7: Proteins identified for each sample with Mascot score probabilities and Scaffold software results: 
1Probability of protein identification, 2 Number of unique peptides and 3Total spectrum count. 
Fat aspirate 
Non treated biopsy Decellularised biopsy 
Amyloid 
protein  
MASCOT 
Score 
SCAFFOLD RESULTS Amyloid  
protein 
MASCOT 
Score 
SCAFFOLD RESULTS 
1P 2EUP 3TS 1P 2EUP 3TS 
Patient-1 
 809 100% 10 28  2682 100% 7 79 
 560 100% 8 15  427 100% 6 11 
Patient-2 
 883 100% 12 30  1793 100% 11 67 
TTR 481 100% 9 11 TTR 359 100% 8 9 
Patient-3 
TTR 764 100% 15 24 TTR 377 100% 12 16 
 296 100% 4 8  66 100% 2 2 
Patient-4 
 350 100% 4 10  513 100% 9 26 
 60 100% 2 3 0 0 0 0 0 
Patient-5 
 505 100% 5 15  614 100% 6 17 
 205 100% 5 7  261 100% 4 7 
Patient-6 
 568 100% 6 21  1669 100% 11 75 
 227 100% 4 9  49 0 0 0 
Patient-7 
 3286 100% 3 101  2965 100% 2 94 
ApoA1 576 100% 13 18 0 0 0 0 0 
Patient-8 
 287 100% 5 14  997 100% 5 29 
TTR 132 100% 2 3 TTR 132 0 0 0 
Patient-9 
 553 100% 4 26  914 100% 7 34 
 119 100% 4 6 0 0 0 0 0 
Patient-10 
TTR 578 100% 7 13 TTR 1799 100% 15 63 
 680 100% 5 20  277 100% 3 9 
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Starting from non-unique identification of amyloid protein, the analysis shows that after 
decellularization has been possible to obtain a substantial increase in Mascot score for 
amyloidogenic protein and a significant reduction, or in some cases total absence, of protein not 
part of amyloid fibrils, such as for patients 6, 7, 8 and 9. 
Moreover, these results are particularly significant also for the cases 2, 3, 10, exhibiting a 
consistent presence of both IgG light chain and TTR protein and giving rise to ambiguous cases. 
In these situations, the identification of the real amyloidogenic protein is fundamental to 
understand amyloid type and then for the choice of the correct therapeutic approach. An example 
is the case number 10: in untreated sample, k light chain is equivalent, in term of Mascot score e 
total spectra, to those related to TTR protein. After decellularization process, Mascot score and 
number of peptides and spectra of k light chain decrease, while Mascot score of TTR triples and 
its total spectra become five times higher than before the procedure. 
This result allows to clarify the amyloidogenic protein identity, in this case, TTR. This is extremely 
important since the application of a wrong therapy, in this case chemotherapy, used for light chain 
amyloidosis treatment, would harm the patient. 
By reporting the natural logarithm of total spectra ratio of amyloidogenic (A) and non 
amyloidogenic protein (B), ln(TsA/TsB), before and after decellularization (Figure 4.14), the 
general effect of decellularization procedure are more evident. Notably, the ratios are always 
higher after treatment than before, except for case number 5, suggesting that the decellularization 
procedure certainly improved the identification of amyloidogenic protein. 
The parameters, including unique peptides, unique spectra and total spectra, provided by Scaffold, 
using Mascot and X!Tandem algorithms, were consistent with Mascot score. 
In Figure 4.15 xy-plots show Mascot score versus total spectra of related proteins for each patient. 
Empty symbols refer to the results obtained though the standard procedure, while red symbols are 
the data obtained after decellularization. Triangle refers to the amyloidogenic protein and it is 
straight forward that almost in all cases the decellularization enhances the mascot score and total 
spectra of the culprit protein.  
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Figure 4.14: Total spectra ratio A/B, where A is amyloidogenic protein and B non amyloidogenic protein, 
ln(TsA/TsB), in untreated and decellularised samples. 
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Figure 4.16: TSPOST-DECELLULARIZATION/TSPRE-DECELLULARIZATION of ATPB, GPDA, G3P, ALDH2, FAS, PLIN1, 
PLIN4, CLUS, VTNC, SRPX proteins identified in human adipose tissue biopsies. 
This result suggests that decellularization procedure improves the identification of proteins 
belonging to ECM, therefore also amyloid protein, removing most of cellular protein background 
as demonstrated by the reduction of the amount of enzymes identified after the application of 
decellularization protocol. 
4.3.3 Conclusions 
Fine needle fat aspiration has the advantages to be a safe, simply and non-invasive technique to 
extract accumulated amyloid from tissue. Its disadvantage is that the proteome of the fine needle 
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aspiration biopsy typically contains more than one potential amyloid fibril protein precursor 
challenging the precise identification of the pathogenic protein. 
The innovative strategy of decellularization of fresh fat aspirate specimens represents an intelligent 
and simple way to improve the accuracy and specificity of identification of amyloid fibril type 
removing most of cellular and plasma proteins background without altering properties of amyloid 
fibrils. Indeed, proteomic analysis revealed that in the clinical cases in which there was an 
ambiguous situation about amyloid protein identification, the decellularization procedure was able 
to improve the chemical classification of amyloid deposits. 
This approach, allowing to clarify amyloidogenic protein identity, is extremely important to 
employ a right focused theraphy thus to increase the effectiveness and reduce side effects which 
would harm the patient. 
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 Neutron scattering, 8 hours, October 2015 (Prof. Zorn)
2) Attended Seminars:
Title Speaker Date Place 
Studio delle basi molecolari 
dell’acidemia metilmalonica 
Dr. Marianna 
Caterino 
6/06/2014 
CEINGE 
Biotecnologie Avanzate 
Evidenze genetiche sulle prime 
espansioni umane dall’Africa 
Prof. Guido 
Barbujani 
23/10/2014 
Università degli Studi di 
Napoli “Federico II” 
Antibodies and Mass 
Spectrometry…collaborators or 
competitors? 
Prof. Pietro Pucci 12/12/2014 
CEINGE 
Biotecnologie Avanzate 
Huntington: storia di un gene tra 
evoluzione e meccanismi di 
patologia 
Prof. Chiara Zuccato 15/01/2015 
CEINGE 
Biotecnologie Avanzate 
Alessandro Ballio e la chimica a 
Napoli negli anni ‘60 
Dr. Andrea 
Carpentieri 
18/06/2015 
Università degli Studi di 
Napoli Federico II 
Le transglutaminasi..dalle 
poliammine alle bioplastiche 
Prof. Raffaele Porta 30/06/2015 
Università degli Studi di 
Napoli Federico II 
Introduction to bioinformatics Dr. Remo Sanges 18/12/2015 
Università degli Studi di 
Napoli Federico II 
Biopesticides which target voltage-
gated ion channels: efficacy and 
biosafety 
Prof. Angharad 
M.R.Gatehouse 
14/01/2016 
Università degli Studi di 
Napoli Federico II 
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Title Speaker Date Place 
1,1,2,2-tetraethoxybutyne-Exciting 
to make and work with 
Prof. Leiv K. Sydnes 14/01/2016 
Università degli Studi di 
Napoli Federico II 
Functionalized and artificial 
enzymes:newbio-derived catalysts 
Prof. Therrytron 14/01/2016 
Università degli Studi di 
Napoli Federico II 
Secondary metabolites from higher 
land and sea plants in Chemical 
ecology and Chemosystematics 
Prof. Christian 
Zidorn 
27/01/2016 
Università degli Studi di 
Napoli Federico II 
Cardiac ageing: a matter of 
monoamino oxidases? 
Prof. Angelo Parini 18/10/2016 
Royal Free Campus, 
University College 
London 
Hepatology become non-invasive 
Prof. Massimo 
Pinzani 
19/10/2016 
Royal Free Campus, 
University College 
London 
3) Visiting periods in Institutions different from University of Naples Federico II:
Host Institution Country Start Date End Date 
San Raffaele 
Hospital of Milan 
Milan 
(Italy) 
24th November 2014 5th December 2014 
University College London 
London 
(United Kingdom) 
1st April 2016 20th December 2016 
4) Publications (include submitted and in preparation):
 Chesi G.; Hegde R.N.; Iacobacci S.; Concilli M.; Parashuraman S.; Festa B.P.; Polishchuk
E.V.; Di Tullio G.; Carissimo A.; Montefusco S.; Canetti D.; Monti M.; Amoresano A.;
Pucci P.; van de Sluis B.; Lutsenko S.; Luini A.; Polishchuk R.S. Identification of p38
MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants.
Hepatology 2016, 63(6), 1842-1859.
 Del Giudice R.; Arciello A.; Itri F.; Merlino A.; Monti M.; Buonanno M.; Penco A.;
Canetti D.; Petruk G.; Monti S.M.; Relini A.; Pucci P.; Piccoli R.; Monti D.M. Protein
conformational perturbations in hereditary amyloidosis: Differential impact of single
point mutations in ApoAI amyloidogenic variants. Biochimica et Biophysica Acta
2016,1860(2), 434-444.
 Butturini E.; Gotte G.; Dell'Orco D.; Chiavegato G.; Marino V.; Canetti D.; Cozzolino
F.; Monti M.; Pucci P.; Mariotto S. Intermolecular disulfide bond influences
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unphosphorylated STAT3 dimerization and function. Biochemical Journal 2016, 
473(19), 3205-3219. 
 Mangione P.P.; Mazza G.; Gilbertson J.A.; Rendell N.; Canetti D.; Giorgetti S.;
Frenguelli L.; Curti M.; Rezk T.; Raimondi S.; Pepys M.B.; Hawkins P.N.; Gillmore J.D.;
Taylor G.W.; Pinzani M.; Bellotti V. Increasing the accuracy of proteomic typing by
decellularisation of amyloid tissue biopsies (work in preparation).
 Canetti D. et al. Methyl lysine formation in formalin-fixed paraffin-embedded amyloid
tissue: misidentification of transthyretin and immunoglobulin variants (work in
preparation).
5) Attended congresses/workshops/summer schools/contribution:
 Canetti D.; Monti M.; Chesi G.; Concilli M.; Polishchuk R.; Pucci P. Investigation of
molecular mechanisms impaired in Wilson disease. 9th ItPA (Italian Proteomics
Association) National Congress – Naples, Italy (24th – 27th June 2014).
Oral Communication.
 Monti M.; Canetti D.; Porto C.; Parenti G.; Pucci P. Dissecting acid alpha glucosidase
pathways in pathophysiology of Pompe disease. 9th ItPA (Italian Proteomics Association)
National Congress – Naples, Italy (24th – 27th June 2014). Poster.
 Monti M.; Canetti D.; Chesi G.; Concilli M.; Polishchuk R.; Pucci P. Investigation of
molecular mechanisms impaired in Wilson disease. 13th HUPO (Human Proteome
Organization Word Congress) – Madrid, Spain (5th – 8th October 2014). Poster.
 Canetti D.; Monti M.; Zappa F.; De Matteis A.; Polishchuk R.; Pucci P. Investigation of
CLIC-1 interactome. 10th EuPA (European Proteomics Association) Annual Congress –
Milan, Italy (23rd – 28th June 2015). Poster.
 Landolfi A.; Canetti D.; Cozzolino F.; Battaglia E.; Zuccato C.; Monti M. Label free
quantitation: comparative analysis of XIC and SpCs based methods. 11th ItPA (Italian
Proteomics Association) National Congress – Perugia, Italy (16th -19th May 2016).
Poster.
 Japan-UK workshop on Amyloidosis – London, United Kingdom (18th -20th September
2016). Attendee.
 Cozzolino F.; Canetti D.; Iacobucci I.; Landolfi A.; Moccia F.; Napodano E.; Pucci P.;
Monti M. Functional proteomics in the elucidation of cellular mechanisms. Workshop
BIO/10 -Naples, Italy (18th January 2017). Poster.
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